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ABSTRACT 
 
Measuring and reporting performance have become the norm.  The purpose of this 
descriptive multi-site (N = 36 NDNQI-participating hospitals) study was to examine the 
reliability of the National Database of Nursing Quality Indicators® (NDNQI®) pressure ulcer 
(PrU) risk and prevention measures.  This is the first known study to examine the inter-rater 
reliability of these measures. 
 Data for Part 1 of this two-part study were extracted from 1,637 patient records by 120 
raters.  One rater at each hospital was considered the “expert”.  Agreement between the expert 
and non-expert raters was calculated for the risk measures.  Among the patients, 530 were “at 
risk” for PrU, and included in calculations of agreement for the prevention measures.  In Part 2, 
raters completed an online survey about the methods they use to collect these data. 
Cohen’s kappa values varied widely within and across hospitals.  Because most patients 
were assessed for PrU risk, and those at risk received prevention, the prevalence of a “Yes” 
response was high suggesting prevalence-adjusted kappa (PAK) may be a better estimate of 
inter-rater reliability than Cohen’s kappa.  PAK values for:  Skin assessment, PAK = .977, 95% 
CI [.966 – .989]; Risk assessment, PAK = .978, 95% CI [.964 –.993]; Time since last risk 
assessment, PAK = .790, 95% CI [.729 – .852]; Risk assessment scale, PAK = .997, 95% CI 
[.991 – 1.0]; Risk status, PAK = .877, 95% CI [.838 – .917]; Any prevention, PAK = .856, 95% 
[.769 – .943]; Skin assessment documented, PAK = .956, 95% CI [.904 – 1.0]; and Pressure-
redistribution surface use, PAK = .839, 95% CI [.763 – .916] indicated substantial to near 
perfect agreement.  PAK values for:  Routine repositioning, PAK = .577, 95% CI [.494 – .661]; 
iv 
Nutritional support, PAK = .500, 95% CI [.418 – .581]; and Moisture management, PAK = .556, 
95% CI [.469 – .643] indicated moderate agreement. 
Results provide support for the reliability of all (5) PrU risk measures, and three of six 
prevention measures.  Areas of disagreement between the expert and non-expert raters should 
direct education to improve reliability.  Results of the online survey suggest raters need further 
training on the NDNQI guidelines for PrU data collection. 
v 
ACKNOWLEDGEMENTS 
 
 Thank you to my dissertation committee, Dr. Sandra Bergquist-Beringer,  Dr. Karen 
Wambach, Dr. Shin Hye Park, Dr. Jianghua He (Wendy), and Dr. Lynne Connelly, for their time 
and guidance.  Special appreciation is given to my program advisor and dissertation committee 
chair, Dr. Bergquist-Beringer, for her expertise, tireless efforts, high standards, prompt feedback, 
and attention to detail.  Without her, this dissertation could not have taken place.  Special 
appreciation is also given to Dr. He for her patience, kindness, and guidance while overseeing 
my statistical analyses.  I would be remiss if I did not acknowledge other faculty members who 
taught and mentored me here at the University of Kansas, as well as at Washburn University.  
Thank you to the many graduate biostatistics students who helped me along the way.  They 
developed the Excel table I used to calculate the Cohen’s kappa and prevalence-adjusted kappa 
values.  My appreciation is extended to the NDNQI staff who oversaw this research.  They were 
always available to me, and their expertise in NDNQI research is truly impressive.  My gratitude 
is given to the hospitals who participated in this study. 
 Others who made it possible for me to complete this journey include my classmates.  
Without your friendship and support I could not have earned this degree.  Finally, thank you to 
my family and friends for “picking up the slack”, understanding my absence, and expecting me 
to succeed.  I would like to dedicate this research to the nurses who provide these pressure ulcer 
risk and prevention interventions.  They are the heart and soul of nursing.  
vi 
TABLE OF CONTENTS 
 
            Page 
ABSTRACT……………………………………………………………………………….. iii 
 
ACKNOWLEDGEMENTS……………………………………………………………….. v 
 
LIST OF TABLES…………………………………………………………………………. ix 
 
LIST OF FIGURES………………………………………………………………………... xii 
 
CHAPTER I: INTRODUCTION………………………………………………………….. 1 
A. Pressure Ulcers…………………………………………………...……………..1 
  1.  Definition and Classification…………………………................ 2 
  2.  Prevalence and Incidence………………………………………. 5 
B. Clinical Guidelines for Pressure Ulcer Prevention……………………………. 6 
 1.  Pressure Ulcer Risk Assessment and Skin Assessment………… 7 
 2.  Pressure Ulcer Prevention Interventions……………………….. 8 
C. The National Database for Nursing Quality Indicators®……………………… 10 
D. Measuring Quality of Care…………………………………………………….. 12 
E. Statement of the Problem ……………………………………........................... 13 
F. Significance……………………………………………………………………..14 
G. Specific Aims and Research Questions………………………………………... 15 
H. Conceptual Framework………………………………………………………… 17 
I. Definition of Terms……………………………………………………………..21 
J. Assumptions……………………………………………………………………. 24 
 
CHAPTER II: REVIEW OF THE LITERATURE……….………………………………. 25 
A. National Quality Indicators on Pressure Ulcers………………........................... 25 
1. Agency for Healthcare Research and Quality ……………............... 26 
2. Centers for Medicare and Medicaid Services……………................ 30 
3. Joint Commission………………………………………………..... 33  
4. National Quality Forum…………………………………………… 34 
B. Recommended Pressure Ulcer Prevention Interventions: 
 Literature Review……………………………...……………………………37 
1. Pressure Ulcer Risk Assessment………………………………….... 37 
2. Skin Assessment…………………………………………………… 41 
3. Minimizing Shear…………………………………………………...42 
4. Minimizing Pressure……………………………………………….. 45 
5. Moisture Management and Skin Care………………………………54 
6. Nutritional Support………………………………………………… 56 
7. Education…………………………………………………………... 59 
C. Pressure Ulcer Prevention Programs…………………………………………... 62 
D. Criteria for a Sound Measure…………………………………………………... 67 
1. Validity…………………………………………………………….. 67 
2. Reliability………………………………………………………….. 68 
vii 
E. Reliability Studies of the NDNQI Measures…………………………………. 78 
 
CHAPTER III: METHODOLOGY………………………………………………………... 87 
A. Research Design………………………………………………………………...87 
B. Setting and Sample…………………………………………………………….. 88 
C. Study Variables and Measures…………………………………………………. 89 
 1.  NDNQI Pressure Ulcer Risk and Prevention Variables and Measures 
  ……………………………………………………………... 89 
 2.  The Pressure Ulcer Risk and Prevention Reliability Survey…… 98 
D. Procedures…….………………………………………………........................... 105 
E. Human Subject Review…………………………………………………………112 
F. Data Analysis………………………………………………………………….. 113 
 1.  Preparation of the Data for Analysis……………………………. 113 
 2.  Data Analysis by Study Aim and Research Question…………... 115 
  a. Aim 1……………………………………………. 115 
  b. Aim 2………………………………………….... 127 
G. Pilot Study ……………………………………………………........................... 128 
H. Study Timeline…………………………………………………………………. 129 
 
CHAPTER IV: RESULTS……….………………………………………………............... 130 
A. Descriptive Statistics …………………………………………..…………......... 130 
 1.  Hospitals………………………………………………………... 130 
 2.  Patients………………………………………………………….. 133 
 3.  Participant Raters……………………………………………….. 136 
B. Results by Study Aim………………………………………………………….. 140 
 1.  Aim 1…………………………………………………………… 140 
  a. Question 1……………………………………….. 140 
  b. Question 2……………………………………….. 158 
  c. Question 3……………………………………….. 162 
  d. Question 4……………………………………….. 162 
  e. Question 5……………………………………….. 165 
 2.  Aim 2…………………………………………………………… 171 
 
CHAPTER V: DISCUSSION, RECOMMENDATIONS, AND CONCLUSION………... 192 
A. The Sample…………………………………………………………………….. 192 
B. Aim 1:  Calculation of Rater Agreement on the 11 NDNQI Pressure 
Ulcer Risk and Prevention Measures………………………………………….. 195 
C. Aim 2:  Methods and Processes Used to Collect NDNQI Pressure Ulcer 
Risk and Prevention Data………………………………………………………. 206 
D. Implications for the Conceptual Framework………………………… ………. 212 
E. Implications for Practice……………………………………………………….. 213 
F. Limitations……………………………………………………………………... 214 
G. Future Research………………………………………………………………... 216 
H. Conclusion……………………………………………………………………... 217 
 
REFERENCES…………………………………………………………………………….. 219 
viii 
APPENDIX A.  NATIONAL QUALITY FORUM’S ALGORITHMS FOR EVALUATING 
MEASURES ………………………………………………………………………………. 249 
 
APPENDIX B.  DATA COLLECTION FORM………………….……………………….. 253 
 
APPENDIX C.  THE PRESSURE ULCER RISK AND PREVENTION RELIABILITY 
SURVEY….….……………………………………………………………………………. 254 
 
APPENDIX D.  INVITATION TO PARTICIPATE………………………………………. 262 
 
APPENDIX E.  REPLY TO INVITATION TO PARTICIPATE ……………………….... 265 
 
APPENDIX F.  OVERVIEW OF THE PRESSURE ULCER RISK AND PREVENTION 
RELIABILITY STUDY……………………………..…………………………………….. 266 
 
APPENDIX G.  SITE COORDINATOR INSTRUCTIONS………………………...…..... 268 
 
APPENDIX H.  PARTICIPANT RATER INSTRUCTIONS……………………………... 272 
 
APPENDIX I.  EMAIL SENT WITH STUDY MATERIALS……………………………. 276 
 
APPENDIX J.  TELECONFERENCE INSTRUCTIONS………………………………… 278 
 
APPENDIX K.  PILOT STUDY FEEDBACK AND RESPONSES…………………....... 279 
  
ix 
LIST OF TABLES 
Table            Page 
1. Illustration of Prevalence in a Distribution of 100 Subjects by Rater and  
Response Category………………………………………………………….………73 
 
2. Illustration of the Influence of Bias on Kappa Value……………………………… 75 
3. Example of Calculating Prevalence-Adjusted Kappa and Change in  
Kappa Value………………………………………………………………………...75 
 
4. Review of Literature: Reliability of NDNQI Measures……………………………. 79 
5. Major Study Variables:  NDNQI Pressure Ulcer Risk and Prevention Measures..... 91 
6. Participant Rater Characteristics of Interest……………………………………….. 99 
7. Illustration for Calculating Observed Agreement and Expected Agreement……… 119 
8. Illustration of Cell Counts used to Calculate PAK from Actual Cell Counts…..…. 120 
 
9. Illustration of an Agreement Matrix for Hypothetical Data: Routine  
Repositioning............................................................................................................. 127 
 
10. Study Timeline……………………………………………………………………... 129 
11. Hospital Characteristics (N = 36):  Size, Teaching Status, Magnet Status, and 
Metropolitan Status………………………………………………………………… 132 
 
12. Patient Age and Gender, Number of Participant Raters (N = 120), and Number of  
Patients (N = 1,637) by Hospital (N = 36)………………………………...……….. 134 
 
13. Participant Rater (N = 120) Characteristics:  Job Title, Education, and 
Certifications……………………………………………………………………….. 137 
 
14. Aim 1 Question 1:  “Skin Assessment Documented within 24 hours of  
Admission”—Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s 
Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital  
(N = 36)….................................................................................................................. 141 
 
15. Aim 1 Question 1:  “Risk Assessment within 24 hours of Admission”— 
Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s Kappa, 
Prevalence-Adjusted  Kappa, and Percent Agreement by Hospital (N = 36) 
………………………………………………………………………………..……. 143 
 
x 
16. Aim 1 Question 1:  “Time since Last Pressure Ulcer Risk Assessment”— 
Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s Kappa, 
Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 36) 
……………….………………………………………………………………..…... 144 
 
17. Aim 1 Question 1:  “Risk Assessment Scale”—Number of Expert/Non-Expert  
Pairs, Number of Patients Rated, Cohen’s Kappa, Prevalence-Adjusted Kappa, and 
Percent Agreement by Hospital(N = 36)…………………………………………… 146 
 
18. Aim 1 Question 1:  “Risk Status”—Number of Expert/Non-Expert Pairs, Number of 
Patients Rated, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by 
Hospital (N = 36)…………………………………………………………………... 147 
 
19. Aim 1 Question 1:  “Any Prevention provided within the Last 24 hours”— 
Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s Kappa, 
Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 36)………. 149 
 
20. Aim 1 Question 1: “Skin Assessment Documented within the Last 24 hours”— 
Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s Kappa, 
Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 36)....……. 150 
 
21. Aim 1 Question 1:  “Pressure-Redistribution Surface Use within the Last  
24 hours”—Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s 
Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital  
(N = 36)…………………………………………………………………………….. 152 
 
22. Aim 1 Question 1:  “Routine Repositioning as Prescribed within the Last  
24 hours”—Number of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s 
Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 36) 
…………………………………………………………………………….…....…. 154 
 
23. Aim 1 Question 1:  “Nutritional Support within the Last 24 hours”—Number of 
Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s Kappa, Prevalence-
Adjusted Kappa, and Percent Agreement by Hospital (N = 36)………………..…. 155 
 
24. Aim 1 Question 1:  “Moisture Management within the Last 24 hours”—Number  
of Expert/Non-Expert Pairs, Number of Patients Rated, Cohen’s Kappa, Prevalence-
Adjusted Kappa, and Percent Agreement by Hospital (N = 36)…………………... 157 
 
25. Aim 1 Question 2:  Overall Agreement for the Five Pressure Ulcer Risk Measures  
by Hospital (N = 36 Hospitals)…………………………………………………….. 159 
 
26. Aim 1 Question 2:  Overall Agreement for the Six Pressure Ulcer Prevention  
Measures by Hospital (N = 36 Hospitals)………………………………...……….. 160 
 
xi 
27. Aim 1 Question 3: Mean Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent 
Agreement for Each Pressure Ulcer Risk and Prevention Measure  
(N = 11 Measures) Across Hospitals (N = 36 Hospitals)…………………………... 163 
 
28. Aim 1 Question 4: Intraclass Correlation Coefficients for Cohen’s Kappa and  
Prevalence-Adjusted Kappa Values Across Hospitals for Pressure Ulcer Risk  
and Prevention Measures (N = 72 Cohen’s Kappa Values; N = 72 PAK Values)… 164 
 
29. Aim 1 Question 5: Agreement Matrices—Agreement between the Expert (N = 36)  
and Non-Expert (N = 84) Raters for Each of the 11 NDNQI Pressure Ulcer Risk  
and Prevention Measures…………………………………………………….…….. 166 
 
30. Aim 2:  Participant Rater Characteristics—Training in and Experience Collecting 
Pressure Ulcer Data…………………………………………………………………172 
 
31. Aim 2: Methods and Processes Used to Collect NDNQI Pressure Ulcer Risk and 
Prevention Data (n = 36 Experts, n = 84 Non-Experts)…………………...……….. 176 
  
xii 
LIST OF FIGURES 
Figure            Page 
1. Substruction: Donabedian’s Model Modified for Measuring Healthcare System 
Performance …………………………………………………………………...…... 19 
 
2. Expert to Non-Expert Pairs………………………………………………………… 117 
 
3. Derivation of the Hospital Sample ………………………………………………… 131 
 
1 
CHAPTER I:  INTRODUCTION 
 “. . . if he has a bed-sore, it is generally the fault not of the disease, but of the nursing.” 
Florence Nightingale (1860) 
 
The problem of pressure ulcers (PrUs) is well-documented.  While not all PrUs are 
avoidable, most are (Black et al., 2011), thus they are now considered to be the result of poor 
patient quality of care.  A number of non-profit and governmental agencies have worked to 
decrease PrU occurrence through programs that promote use of interventions to prevent them.  
Measurement of these interventions is necessary to evaluating quality of care initiatives toward 
decreasing PrU occurrence.  No studies were found that examined the reliability of PrU risk and 
prevention measures. 
Pressure Ulcers 
Pressure ulcers are extremely painful (Rastinehad, 2006) and decrease quality of life 
(Gorecki et al., 2009).  They are associated with increased mortality (Lyder et al., 2012; Russo, 
Steiner, & Spector, 2008), increased likelihood of readmission within 30 days of discharge, and 
increased hospital length of stay (11.2 days compared to 4.8 days) (Lyder et al., 2012).  In 2006, 
503,300 hospital stays included a Stage III or Stage IV PrU diagnosis (Russo et al., 2008).  These 
patients were more likely to be discharged to a long-term care facility compared to those without 
a PrU.  Almost 75% of those with a hospital-acquired PrU (HAPU) are 65 years of age and older. 
While treatment costs associated with PrUs varies according to severity of the wound, a 
Stage III or Stage IV PrU can take several months to more than two years to heal, at an estimated 
cost of $105,846 (Chan et al., 2012) to more than $240,000 (Schessel, Ger, & Oddsen, 2012) per 
PrU.  Overall costs for all PrU stages are estimated to exceed $4200/month (Chan et al., 2012).  
2 
These costs do not include lost wages.  Treatment costs far exceed costs associated with PrU 
prevention (Padula, Mishra, Makic & Sullivan, 2011; Pham et al., 2011; Spetz, Brown, Aydin, & 
Donaldson, 2013). 
The Institute of Healthcare Improvements’ 5 Million Lives Campaign encouraged 
hospitals to adopt interventions aimed at preventing patient harm, including pressure ulcers 
(Ayello & Lyder, 2008; Duncan, 2007).  The goal of this 2007 – 2008 campaign was zero PrU 
occurrences.  Healthy People 2020 set the goal of eliminating PrU hospitalizations among older 
adults by 10% (Department of Health and Human Services, 2007).  One of the most influential 
PrU prevention initiatives was the Center for Medicare and Medicaid Services’ (CMS) decision 
to deny payment for the cost of treating Stage III and Stage IV hospital-acquired PrUs effective 
October 1, 2008; private payers followed suit (Blue Cross & Blue Shield, 2012).  More recently, 
the Partnership for Patients Initiative, a public-private partnership of physicians, nurses, 
hospitals, employers, patients, and governmental agencies; identified PrUs as one of ten core 
patient safety focus areas.  This initiative’s goal was to reduce the 2010 rate of hospital-acquired 
Stage III or Stage IV pressure ulcers by 40% (CMS, n. d.).  Performance of “multicomponent 
interventions to reduce pressure ulcers” was among the top ten strategies “strongly 
recommended” (p. 366) for immediate implementation by an international panel of 21 
stakeholders and evaluation experts (Shekelle et al., 2013).  This list was based on evaluations of 
the effectiveness of these strategies. 
Definition and Classification 
A pressure ulcer is defined as a “localized injury to the skin and/or underlying tissue 
usually over a bony prominence, as a result of pressure, or pressure in combination with shear.  
A number of contributing or confounding factors are also associated with pressure ulcers; the 
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significance of these factors is yet to be elucidated” (NPUAP/EPUAP, 2009, p. 19).  The 
National Pressure Ulcer Advisory Panel (NPUAP), (2012) defines and classifies pressure ulcers 
according to the amount of tissue damage (para 5-10). 
Category/Stage I: Non-blanchable erythema 
Intact skin with non-blanchable redness of a localized area usually over a bony prominence.  
Darkly pigmented skin may not have visible blanching; its color may differ from the 
surrounding area.  The area may be painful, firm, soft, warmer or cooler as compared to 
adjacent tissue.  Category I may be difficult to detect in individuals with dark skin tones.  
May indicate “at risk” persons. 
Category/Stage II: Partial thickness 
Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound 
bed, without slough.  May also present as an intact or open/ruptured serum-filled or sero-
sanginous filled blister.  Presents as a shiny or dry shallow ulcer without slough or bruising 
[bruising may indicate deep tissue injury].  This category should not be used to describe skin 
tears, tape burns, incontinence associated dermatitis, maceration or excoriation. 
Category/Stage III: Full thickness skin loss 
Full thickness tissue loss.  Subcutaneous fat may be visible but bone, tendon or muscle are 
not exposed.  Slough may be present but does not obscure the depth of tissue loss.  May 
include undermining and tunneling.  The depth of a Category/Stage III pressure ulcer varies 
by anatomical location.  The bridge of the nose, ear, occiput and malleolus do not have 
(adipose) subcutaneous tissue and Category/Stage III ulcers can be shallow.  In contrast, 
areas of significant adiposity can develop extremely deep Category/Stage III pressure ulcers.  
Bone/tendon is not visible or directly palpable. 
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Category/Stage IV: Full thickness tissue loss 
Full thickness tissue loss with exposed bone, tendon or muscle.  Slough or eschar may be 
present.  Often includes undermining and tunneling.  The depth of a Category/Stage IV 
pressure ulcer varies by anatomical location.  The bridge of the nose, ear, occiput and 
malleolus do not have (adipose) subcutaneous tissue and these ulcers can be shallow.  
Category/Stage IV ulcers can extend into muscle and/or supporting structures (e.g., fascia, 
tendon or joint capsule) making osteomyelitis or osteitis likely to occur.  Exposed 
bone/muscle is visible or directly palpable. 
Unstageable/Unclassified: Full thickness skin or tissue loss – depth unknown 
Full thickness tissue loss in which actual depth of the ulcer is completely obscured by slough 
(yellow, tan, gray, green or brown) and/or eschar (tan, brown or black) in the wound bed.  
Until enough slough and/or eschar are removed to expose the base of the wound, the true 
depth cannot be determined; but it will be either a Category/Stage III or IV.  Stable (dry, 
adherent, intact without erythema or fluctuance) eschar on the heels serves as “the body’s 
natural (biological) cover” and should not be removed. 
Suspected Deep Tissue Injury – depth unknown 
Purple or maroon localized area of discolored intact skin or blood-filled blister due to 
damage of underlying soft tissue from pressure and/or shear.  The area may be preceded by 
tissue that is painful, firm, mushy, boggy, warmer or cooler as compared to adjacent tissue.  
Deep tissue injury may be difficult to detect in individuals with dark skin tones.  Evolution 
may include a thin blister over a dark wound bed.  The wound may further evolve and 
become covered by thin eschar.  Evolution may be rapid exposing additional layers of tissue 
even with optimal treatment. 
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Prevalence and Incidence 
Fortunately, once highly prevalent, hospital-acquired pressure ulcer (HAPU) rates have 
decreased over time.  Claims data from the nearly 40 million Medicare patients who were 
hospitalized from 2009 through 2011 revealed 8,812 Stage III, Stage IV, or unstageable HAPUs 
(0.65 cases/1,000 patients) (HealthGrades, 2013).  This HAPU rate is notably lower than the 
2007 through 2009 rate of 368,261 Stage III, IV, or unstageable HAPUs among 14 million 
Medicare hospitalizations (26.64 cases/1,000 patients)—which cost Medicare $1.99 billion 
(Reed & May, 2011).  Others have reported similar trends.  The International Pressure Ulcer 
Prevalence SurveyTM reported U.S. hospital-acquired Stage II or higher PrU (HAPU2+) 
prevalence rates were 6.4% in 2006 compared to 5.0% in 2009 (VanGilder, Amlung, Harrison, & 
Meyer, 2009), and 3.6% in 2012 (VanGilder, Lachenbruch, Harrison, & Meyer, 2013 ).  The 
percentages that these 2012 HAPUs were classified as were Stage I (33.8%), Stage II (37.3%), 
Stage III (3.3%), Stage IV (1.2% ), unstageable (9.2%), suspected deep tissue injury (13.6%), 
indeterminable (1.1%), and stage not collected (0.5%).  These data highlight the degree to which 
HAPU rates are underestimated by indicators that do not count all PrU categories/stages. 
Data on all stages of HAPUs showed similar trends.  These overall rates decreased each 
year from a high of 10.4% in 2003 to a low of 1.8% in 2010 (Stotts, Brown, Donaldson, Aydin, 
& Fridman, 2013).  The National Database of Nursing Quality Indicators® (NDNQI®) PrU data 
collected in 2010 revealed a HAPU rate of 3.6% (Bergquist-Beringer, Dong, He, & Dunton, 
2013); compared to 6.5% from 2006 through 2007 (Bergquist-Beringer, Gajewski, & Davidson, 
2012).  He, Staggs, Bergquist-Beringer, and Dunton (2013) reported a statistically significant 
decrease in HAPU rates from 2004 to 2007, and even more so from 2008 to 2011.  Reduction in 
HAPU occurrence has been attributed to national initiatives (O’Reilly, 2008) and prevention 
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programs (Chou et al., 2013; Niederhauser et al., 2012, Soban, Hempel, Munjas, Miles, & 
Rubenstein, 2011; Sullivan & Schoelles, 2013) that promote use of the interventions to prevent 
them, such as the PrU risk and prevention measures examined in this study. 
Clinical Guidelines for Pressure Ulcer Prevention 
Clinical guidelines for PrU prevention provide practitioners with concise instructions for 
reducing PrUs that are based on current scientific evidence (Langemo et al., 2008).  They also 
bring to light healthcare issues, influence public policy, and improve quality of care (Woolf, 
Grol, Hutchinson, Eccles, & Grimshaw, 1999).  The original guidelines for PrU prevention and 
treatment were developed in 1992 by the Agency for Healthcare Policy and Research—now the 
Agency for Healthcare Research and Quality (AHRQ).  These guidelines were re-endorsed in 
2001 (Shekelle et al., 2001). 
Most recently, members of the NPUAP and EPUAP, and the Pan Pacific Pressure Injury 
Alliance (PPPIA)—an alliance of wound care organizations across Australia, New Zealand, 
Hong Kong, and Singapore—collaborated to update the NPUAP and EPUAP 2009 Clinical 
Practice Guidelines for the Prevention and Treatment of Pressure Ulcers.  These guidelines were 
released October of 2014 (NPUAP, EPUAP, PPPIA, 2014).  Others have developed guidelines 
including the Wound Ostomy Continence Nurses (WOCN) Society guidelines that were first 
developed in 2003, and updated in 2010 (Ratliff, Tomaselli, & The Guideline Task Force, 2010).  
The NPUAP/EPUAP/PPPIA guidelines and the WOCN guidelines are well-known, easily 
accessible, and commonly accepted (Berlowitz et al., n. d.; Soban et al., 2011). 
These PrU prevention guidelines focus on reducing risk for PrU development.  The first 
step in prevention is gathering information on an individual’s risk for PrU development and the 
status of their skin.  Based on this information, specific PrU prevention interventions are selected 
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for implementation.  These interventions include: (1) PrU risk assessment; (2) skin assessment; 
(3) reducing risk by minimizing shear and minimizing pressure through routine repositioning, 
use of a pressure-redistribution surface, and offloading pressure from the heels (elevating the 
lower legs to completely lift the heel from the bed); (4) moisture management and skin care; (5) 
nutritional support; and (6) patient and caregiver education (NPUAP/EPUAP/PPPIA, 2014; 
Ratliff et al., 2010). 
Pressure Ulcer Risk Assessment and Skin Assessment 
Pressure ulcer risk assessment is determining the degree that an individual is at risk for 
PrU development.  A risk assessment involves identifying patient factors known to be associated 
with PrU development.  A PrU risk assessment should be completed (and documented) using a 
reliable and valid tool within 8 hours of admission, at regular intervals, and after a change in 
patient status.  These assessments guide which prevention interventions are to be performed.  
Additional risk factors (not on the structured PrU risk assessment tool) should be considered; 
such as advanced age, obesity, tobacco use, co-morbid conditions, and history of PrU.  Risk 
status, therefore, should be determined by a mixture of clinical judgment and a risk assessment 
tool. 
Skin assessment is a head-to-toe assessment of an individual’s skin.  It includes visual 
inspection of the entire body, as well as assessment of skin temperature, moisture, color, turgor, 
integrity (Ayello et al., 2009), edema, tissue density (firm or mushy), and localized pain.  Skin 
assessments should be systematically performed and documented upon admission, at regular 
intervals, with each PrU risk assessment, and after a change in status.  A skin assessment must be 
performed and documented as close as possible to the time of admission in order to accurately 
determine if a PrU is hospital-acquired or community-acquired (i.e. present-on-admission). 
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Pressure Ulcer Prevention Interventions 
Minimizing shear involves keeping skin clean and dry, using lift sheets, maintaining the 
head of the bed at or below 30 degrees, lowering the head of the bed one hour after meals, use of 
overhead trapeze bars, avoiding vigorous massage over bony prominences, and applying 
transparent films or hydrocolloids to bony prominences. 
Pressure is minimized by routine repositioning at a frequency determined by individual 
activity/mobility level and medical condition(s)—usually every 2 hours (while on a standard 
mattress) or every 4 hours (while on a pressure-redistribution mattress), and at least every 1 hour 
while seated.  Those seated who can reposition themselves, however, should relieve pressure 
every 15 minutes, such as by a chair push-up or forward-leaning.  Pressure-redistribution 
surfaces (foam, gel, or air mattresses/overlays/cushions) are recommended while in bed or a 
chair; as are frequent small position changes using pillows and wedges.  Heels should be 
offloaded.  Strategies to reduce PrUs among patients in the operating room include the use of a 
pressure-redistribution surface for surgeries lasting four hours or longer.  Minimizing 
hypotensive and low body temperature episodes during surgery are also important as are proper 
body positioning to minimize pressure—including offloading of the heels. 
Moisture management and skin care includes establishing a bowel/bladder retraining 
program.  Skin must be kept clean and dry using gentle, pH-balanced cleansers and smooth 
disposable wipes.  Other interventions are the use of skin protectants such as barrier 
creams/ointments/pastes, fecal management systems, and high-quality disposable diapers/pads. 
Nutritional support equals offering the person at nutritional and PrU risk at least 30 – 
35 kcal/kg/day that includes 1.25 – 1.5 g/kg/day of protein, and 1 ml of fluid/kcal/day.  In 
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addition, these individuals should receive a dietary consult.  In general, nutritional intake must be 
monitored and appropriate nutritional interventions provided through the appropriate route. 
Patient and caregiver education on causes and risk factors for PrUs, as well as how to 
decrease these risks, should be presented.  Specifically, patients and caregivers must be taught 
the importance of (and how to properly perform) routine repositioning, regular skin inspections, 
maintaining adequate nutritional and fluid status, preventing friction and shear, and keeping the 
skin clean and dry. 
The NPUAP/EPUAP/PPPIA and the WOCN Society Guidelines provide strength of 
evidence ratings for each of their recommendations with Level A being the strongest, followed 
by Level B, and then Level C (the weakest).  Within the WOCN Society Guidelines, a Level A 
rating indicates that the recommendation was supported by (a) at least two randomized 
controlled trials (RCTs) of at least 10 people with PrUs, (b) a meta-analysis of RCTs, or (c) a 
Cochran Review of RCTs.  A Level B rating indicates that the recommendation was supported 
by (a) at least one controlled trial of at least 10 people with PrUs, or (b) at least two supporting 
non-randomized trials of at least 10 people with PrUs.  The lowest level, a Level C rating, 
indicates that the recommendation was supported by (a) two supporting case series of at least 10 
people with PrUs, or (b) expert opinion.  Within the WOCN Guidelines, only three of 22 (12%) 
recommendations were supported by Level B evidence, while 22 of 25 (88%) recommendations 
were supported by Level C evidence (Ratliff et al., 2010).  There were no Level A ratings. 
The NPUAP/EPUAP/PPPIA definition of Level A differs slightly from the WOCN’s 
definition.  Level A is defined by NPUAP/EPUAP/PPPIA as “direct scientific evidence from 
properly designed and implemented controlled trials on pressure ulcers in humans (or humans at-
risk for pressure ulcers); providing statistical results that consistently support the guideline 
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statement (Level 1 studies required)” (NPUAP, EPUAP, & PPPIA, 2014, p. 4).  Level 1 studies 
are “Random trial(s) with clear-cut results and low risk of error OR systematic literature review 
or meta-analysis according to the Cochrane methodology or meeting at least 9 out of 11 quality 
criteria according to AMSTAR appraisal tool” (p. 4).  Within the NPUAP/EPUAP/PPPIA 
Guidelines, none of the recommendations were supported by Level A evidence, 24% by Level B 
evidence, and 76% by Level C evidence (NPUAP/EPUAP/PPPIA, 2014). 
The National Database for Nursing Quality Indicators® 
The NDNQI was established by the American Nurses Association (ANA) in 1998 as part 
of its Safety and Quality Initiative (ANA, 2014; Montalvo, 2007).  During the 1990s, healthcare 
saw a reduction in patient care provided by registered nurses (RNs), decreased length of patient 
stay, and other cost-cutting measures.  As a result, the ANA sought to collect data to show that 
RNs affect quality of care, and to fill the need for collecting nurse-sensitive outcomes—as 
opposed to the medical-focused outcomes commonly reported at that time (ANA, 2014; 
Montalvo, 2007).  The purpose of the NDNQI is to (1) collect data on quality indicators 
amenable to nursing care, (2) provide information to participating hospitals so they may compare 
their own performance over time and to similar hospitals and nursing units, and (3) to build 
evidence on the relationship between nurse staffing and patient outcomes (ANA, 2014).  The 
NDNQI was managed by the University of Kansas Medical Center (KUMC), School of Nursing 
under contract with the American Nurses Association and with Press Ganey through December, 
2014. The NDNQI is an accepted nurse registry that satisfies CMS voluntary reporting (ANA, 
2013).  It also meets Magnet application requirements (ANA, 2013). 
From its beginning, the NDNQI began collecting data on their PrU outcome indicator, 
but quarterly HAPU data collection did not begin until the year 2000 – 2001 (Bergquist-
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Beringer, 2011).  Over the years, this data collection was expanded to include suspected deep 
tissue injury in 2008, and pediatric units in 2009.  Also, inter-rater reliability studies were 
conducted on PrU identification, staging, and origin in 2004 through 2006; the online PrU 
Training program was developed in 2006, and has been updated routinely (2007, 2008, 2009, 
2010, 2012, and 2014) (S. Bergquist-Beringer, personal communication, March 19, 2014).  The 
NDNQI PrU advisory committee was formed in 2007. 
The NDNQI Stage II and higher HAPU rate (HAPU2+) is a National Quality Forum 
(NQF) endorsed measure.  For a measure to be endorsed by the NQF, it must go through a 
rigorous process and meet specific criteria.  Endorsed measures are generated from (and based 
on) established guidelines and an expert panel review, which continues until the measure is 
retired.  This endorsement process is described in Chapter II.  The NDNQI uses surveillance data 
to determine HAPU rates.  This means the skin of all patients is directly examined for PrUs on a 
single day (point in time).  Those PrUs identified are classified as community-acquired or 
hospital-acquired and staged.  A hospital-acquired PrU (HAPU) is a PrU that developed after 
admission to the hospital.  Any PrU that is not documented in the patient record upon admission 
is considered to be a HAPU (NDNQI, 2013).  The NDNQI counts all categories/stages of 
HAPUs. 
Since 1998, the following process measures have been added to the suite of NDNQI 
pressure ulcer measures (a) Skin assessment on admission, (b) PrU risk assessment on 
admission, (c) Time since last PrU risk assessment, (d) Risk assessment method, (e) Risk status, 
(f) Performance of PrU prevention (yes/no), (g) Pressure-redistribution surface use, (h) 
Nutritional support, (i) Routine repositioning, (j) Skin assessment within the past 24 hours, and 
(k) Moisture management (Bergquist-Beringer et al., 2013). 
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The accuracy of the NDNQI pressure ulcer data is supported by ongoing: (a) data checks 
by the NDNQI staff and participating hospitals, as well as error report alerts; (b) training of data 
collectors; and (c) assurance by facilities’ site coordinators that data are collected in accordance 
with NDNQI’s definitions and collection requirements (NDNQI, 2013).  It is essential, however, 
that empirical support for the NDNQI PrU risk and prevention data’s reliability be established, 
something that has not been done.  This study hopes to begin establishing that support. 
Measuring Quality of Care 
Measuring quality is the first step to improve quality of care and typically involves 
measuring healthcare structures, processes, and patient outcomes.  Structures include elements 
such as the physical characteristics, size, and type of facility; organizational structure; resources 
and equipment; qualifications and numbers of staff; and financing.  Processes are the care itself, 
such as the activities that go on between the caregiver and the patient.  These include 
characteristics of care such as if care is timely, appropriate, and comprehensive.  Outcomes are 
measures of the end results of care such as morbidity, mortality, prevalence, incidence, 
readmissions, adverse events, cost of services provided, and patient satisfaction and quality of 
life (Donabedian, 1978).  Collectively, these measures are called quality indicators.  Data from 
the measurement of quality indicators are used to measure quality of care, and monitor and guide 
quality improvement efforts (de Vos, Graafmans, Kooistra, Meijboom, & Westert, 2009). 
Sound measurement is essential if research findings are to be credible: it is the 
cornerstone of quality research.  It is imperative that what is intended to be measured is actually 
measured, and the same or similar results are produced when the measurement process is 
repeated.  Two fundamental components of any measurement tool or measuring method are 
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validity and reliability.  Valid tools measure what they are intended to measure, while reliability 
is concerned with consistency of measures (DeVon et al., 2007; Salkind, 2006). 
Establishing reliability is the first step in making sure an instrument is psychometrically 
sound (Fleiss, Levin, & Paik, 2003; Portney & Watkins, 2009; Salkind, 2006).  While a measure 
can be reliable and not valid, it cannot be valid without also being reliable: It is meaningless to 
even ask what is associated with a variable when values given to it cannot be trusted (Fleiss et 
al., 2003; Salkind, 2006; Shrout, 1998). 
While numerous studies have examined PrU processes and outcomes (Bergquist-Beringer 
et al., 2013; Niederhauser et al., 2012, Soban et al., 2011; Sullivan & Schoelles, 2013), the 
processes themselves—as well as how they were measured—vary across studies.  Only one 
study used standardized measures of process indicators to evaluate PrU risk and prevention 
performance (Bergquist-Beringer et al., 2013).  Especially noteworthy, however, is that there is a 
scarcity of evidence supporting the reliability of the data on these process of care indicators; and 
no studies have examined the reliability of data collected from the NDNQI PrU risk and 
prevention process care measures. 
Statement of the Problem 
Healthcare consumers and payers demand that care be effective, efficient, timely, 
accessible, and cost-effective.  As a result, measuring and reporting performance indicators have 
become the norm.  Measurements of quality indicators guide improvement efforts, inform 
consumers, and are increasingly used by public and private payers for payment. 
While numerous research studies have been conducted on PrU prevention, recent 
literature reviews have shown that the majority of these studies have focused on patient 
outcomes (Niederhauser et al., 2012; Soban et al., 2011; Sullivan & Schoelles, 2013).  Few have 
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evaluated process of care measures.  In addition, how these process of care measures have been 
operationalized has varied.  Most concerning, however, is the lack of evidence for these 
measures’ reliability, even though reliability is crucial to ensure findings are credible. 
Because nursing is the largest group of professionals in the healthcare workforce, their 
impact on quality is significant.  It is crucial, therefore, that reliable nurse-sensitive indicators 
serve as a strong foundation for quality improvement efforts.  Although the NDNQI performs 
rigorous cleaning of data submitted to them by participating hospitals (Klaus, Dunton, Gajewski, 
& Potter, 2013), verifying the reliability of data is essential to establish their accuracy.  
Credibility of these PrU risk and prevention indicators is suggested by the fact that (a) CMS 
recognizes NDNQI as an accepted nurse registry for CMS’s reporting requirements, (b) 
submission of these indicators fulfill Magnet application requirements, and (c) select NDNQI 
indicators have been endorsed by the National Quality Forum (ANA, 2014).  However, no 
studies have evaluated the reliability of NDNQI pressure ulcer risk and prevention indicators. 
Significance 
This study is significant in that it is the first study to examine the inter-rater reliability of 
PrU risk and prevention data from the NDNQI.  Establishing reliability is necessary because the 
data are used to drive improvement efforts, yet their accuracy has not been established.  Because 
of the nation’s demand for quality patient care, the fact that nurses are the largest workforce in 
providing that care, and that the NDNQI collects nurse-sensitive process measures for PrU risk 
and prevention from more than 1,400 hospitals across the U.S., there is widespread interest in 
the findings this data generates.  Those involved with the NDNQI, therefore, should ensure data 
are accurate. 
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Specific Aims and Research Questions 
Purpose Statement: The purpose of this study was to examine the reliability of the NDNQI 
pressure ulcer risk and prevention measures.  The specific aims of this study are: 
Aim 1: Examine the reliability of the NDNQI pressure ulcer risk and prevention 
measures within and across NDNQI hospitals.  For this aim, this study used Cohen’s kappa, 
prevalence-adjusted kappa (PAK) (see discussion on p. 73 – 76), percent agreement, intraclass 
correlation coefficient (ICC), and agreement matrices/descriptive statistics. 
Question 1: What is the agreement between expert participant ratings and non-expert 
participant ratings for each of the 11 NDNQI pressure ulcer risk and prevention measures within 
each hospital?  This question was answered by hospital.  A Cohen’s kappa value for each of the 
expert to non-expert comparisons was calculated for every risk and prevention measure.  The 
Cohen’s kappa values obtained from these comparisons for each measure were averaged.  This 
yielded one Cohen’s kappa value for each of the 11 NDNQI risk and prevention measures per 
hospital.  Prevalence-adjusted kappa (PAK) values and percent agreement were calculated in the 
same way to obtain one PAK value and one percent agreement value for each of the 11 NDNQI 
risk and prevention measures per hospital. 
Question 2: What is the overall agreement between expert participant ratings and non-
expert participant ratings for the NDNQI PrU risk measures per hospital and the overall 
agreement between expert participant ratings and non-expert participant ratings for the NDNQI 
PrU prevention measures per hospital?  The average Cohen’s kappa value obtained for each 
measure in Question 1 was used to answer Question 2.  Specifically, the average Cohen’s kappa 
value obtained at each hospital from the expert and non-expert comparisons for each of the five 
PrU risk measures (skin assessment on admission, risk assessment on admission, time since last 
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risk assessment, risk assessment scale, and risk status) was averaged to obtain one overall kappa 
value for pressure ulcer risk per hospital.  Similarly, the average Cohen’s kappa value obtained 
from the expert and non-expert comparisons for each of the six PrU prevention measures (any 
PrU prevention, skin assessment, pressure-redistribution surface use, routine repositioning, 
nutritional support, and moisture management) at each hospital was averaged to obtain one 
overall Cohen’s kappa value for PrU prevention per hospital. 
Using this same method, each hospital’s average PAK value obtained in Question 1 for 
each measure was used to answer Question 2.  Specifically, the average PAK value obtained 
from the expert and non-expert comparisons for each of the five PrU risk measures (skin 
assessment on admission, risk assessment on admission, time since last risk assessment, risk 
assessment scale, and risk status) at each hospital were averaged to obtain one overall PAK value 
for pressure ulcer risk per hospital.  Similarly, the average PAK value obtained from the expert 
and non-expert comparisons for each of the six PrU prevention measures (any PrU prevention, 
skin assessment, pressure-redistribution surface use, routine repositioning, nutritional support, 
and moisture management) at each hospital were averaged to obtain one overall PAK value for 
PrU prevention per hospital. 
Question 3: What is the average of the within hospital agreements between expert 
participant ratings and non-expert participant ratings for each of the 11 NDNQI pressure ulcer 
risk and prevention measures across hospitals?  The average Cohen’s kappa value that was 
obtained for each measure to answer Question 1 was used to answer Question 3.  Specifically, 
the average Cohen’s kappa value that was obtained for each pressure ulcer risk and prevention 
measure at each hospital was averaged across hospitals to obtain one Cohen’s kappa value for 
each risk and prevention measure across hospitals.  Similarly, the average PAK value that was 
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obtained for each pressure ulcer risk and prevention measure at each hospital was averaged 
across hospitals to obtain one PAK value for each risk and prevention measure across hospitals.  
In addition, the average percent agreement value that was obtained for each PrU risk and 
prevention measure per hospital was averaged to obtain the percent agreement for each risk and 
prevention measure across hospitals. 
Question 4: What is the intraclass correlation coefficient (agreement) between expert 
participant ratings and non-expert participant ratings for each of the 11 NDNQI PrU risk and 
prevention measures across hospitals?  To answer this question, the Cohen’s kappa value 
obtained from each of the expert to non-expert comparisons per risk and prevention measure at 
each hospital, was used to calculate an ICCkappa for each of the 11 NDNQI risk and prevention 
measures across hospitals.  Similarly, the PAK value from each of the expert to non-expert 
comparisons per risk and prevention measure at each hospital was used to calculate an ICCPAK 
for each of the 11 NDNQI risk and prevention measures across hospitals. 
Question 5: Where is the lack of agreement between expert and non-expert participant 
ratings on the 11 NDNQI pressure ulcer risk and prevention measures occurring?  For instance, 
is the lack of agreement most often between “No” and “Unnecessary for patient”, or “No” and 
“Patient refused”, and least often between “No” and “Yes”?  To answer this question, agreement 
matrices and descriptive statistics were created. 
Aim 2: Examine the methods and processes used by participant raters to gather data on 
the NDNQI PrU risk and prevention measures.  Descriptive analysis was used to address Aim 2. 
Conceptual Framework 
Donabedian’s model of measuring healthcare system performance (Donabedian, 1978) 
guided this study.  Donabedian (1919 – 2000) was a physician and health services researcher.  In 
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1966, while teaching at the University of Michigan, Donabedian first identified his structure-
process-outcome model.  This model posits that healthcare quality is influenced by structures, 
processes, and outcomes; each of which influences the others.  Donabedian’s purpose for 
building this model was to develop a sound method for evaluating healthcare quality because, at 
that time, he found the current methods of evaluating care to be inadequate (Donabedian, 2005).  
Donabedian’s 1966 article, reprinted in 2005 (Donabedian, 2005), is considered a citation classic 
among healthcare systems research (Frenk, 2000).  His early model was criticized for being too 
linear (Mitchell, Ferketich, & Jennings, 1998), and was modified to give details of the give-and-
take relationships among “the system, interventions, client, and outcome components” (Duffy, 
2009, p. 29).  Provision of patient care, therefore, is mediated by characteristics of the patient 
and the system; and outcomes are influenced by all the variables in the model.  The more current 
model, therefore, reflects multidirectional relationships between the concepts of structure, 
process, and outcome, and is used by the NDNQI; offering a comprehensive method for 
evaluating nursing-sensitive measures as they relate to healthcare quality (Montalvo, 2007). 
Donabedian’s modified model relevant to the NDNQI PrU outcome and process 
measures is presented in Figure 1.  Structures include characteristics of the community, 
institution, patient, and provider.  In general, structures are easily quantified and measured.  For 
this study, structures are operationalized as: (a) data collection team members’ characteristics 
that include expert status, job title, education level, review of the NDNQI Guidelines for Data 
Collection and Submission of Pressure Ulcers, completion of the NDNQI Pressure Ulcer 
Training program, other PrU data collection education, years as an NDNQI PrU data collector, 
other roles (besides chart reviewer) in NDNQI PrU data collection, wound care certification, and 
wound/skin care nurse status (b) the unit type that reflects the patient population in adult.  
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medical-surgical, medical, and surgical units; and (c) the hospital type of General Acute Care, 
number of staffed beds, teaching status, Magnet status, and metropolitan status 
Processes include the care itself, such as the activities that go on between the caregiver 
and the patient.  These patient care characteristics are to capture if the care is timely, appropriate, 
and comprehensive.  Measuring these characteristics, therefore, is challenging.  “Timely”, 
“appropriate”, and “comprehensive” must be defined, and those definitions vary among patient 
populations.  Processes considered relevant to PrUs by the NDNQI are the performance of 
routine skin assessments and PrU risk assessments, identifying PrU risk status, and 
implementation of appropriate PrU prevention interventions for those “at risk” (skin assessment, 
pressure-redistribution surface use, repositioning, nutritional support, and moisture 
management).  Pressure ulcer care process measures are rarely standardized measures, and data 
derived from them lack evidence of reliability. 
Outcomes measure the end result of care and include morbidity, mortality, prevalence, 
incidence, readmission, and adverse event rates; cost of services provided; and patient 
satisfaction and quality of life (Donabedian, 1978).  Outcomes considered relevant to PrUs by 
the NDNQI include HAPU rates, unit-acquired HAPU rates, and PrU stage/category (all 
stages/categories are included).  No outcomes were measured in this study. 
To test Donabedian’s model—the influence of structure and process on outcome—one 
must assume that care processes are being accurately and reliably measured.  Relevant to this 
study, the NDNQI uses Donabedian’s model to understand the influence of PrU processes on 
PrU outcomes.  The model implies that in order to understand the relationships between PrU 
processes and PrU outcomes, the reliability of the NDNQI PrU process measures have been 
established, however, this is something that has not been done.  Specifically, different NDNQI 
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data collectors evaluating the same patient should come to the same (or similar) conclusions 
about the performance of PrU risk and prevention.  This study addressed this gap. 
Definition of Terms 
Reliability 
Conceptual definition.  Reliability is “the degree to which observations or measures are 
consistent or stable” (Rosenthal & Rosnow, 2008, p. 757).  Reliability of the observed score 
(True Variance /Observed Variance) is written as (Waltz, Strickland, & Lenz, 2010): 
   True Variance  = 1.0 — Error Variance 
   Observed Variance    Observed Variance 
Operational definition.  Inter-rater reliability (IRR) is the degree to which two or more 
participant raters agree on their judgments of an outcome (Rosenthal & Rosnow, 2008).  The 
IRR parameters for this study are Cohen’s kappa, PAK, percent agreement, and intraclass 
correlation coefficients (ICCs). 
Kappa.  Kappa (k) is a statistical measure for inter-rater agreement and can be 
mathematically written as 
k = (Po - Pe) / (1 - Pe) 
where Po is the proportion of observed total agreement, and Pe is the proportion of agreement that 
is expected by chance (Feinstein & Cicchetti, 1990, p. 544).  Kappa, therefore, is the proportion 
of agreement greater than what is expected by chance alone (Sim & Wright, 2005). 
Prevalence-adjusted kappa.  Kappa can be adjusted for high or low category prevalence 
by using average cell counts of agreement (cells on the diagonal) in place of actual cell counts of 
agreement, while calculating kappa.  This is called prevalence-adjusted kappa (PAK) and is 
discussed in detail in Chapter II. 
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 Percent agreement.  Percent agreement is the proportion of cases that two raters agree in 
their ratings (Fleiss et al., 2003). 
Intraclass correlation coefficient (ICC).  The intraclass correlation coefficient (ICC) is 
the ratio of between-subjects variance to total variance.  Theoretically, an ICC has a possible 
value of 0 to 1.0 with 1.0 representing perfect reliability (Portney & Watkins, 2009).  However, 
an ICC will be negative when the average covariance within subjects is negative (Nichols, 1999).  
For the purpose of the study, ICC is defined as the ratio (Hart, Bergquist, Gajewski, & Dunton, 
2006): 
(Variability of kappa’s between hospitals) 
(Variability of kappa’s between hospitals) + (Variability of kappa’s within hospitals)  
Therefore, an ICC near zero is desirable and suggests within-hospital variance is much greater 
than between-hospital variance (Hart et al., 2006). 
Expert 
Because an expert is considered to have a high degree of skill in PrU data collection, and 
a high level of knowledge about skin and wound care; expert is operationalized as the person 
identified by each site coordinator as the individual with the most experience and/or skill in chart 
abstraction on the PrU data collection team.  The non-expert rater is defined as (a) not the 
expert, and (b) part of the PrU data collection team who usually reviews patient records for data 
on PrU risk and prevention. 
Pressure Ulcer Risk and Prevention 
Pressure ulcer risk is the degree to which a person is susceptible to develop a PrU.  Risk 
status is determined by a risk assessment tool (i.e. Braden or Norton Scales) and by clinical 
judgment based on the presence of other factors (e.g. advanced age, low body weight, current or 
previous PrU, poor perfusion, and co-morbidities).  Pressure ulcer risk is operationalized as the 
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performance of PrU risk assessment(s) and skin assessment(s), and determination of PrU risk 
status; as documented in the patient record.  Pressure ulcer prevention is minimizing risk for 
PrU development, and is operationalized as performance of a documented skin assessment, 
pressure redistribution surface use, routine repositioning as prescribed, nutritional support, or 
moisture management; within the 24 hours prior to data collection for patients “at risk” for PrU 
development. 
Participant Rater, Unit, and Hospital Characteristics 
Participant rater characteristics are the characteristics of the chart abstractors and PrU 
team leaders.  The NDNQI data collection guidelines state PrU team leaders should be: (a) 
certified in wound care; or (b) have received formal education in skin assessment, PrU risk 
assessment, PrU identification/staging, and PrU prevention (Bergquist-Beringer & Davidson, 
2014).  Team members may be wound care certified, but before data collection they must receive 
training in PrU risk, identification, staging, prevention, data collection, and be skilled at reading 
patient health records.  Participant characteristics is operationalized as expert status, and self-
reported information on job title, highest level of education, review of the NDNQI Guidelines for 
Data Collection and Submission of Pressure Ulcers, other PrU training or review, years 
collecting NDNQI PrU data, other roles in NDNQI PrU data collection (besides chart abstractor), 
and wound care certification status.  The data collection team characteristic of interest is whether 
or not the PrU team is led by a certified wound nurse or wound/skin care nurse, as reported by 
participant raters at the time of participation in the study. 
Unit characteristics are the characteristics of the nursing unit from which data are 
collected.  This is operationalized as the unit identification (ID) code as recorded on the Data 
Collection Form by participant raters at the time of data collection.  Unit ID identifies unit type.  
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Unit type included adult medical-surgical, adult medical, and adult surgical units.  Unit ID was 
the unit identifier code that NDNQI uses to identify each unit within that hospital. 
Hospital characteristics are characteristics of the hospital from which data are collected, 
and is operationalized as staffed bed size, hospital type (General Acute Care), Magnet status, 
teaching status, and metropolitan status; as found on record with the NDNQI.  All variables are 
discussed in detail in Chapter III. 
Assumptions 
1. Data collectors use multiple sources to gather PrU data, such as the electronic health 
record, paper patient records, direct observation, and input from patient care staff. 
2. Participant raters rated patients independently of each other. 
3. During the study, participant raters rated patients in a manner similar to how they rate 
patients during routine NDNQI PrU data collection. 
4. Participant raters provided thoughtful and accurate responses. 
5. “Expert” participant raters were accurately identified. 
6.  “Expert” participant raters accurately rated patients on the PrU risk and prevention items. 
7. Documentation in the patient record accurately reflected performance of process 
measures. 
8. Intra-rater reliability was assumed.  
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CHAPTER II:  REVIEW OF THE LITERATURE 
 
Pressure ulcers are considered avoidable and due to poor quality of care (Black et al., 
2011).  The first step in decreasing pressure ulcers is PrU prevention.  Clinical Practice 
Guidelines have been published that translate what is known about interventions to prevent PrUs 
for healthcare use.  The NDNQI® collects data on PrU risk and prevention for quality 
improvement purposes to decrease PrU rates.  The reliability of this data, however, has not been 
reported.  This chapter will review (a) national quality indicators on PrUs, (b) recommended PrU 
prevention interventions, (c) PrU prevention programs, (d) criteria for a sound measure, and (e) 
reliability studies of the NDNQI PrU measures. 
National Quality Indicators on Pressure Ulcers 
Quality is a complex and abstract term.  In 2007—while Director of the Agency for 
Healthcare Research and Quality (AHRQ)—Carolyn Clancy, MD defined quality in healthcare 
as “the right care, for the right person, at the right time; the first time” (Clancy, 2008, slide #3).  
The Institute of Medicine (IOM) defined quality care as care that is safe, timely, effective, 
efficient, equitable, and patient-centered (IOM, 2001). 
Established in 1970, the IOM is an independent, non-profit organization that provides 
recommendations to decision makers regarding the nation’s healthcare system (IOM, 2013).  In 
1999, the IOM released its report “To Err is Human: Building a Safer Health System” (National 
Research Council, 2000).  This report identified PrUs as a commonly occurring adverse event, 
and recommended strategies to reduce them.  These recommendations included voluntary and 
mandatory reporting of adverse events, including PrUs.  As a result, many state laws were passed 
in 2003 to 2005 mandating hospitals report PrUs and other adverse events.  Mandatory reporting 
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within Minnesota found Stage III, Stage IV, and unstageable PrUs, were the most commonly 
occurring serious adverse health event in 2013 (Minnesota Department of Health, 2014). 
Healthcare quality varies across settings and individuals, and this variability is not clearly 
associated with dollars spent (Clancy, 2008).  As a result, Congress enacted the Medicare 
Modernization Act of 2003, which mandated that the IOM examine healthcare quality (Library 
of Congress, 2003).  With the goal of improving quality and safety by reducing the number of 
adverse events, The Patient Safety and Quality Improvement Act of 2005 (Patient Safety Act) 
established a system for voluntary reporting of adverse events (including Stage III, Stage IV, and 
unstageable PrUs) and medical errors (Department of Health and Human Services, n. d.).  To 
encourage participation, the confidentiality of this patient safety information is federally 
protected.  Concomitant efforts to improve quality have been put forth by governmental agencies 
such as the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare 
and Medicaid Services (CMS); and private organizations such as the National Quality Forum 
(NQF), and the Joint Commission (IOM, 2005).  These efforts include strategies to reduce PrU 
occurrence. 
The Agency for Healthcare Research and Quality (AHRQ) 
The AHRQ is a federal agency within the Department of Health and Human Services 
(AHRQ, 2012a).  Established in 1989 in response to the Omnibus Budget Reconciliation Act of 
1987, the AHRQ focuses on research to improve the quality, safety, efficiency, and effectiveness 
of healthcare.  To achieve its goal, the AHRQ has developed indicators to measure hospital 
healthcare quality from available inpatient data, including PrUs. 
Patient Safety Indicator #3 and Pediatric Quality Indicator #2.  The AHRQ quality 
indicators on PrUs include Patient Safety Indicator (PSI) #3 and Pediatric Quality Indicator 
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(PDI) #2.  These quality measures are derived from claims data; specifically the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, diagnostic 
related groups (DRGs), and patient age and/or gender if included in the claims data (AHRQ, 
2012b).  The PSI #3 is defined as the number of medical/surgical discharges with a secondary 
diagnosis (not present on admission) of a Stage III, Stage IV, or unstageable PrU per 1,000 
discharges, for those adults (18 years of age and older) hospitalized at least 5 days (AHRQ, 
2013b & 2013c; Zhan & Miller, 2003).  The PDI #2 is almost identical to the PSI #3, except the 
PDI #2 is for those 17 years of age or younger, excluding neonates (AHRQ, 2012b).  Because 
PSI #3 and PDI #2 count only Stage III, IV, and unstageable PrUs, they underestimate the rate of 
all hospital-acquired PrUs by as much as 70% (Bergquist-Beringer et al., 2013; VanGilder et al., 
2013).  Further underestimation is likely because PSI #3 and PDI #2 do not count PrUs among 
those who: (a) are hospitalized less than 5 days; (b) have paralysis; and (c) are transfers from 
skilled nursing facilities, intermediate care, or other hospitals. 
The reliability and validity of PSI #3 and PDI #2 were established during their 
development (Fabian & Geppert, 2011).  The Agency for Healthcare Research and Quality 
(AHRQ) indicator development takes approximately 20 months, and implementation 1½ months.  
Development begins with an extensive literature review.  An expert panel is involved from the 
early stages of development, and continues until the measure is retired.  Technical specifications, 
importance, scientific acceptability, and usability were established.  The feasibility of the PSI #3 
and PDI #2 (as well as the full set of indicators) was pilot tested.  Ongoing reliability and validity 
is empirically examined, though only measures that have support for their validity and reliability 
receive National Quality Forum endorsement (NQF, 2013d).  The PDI #2 is a NQF-endorsed 
measure; the PSI #3 is not. 
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The reliability of the PSI #3 was recently supported by Schone, Hubbard, and Jones 
(2011).  The purpose of their analysis was to provide hospitals with information on the reliability 
and minimum case thresholds for the CMS’s outcome measures proposed for use in the 2014 
Hospital Value-Based Purchasing Program.  Discharge/claims data that were submitted between 
March 2010 through September 2010 to measure value-based purchasing performance were used 
to estimate the reliability of the PSI #3 measure at 6, 12, 18 and 24 months.  A minimum median 
acceptable reliability level of .4 was established by Schone and colleagues.  The study 
determined that the median reliability at 6, 12, 18, and 24 months was .82, .90, .93, and .95 
respectively.  For 6 months of data, the minimum number of cases at which reliability reached .4 
was a reasonable N = 44 PrUs. 
The PSI #3’s validity, however, was questioned when the validity of 
administrative/claims data—such as diagnostic codes used by the AHRQ and CMS to calculate 
HAPU rates—was questioned.  In 2009, from a sample of 196 hospitals in California, Meddings 
et al. (2013) conducted a retrospective analysis of nearly 2 million all-payer administrative 
(discharge) records and 96,355 patients’ surveillance data.  Hospital-acquired Stage II or higher 
PrU rates were determined from administrative (discharge/HAPU incidence) data or surveillance 
(patients examined/point prevalence) data.  Meddings and colleagues expected 
administrative/claims data to return lower HAPU2+ rates than surveillance data because “point-
prevalence assessments collect more data from patients with longer lengths of stay” (p. 508), 
which is a consequence of PrU.  One could argue, however, that the opposite is true because 
point-prevalence data may miss patients who develop a HAPU after direct examination of the 
patient.  When administrative data were used to calculate HAPU2+ rate, the mean rate was 
0.15%, 95% CI [0.13% - 0.17%], compared to a 2.0% rate, 95% CI [1.8% - 2.2%] calculated 
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from surveillance data.  The significance of this difference is even more alarming because three 
of the 49 hospitals found to be in the highest (worst) quartile of HAPU2+ rates (as determined by 
administrative data); were ranked as “superior” when HAPU2+ rates were calculated from 
surveillance data.  Also, 14 other hospitals labeled “worst hospitals” by administrative data, were 
considered “above average” when surveillance data were used.  Certainly, this questions if 
administrative data alone should be used to compare hospitals’ HAPU2+ rates. 
The reliability of PDI #2 has also been questioned.  Although Scanlon, Harris II, Levy, 
and Sedman (2008) found PDI #2 had the highest positive predictive value (51.4%) among all 
PDIs; a later study by Bardach, Chien, and Dudley (2010) reported that only 4 out of 353 (1.1%) 
hospitals in California had the minimum number of 5,956 PDI #2 cases (over 3 years) to allow 
for identification of hospitals with pediatric HAPU rates twice the state’s average.  This two-fold 
“poorer performance” was determined a priori in order to identify “what could be considered a 
moderate deficiency” in providing quality patient care (p. 267). 
Patient Safety Organization – Common Format for pressure ulcers.  Besides the PSI 
#3 and the PDI #2, the AHRQ also collects data on PrUs through the Patient Safety Organization 
(PSO) (AHRQ, n.d.a).  The PSO was sanctioned by the Patient Safety Act of 2005, with the 
purpose of allowing healthcare providers to report quality and patient safety data without fear of 
legal discovery.  The PSO is comprised of public, private, for-profit, and not-for-profit 
organizations; to which hospitals voluntarily submit data on patient safety events.  These 
organizations are regulated and managed by the AHRQ, and allow for confidential collection, 
aggregation, and analysis of patient event data.  Although hospitals voluntarily submit data on all 
PrU stages/categories, the PSO reports only Stage III, Stage IV, and unstageable PrUs.  These 
same stages are included in the PSI #3 and PDI #2; but the PSI and PDI are from 
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administrative/claims data, their submission is not voluntary, and they are used for 
reimbursement purposes. 
For AHRQ PSO data on PrUs, information is collected using the Pressure Ulcer Common 
Format (AHRQ, n. d.a).  The PrU process and structure measures included in the Pressure Ulcer 
Common Format are: (a) performance of a PrU risk assessment (when performed, what scale 
was used, and risk status); (b) PrU prevention (use of a pressure-redistribution surface, 
repositioning, hydration/nutritional support, and skin care practices); (c) risk factors (devices or 
appliances); and (d) contributing factors (not specified) (AHRQ, 2013a).  The first two align with 
the NDNQI pressure ulcer risk and prevention process measures.  Unlike the PSI #3, the PDI #2, 
and the PSO; the NDNQI counts and reports all PrU categories/stages, and includes patients 
hospitalized less than five days, patients with paralysis, and patients transferred from other 
facilities. 
The Centers for Medicare and Medicaid Services (CMS) 
Medicare and Medicaid were enacted into law in 1965 (CMS, 2013b).  The Deficit 
Reduction Act of 2005 required the Secretary of the Department of Health and Human Services 
to identify hospital-acquired conditions (HACs) that (1) are high-cost or high-volume, (2) result 
in a diagnosis-related group (DRG) with a larger payment as a secondary diagnosis than as a 
primary diagnosis, and (3) are preventable.  Currently there are eight HACs—one is Stage III or 
Stage IV HAPU.  Effective October 2008, CMS no longer reimburses providers for treatment of 
hospital-acquired Stage III or Stage IV PrUs (QualityNet, n. d.).  Private insurers followed suit 
(O’Reilly, 2008).  Blue Cross and Blue Shield of Connecticut stopped reimbursing providers for 
treatment of any current or future CMS-identified HAC in March of 2012 (Blue Cross & Blue 
Shield, 2012). 
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Hospital-acquired conditions data come from discharge (administrative/claims) data, data 
with questionable accuracy (Coomer & McCall, 2012; Meddings et al., 2013; Schone et al., 
2011).  Coomer and McCall (2012) examined Medicare claims data (for the years 2009 and 
2010) to determine the accuracy of PrU coding.  These codes are used by CMS to determine the 
HAC of hospital-acquired Stage III or Stage IV PrU rates.  Pressure ulcers are coded by a site 
code and a stage code.  Because CMS does not reimburse for treatment of Stage III or Stage IV 
PrUs, hospitals have reason to miscode PrU stage.  For instance; a Stage III HAPU may be 
miscoded as a Stage II, and a Stage II present-on-admission PrU may be miscoded as a Stage III.  
Another coding concern is that only the first eight secondary-diagnoses are recorded in the 
Medicare data system, but hospitals are not required to list a PrU stage code among the first 
eight.  In other words, while a PrU site code will likely appear among the first eight secondary 
diagnoses, the PrU stage code is often omitted.  Coomer and McCall (2012) found that in 2009 
only 54% of claims with a secondary diagnosis for PrU site had a secondary diagnosis for PrU 
stage.  This increased to 61% in 2010.  When only the first eight secondary-diagnoses were used, 
Stage III or IV HAPU rates were 30% to 62% lower than rates calculated using all secondary 
diagnoses (i.e. beyond the first eight).  The larger the hospital, the less likely a PrU stage code 
accompanied a PrU site code.  Because of these issues, the CMS has now revised their data 
system to include 25 diagnosis codes and 25 procedure codes per claim (Coomer & McCall, 
2012). 
Others have confirmed these doubts about the reliability of the CMS HAC measure. 
Schone and colleagues (2011) examined the reliability estimates and minimum case thresholds 
for the 2014 Hospital Value-Based Purchasing Program measures.  The median reliability 
estimates for 6, 12, 18, and 24 months of PrU data were R = .28, .40, .50, and .53 respectively.  
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At least 12 months of data, therefore, are required for CMS’s PrU data to be reliable at the 
minimum level of R = .4.  In addition, the minimum number of cases at which R reached .4 was 
2,195 Stage III or IV PrUs.  This is much larger than the 44 PrUs needed for AHRQ’s PSI #3 to 
reach R = .4.  These investigators concluded the measure is unreliable in the short term and with 
smaller Stage III and Stage IV PrU rates.  Because of these issues, starting in 2015, CMS will 
use the PSI Composite #90 (which includes PSI#3) as its HAC measure (CMS, 2013a). 
From 2001 to 2007, CMS led the development and implementation of the Medicare 
Patient Safety Monitoring System (MPSMS) (Qualidigm, 2013a & 2013b).  This was done in 
collaboration with the AHRQ, the Centers for Disease Control and Prevention, the Food and 
Drug Administration, the Office of the National Coordinator for Health Information Technology, 
and the Veterans Health Administration.  Collectively these organizations are known as the 
Federal Agency Work Group (Qualidigm, 2013a).  In 2009, the AHRQ took over the primary 
responsibility for the MPSMS in partnership with CMS.  Using 21 measures, this national 
surveillance program has the goal of measuring adverse events among hospitalized patients, and 
includes all stages/categories of HAPUs (Hunt et al., 2005; Lyder et al., 2012).  The MPSMS 
data are collected from a subset of inpatient records and administrative/claims data (versus PSI 
#3, PDI #2, and CMS’s HAPU rates, which are based solely on claims data).  Each year a 
random sample of more than 40,000 hospital records are sent to one of two Clinical Data 
Abstraction Centers.  Until 2009, only Medicare recipients’ were included in the MPSMS.  Now 
this surveillance program also includes hospitalized patients 18 years of age or older; who were 
admitted for heart failure, acute myocardial infarction, pneumonia, or a subset of major 
surgeries.  Patients included in MPSMS account for 26% of the nation’s annual hospitalizations 
(Qualidigm, 2013a). 
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The reliability of the MPSMS is evaluated monthly: 40 randomly selected abstracted 
charts are exchanged between the two abstraction centers (Hunt et al., 2005).  Percent agreement 
between the two abstraction centers was 96.66%.  Accuracy of the raters was reported as 
98.03%; which is the agreement between the aggregated agreement of the two abstractors and 
the gold standard of the expert abstractor (Hunt et al., 2005).  Reporting only percent agreement, 
however, limits the usefulness of this reliability estimate because agreement due to chance alone 
is not accounted for (Fleiss et al., 2003). 
The Joint Commission 
The Joint Commission is an independent, non-profit organization that was established in 
1951.  Its mission is “to continuously improve healthcare for the public, in collaboration with 
other stakeholders, by evaluating healthcare organizations and inspiring them to excel in 
providing safe and effective care of the highest quality and value” (Joint Commission, 2013a, 
“Our Mission”).  The Joint Commission accredits more than 20,000 healthcare organizations 
(Joint Commission, 2013b). 
Each year, the Joint Commission publishes National Patient Safety Goals to promote 
improvements in patient safety (Joint Commission, 2013c).  Goal #14: Prevent health care-
associated pressure ulcers (decubitus ulcers), applies only to long-term care settings (Joint 
Commission, 2013c).  Meeting Goal #14 includes (1) creating a written plan for identifying PrU 
risk and prevention, (2) performing a PrU risk assessment upon admission, (3) performing a 
systematic PrU risk assessment using a validated tool, (4) reassessing risk at intervals determined 
by the facility, (5) implementing PrU prevention measures for identified risks, and (6) educating 
staff on PrU risk and prevention (Joint Commission, 2013c).  These align with the 
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NPUAP/EPUAP/PPPIA guidelines (NPUAP, EPUAP, & PPPIA, 2014) and—with the exception 
of staff education—are similar to the NDNQI pressure ulcer risk and prevention measures. 
The Robert Wood Johnson Foundation provided funding to The Joint Commission for the 
testing of NQF-endorsed measures, including the PrU measure; NQF 0201.  The NQF 0201 is 
HAPU2+ prevalence among acute care patients.  This measure is the same as the HAPU2+ 
measure from the NDNQI.  The Joint Commission evaluated the reliability of PrU data by 
conducting on-site reliability testing in 19 of 20 randomly selected sites from April through 
August 2008 (Joint Commission, 2010).  Based in part on the results of these reliability tests, the 
HAPU2+ measure was subsequently endorsed by the NQF.  However, the Joint Commission 
wants to retire their stewardship of this measure because they lack the ability to maintain it 
(Munthali & Morsell, 2013).  This makes sense because the commission does not collect data on 
NQF 0201.  Others will need to take over stewardship of this measure if it is to continue (S. 
Bergquist-Beringer, personal communication, December 18, 2013). 
The National Quality Forum (NQF) 
The NQF is a nonprofit, consensus standards-setting organization established in 1999 
with the mission of improving the nation’s healthcare (NQF, 2003& 2013a).  It endorses 
standardized performance measures through a rigorous process that relies on stakeholder input 
and empirical support:  It does not develop performance measures (NQF, 2013c).  Since 2004, 
the NQF has endorsed hundreds of quality of care indicators aligned with organizational 
(Hospital Quality Alliance, CMS, Joint Commission) and legislative (Deficit Reduction Act) 
measurement requirements (A Crosswalk, n. d.; NQF, 2013c). 
The NQF-endorsed measures specific to PrUs, the target population, and the stewards 
for each include (NQF, 2013b): 
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Outcome measures.  (1) NQF 0181 Increase in number of PrUs (Stages I through IV) 
among home health patients, uses Outcome and Assessment Information Set data (OASIS-C 
form), CMS is the steward; (2) NQF 0201 HAPU2+ point-prevalence among all inpatient 
settings, Joint Commission is the steward; (3) NQF 0337 HAPU2+ rate among hospital/acute 
care patients < 18 years of age, excluding neonates [AHRQ’s PDI #2], the steward is the 
AHRQ; (4) NQF 0678 Percentage of residents or patients with a Stage II through IV PrU that 
are new or worsened among short-stay (≤ 100 days) nursing home/rehab/long-term care 
patients, the steward is CMS; and (5) NQF 0679 Percentage of high risk residents with a Stage II 
through IV PrU among long-stay (> 100 days) hospital/acute care patients, CMS is the steward. 
Process measure.  (1) NQF 0538 PrU prevention and care among home health 
patients—which includes performance of PrU risk assessment, PrU prevention included in the 
plan of care, and PrU prevention implemented during short stays; CMS is the steward.  It is 
noteworthy that there is only one endorsed process measure, and it does not apply to hospitalized 
patients or long-term care residents.  This underscores the need for reliable PrU risk and 
prevention measures for use among acute-care patients.  Addressing this need is the purpose of 
this study. 
The National Quality Forum (NQF) criteria for evaluating the quality of measures for 
endorsement were first published in September of 2003 (Joint Commission, 2014).  Since then, 
numerous revisions have taken place.  Their latest version was published in October, 2013 (NQF, 
2013e).  Measure endorsement is a rigorous process (see Appendix A) and NQF-endorsed 
measures are held as the gold standard of performance measures (NQF, 2013d).  Candidate 
measures submitted for endorsement are examined by a broad and varied group of experts who 
use a consensus-based process of providing input that evaluates: (1) the importance of what is 
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being measured (clinical evidence, performance gap, and priority); (2) if the proposed measure 
meets scientific standards (reliability and validity); (3) feasibility; (4) usability 
(accountability/transparency, improvement); and (5) related or competing measures (NQF, 
2013d & 2013e).  While candidate measures will meet each of these criterions to varying 
degrees, the measure must meet the minimum acceptable level for the first two—which includes 
reliability, or it will not be evaluated on the other three criteria. 
Importance pertains to if (a) the measure assesses a healthcare or patient outcome that is 
related to a process or structure, (b) there is opportunity for improvement in the problem, and (c) 
the measure addresses a high-priority or high-impact aspect of healthcare.  If the measure 
evaluates a process or structure, versus an outcome (such as the NDNQI process measures that 
were evaluated in this study), it can still be endorsed if it is based on a systematic review and 
evidence that corresponds with what is being measured.  It appears from these initial evaluation 
criteria that the NQF is more interested in outcome measures, because the endorsement process 
is more streamlined for outcome measures, than process or structure measures (see Algorithm 1 
in Appendix A).  Scientific acceptability indicates the measure’s reliability and validity has been 
empirically and appropriately supported.  Percent agreement does not fulfill the reliability 
requirement (see Algorithm 2 in Appendix A).  Feasibility represents that the data are readily 
available, and data collection does not impose undue burden.  Usability reflects that those who 
want the data have access to them, and the degree to which using the measure leads to improved 
quality of healthcare.  Finally, a measure should not compete with other endorsed or related 
measures, or it must be clearly superior to such measures in order to justify its use.  EMeasures 
are evaluated using the same criteria as non-emeasures (NQF, 2013e). 
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Recommended Pressure Ulcer Prevention Interventions:  Literature Review 
The etiology of PrUs is complex and poorly understood (Ratliff et al., 2010).  Theories of 
PrU development include (a) tissue ischemia due to capillary occlusion leading to tissue anoxia 
and death, (b) tissue injury due to reperfusion of ischemic tissue, (c) lymphatic dysfunction 
resulting in an accumulation of metabolic wastes, and (d) mechanical bending/twisting of tissues 
(Kottner, Balzer, Dassen, & Heinze, 2009; Peirce, Skalak, & Rodeheaver, 2000).  These theories 
are the basis for recommended interventions that minimize pressure and shear.  In order to 
implement appropriate PrU prevention interventions, first an individual’s risk for PrU 
development must be identified. 
Pressure Ulcer Risk Assessment 
Tools to assess PrU risk have been available and used for decades.  There are more than 
40 PrU risk assessment scales (Kottner & Balzer, 2010).  The most commonly used, however, 
are the Norton Scale, the Waterlow Scale, and the Braden Scale (Anthony, Papanikolaou, 
Parboteeah, & Saleh, 2010).  The Norton Scale has been in use the longest, 48 years.  The 
Waterlow Scale is ever-present in the United Kingdom (Anthony et al., 2010), while the Braden 
Scale is the most commonly used tool in the U.S. (Armstrong et al., 2008).  All have subscale 
scores that are totaled to measure overall risk, and are based on factors related to PrU 
development.  Because more than 100 factors have been associated with PrU risk (Lyder & 
Ayello, 2008), it is not feasible for risk assessment tools to include them all; but tools should 
include factors known to have the greatest impact on risk.  This highlights the importance of 
using clinical judgment in conjunction with validated assessment tools while determining risk. 
Many studies have validated the use of the Braden Scale to identify patients at PrU risk 
(Bergstrom & Braden, 2002; Bergstrom, Braden, Kemp, Champagne, & Ruby, 1998; Bergstrom, 
Braden, Laguzza, & Holman, 1987; Kring, 2007).  There is debate, however, as to what 
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sensitivity and specificity are needed, and the problem of decreasing risk once identified.  Also, a 
risk assessment scale may have high sensitivity and specificity; but if effective PrU prevention is 
provided (and a PrU is avoided), sensitivity and specificity are decreased.  One could reason, 
therefore, that sensitivity and specificity appropriate for a screening tool are acceptable for these 
scales.  While it is difficult to have high sensitivity and high specificity, cut-off scores should be 
where the balance between the two is the most desirable.  A cut-off score is the score at which a 
person is classified “at risk”, and alerts care providers to implement appropriate PrU prevention 
interventions.  Commonly accepted cut-off scores for each scale are Norton (≤ 15 – 16), 
Modified Norton (≤ 20 – 21), Braden (≤ 18) (Källman & Lindgren, 2014), and Waterlow (≥ 17) 
(Serpa, Santos, Peres, Cavicchioli, & Hermida, 2011). 
Using a cross-sectional descriptive design, Källman and Lindgren (2014) examined the 
predictive value of four PrU risk assessment scales (Norton, Modified Norton, Braden, and their 
own Risk Assessment Pressure Sore).  Using the risk assessment scales and the Swedish version 
of the EPUAP minimum data set, data were collected during one day in November 2009 on 346 
adult inpatients (62% were > 70 years of age) at a hospital in Sweden.  Sensitivity, specificity, 
positive predictive values (PPV), and negative predictive values (NPV) were calculated for five 
different cut-off scores per scale.  The investigators found strong support for the use of the Risk 
Assessment Pressure Sore Scale and the Braden Scale.  For the Braden Scale, the best balance 
between sensitivity and specificity was at a cut-off score of ≤ 18 (sensitivity = 74.5%; specificity 
= 73.7%; PPV = 35%).  Others have confirmed similar sensitivity and specificity values for the 
Braden Scale (Bergstrom et al., 1998; Bergstrom et al., 1987; Bergquist & Frantz, 2001; Braden 
& Bergstrom, 1994; Defloor & Grypdonck, 2005; Tannen, Balzer, Kottner, Dassen, Halfens, & 
Mertens, 2010).  These values demonstrate the usefulness of the Braden Scale in screening for 
39 
PrU risk; and despite limitations, risk assessment tools are considered accurate predictors of PrU 
risk (AHRQ, 2011b; Anthony et al., 2010; Ayello & Braden, 2002; Chou et al., 2013). 
Few studies have linked performance of a PrU risk assessment with decreased PrU 
development (Anthony et al., 2010; Ratliff et al., 2010).  In 2010, Moore and Cowman (2010) 
updated a 2008 Cochran Review with the purpose of determining if use of a PrU risk assessment 
tool decreased PrU incidence.  The original (2008) review was unable to find a single study that 
met the inclusion criteria of (1) an RCT comparing the use of a structured PrU risk assessment 
tool to no structured PrU risk assessment, or to unaided judgment; or (2) an RCT comparing 
various structured PrU risk assessment tools to each other.  The updated (2010) review revealed 
that only one randomized study (Saleh, Anthony, & Parboteeah, 2009) met these criteria.  In this 
study, nurses (N = 256) from a military hospital in Saudi Arabia were randomized (by clusters of 
three nursing units per cluster) into one of three groups that received: (1) a mandatory wound 
care management study day, PrU prevention training with specific instruction on the Braden 
Scale, and then staff were required to implement the Braden Scale (n = 74); (2) identical to the 
first group, but staff were not required to implement the Braden Scale (n = 76); or (3) only the 
mandatory wound care study day (n = 106).  Interestingly there was a reduction in PrU 
occurrence within all groups.  No statistically significant difference in PrU incidence between the 
groups, however, was found.  The reviewers (Moore & Cowman, 2010), however, reported Saleh 
et al.’s (2009) study was underpowered.  Anthony et al. (2010) concluded that these (Saleh et al., 
2009) results suggest: (a) education may be the relevant factor, not the Braden Scale; and (b) 
being made aware of a problem improves it.  It is likely the routine performance of assessing PrU 
risk, not the scale used, is the relevant factor. 
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Nonetheless, risk assessment tools are widely used in hospitals to identify those at risk 
and determine appropriate prevention interventions (AHRQ, 2011b; Anthony et al., 2010; Ayello 
& Braden, 2002; Chou et al., 2013).  Anthony and colleagues (2010) reviewed research 
conducted on PrU risk scales—much of which was conducted by them over the past 25 years in 
an attempt to improve these scales.  They concluded that while risk assessment scales predict 
risk, there is no evidence that they reduce PrU development; and that this information is rarely 
sought in studies.  Use of a risk assessment tool, however, has been linked with improved 
performance of PrU prevention interventions.  Specifically, nurses performed prevention 
interventions more frequently and appropriately after training and implementation of the Norton 
Scale (Hodge, Mounter, Gardner, & Rowley, 1990).  Clinical guidelines advocate the use of risk 
assessment tools because they formalize and make routine the assessment of PrU risk 
(NPUAP/EPUAP, 2009; Ratliff et al., 2010).  No one tool, however, has been clearly identified 
as the most accurate PrU risk predictor (Chou et al., 2013; Ratliff et al., 2010; NPUAP/EPUAP, 
2009), and prevention guidelines state clinical judgment should be part of a PrU risk assessment 
(NPUAP/EPUAP/PPPIA, 2014; Ratliff et al., 2010). 
The exception to the findings of other researchers is a single study analyzing NDNQI data 
for the year 2010 (Bergquist-Beringer et al., 2013).  This study is presented in detail later in this 
chapter.  Specifically, after statistically controlling for hospital characteristics and nurse staffing, 
decreased odds of HAPU development were reported for those whose interventions included: (a) 
a PrU risk assessment on admission, OR = 0.82, 95% CI [0.73 – 0.92], p < .001; and (b) a PrU 
risk assessment performed within the 24-hour period before the data were collected, OR = 0.87, 
95% CI [0.81 – 0.92], p < .001.  Although the purpose of this study was to determine the process 
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measures that were associated with HAPU rates, results suggest that performance of risk 
assessment on admission sensitized staff to those who were at risk. 
Skin Assessment 
Early identification of erythema is important to prevent PrUs, and skin status has been 
identified as an independent risk factor for Stage II and higher PrU development (Nixon, Cranny, 
& Bond, 2007).  Among persons with a spinal cord injury; the association between routine, 
systematic, skin inspections—which involves looking and touching—and PrU occurrence is 
unclear.  Garber, Rintala, Hart, and Fuhrer (2000) performed a longitudinal cohort study of 118 
men with spinal cord injury who were living at home.  Researchers found that participants who 
self-reported having a Stage II or higher PrU within the year prior to data collection (n = 37, 
31%) were more likely to perform daily skin checks than those who had not developed a Stage II 
or higher PrU (92% versus 74%), χ2 = 4.98, df = 1, p = .03.  This is surprising because 
commonsense says frequent visual skin assessment would be especially important to prevent PrU 
development among those with loss of sensation.  These findings do not suggest regular 
performance of a skin assessment is associated with higher PrU rates, but rather that performing 
a skin assessment may not affect PrU rate among those with a spinal cord injury.  It is important 
to note this study did not directly measure completion of skin assessments, but rather participants 
retrospectively self-reported if they routinely performed daily skin inspections.  Current PrU 
prevention recommendations for those with a spinal cord injury include at least twice daily total 
body skin inspections (Schubart, & Hilgart, n. d.). 
Bergquist-Beringer et al. (2013), however, found different results when they analyzed 
NDNQI pressure ulcer data (collected in 2010) from more than 1,400 hospitals and 710,626 
patients.  Hierarchical logistic regression revealed a decreased risk of HAPU (all stages) for 
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those who: (a) received a skin assessment on admission compared to those who did not, OR = 
0.76, 95% CI [0.67 – 0.87], p < .001; and (b) received a daily skin assessment compared to those 
who did not, OR = 0.82, 95% CI [0.72 – 0.94], p = .003.  Maybe nurses who are more likely to 
perform (and document) routine skin assessments are more likely to engage in activities to 
prevent PrUs. 
The AHRQ (AHRQ, 2011b), the WOCN Society guidelines (Ratliff et al., 2010), and the 
NPUAP/EPUAP/PPPIA guidelines (NPUAP/EPUAP/PPPIA, 2014), recommend daily skin 
assessments.  Skin assessments may lead to earlier detection of PrUs than without these 
assessments.  More evidence, however, is needed to support that skin assessments prevent PrU 
development. 
Minimizing Shear 
This intervention used to be minimizing friction and shear.  The 2009 NPUAP/EPUAP 
pressure ulcer prevention and treatment guidelines, however, removed reference to friction as a 
factor of PrU development (NPUAP/EPUAP, 2009).  Friction is a concern because it may lead to 
harmful shear and strain on tissues.  To include shear and friction in the definition (of PrU) 
would be unnecessary as well as confusing because friction may cause blisters, which are not 
PrUs.  Shear, therefore, remains the primary causative factor and friction has been eliminated 
from the definition (Antokal et al., 2012).  Shear is “the mechanical force that is parallel rather 
than perpendicular to an area” (Ratliff et al., 2010, p. 48). 
A randomized control trial was performed in Japan by Nakagami et al. (2007) to examine 
the relationship of a specialized shear-reducing dressing on HAPU rates.  The sample consisted 
of 37 bed bound, elderly (M = 86.4 years of age) hospitalized patients at risk for PrU 
development.  The dressing was randomly placed on either the right or left greater trochanter for 
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three weeks, while the other trochanter was left without a dressing.  No HAPUs developed.  
Persistent erythema (defined as a blanchable reddened area that persists for at least 20 minutes), 
however, occurred less often on the trochanters with the dressing than the trochanters without the 
dressing, RR = 0.18, 95% CI [0.05 – 0.73], p = 0.007. 
Weng (2008) conducted a quasi-experimental study to compare the effectiveness of two 
dressings in preventing facial PrUs caused by (the pressure and shear exerted by) oxygen masks.  
These snug-fitting masks are commonly used in the ICU to maintain positive airway pressures.  
Ninety ICU patients (M = 76.4 years of age) in Taiwan received either no dressing (n = 30), 
Tegaderm (n = 30), or Tegasorb (n = 30).  Skin condition was assessed every 30 minutes—it was 
not stated how long these assessments continued and it was assumed assessments continued until 
a PrU developed or the mask was discontinued.  Frequent skin assessments were possible 
because the dressings were transparent.  Those who had a dressing (either one) had: (a) fewer 
face mask PrUs than the controls [no dressing (29/30, 96.7%), Tegaderm (16/30, 53.3%), and 
Tegasorb (12/30, 40%); p < .01]; and (b) a longer duration until PrU occurrence [no dressing 
(1,111 minutes), Tegaderm (2,628 minutes), and Tegasorb (3,272 minutes); p < .01].  
Interestingly, Weng did not find a relationship between PrU development and sensory 
perception, moisture, nutrition provided, nutritional condition, and serum albumin levels.  
Perhaps this is because only mask ulcers developed and were the focus of this study. 
Multivariate logistic regression was performed by Schindler et al. (2011) to identify 
prevention interventions associated with decreased HAPUs among 5,346 pediatric ICU patients; 
545 (10.2%) of whom developed a HAPU.  Data were collected via retrospective chart review on 
all pediatric ICU admissions during the 6-month study period.  The HAPUs were: Stage I 
(63.34%), Stage II (32.07%), Stage III (3.68%), and Stage IV (0.9%).  After controlling for age 
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and risk of mortality, lower odds of PrU development was associated with interventions that 
reduced shear such as: (a) keeping the head of the bed at or below 30º compared to more than 
30º, OR = 0.150, 95% CI [0.117 – 0.193], p < .001; (b) using a draw sheet compared to no draw 
sheet, OR = 0.575, 95% CI [0.403 – 0.820], p = .002; and (c) use of a breathable waterproof 
transparent dressing—not stated but assumed it was placed on the sacral area—compared to no 
dressing, OR = 0.713, 95% CI [0.516 – 0.985], p = .04.  Unfortunately, the generalization of 
findings is limited to at-risk pediatric ICU patients. 
Different results were reported by Brindle and Wegelin’s (2012) RCT of 85 cardiac ICU 
patients from a single CCU (M = 61.8 years of age).  The purpose of this study was to find out if 
use of a foam dressing would decrease sacral PrU incidence.  Participants received either 
standard PrU preventive care (n = 35), or standard preventive care with the application of a self-
adherent silicone border foam dressing (Mepilex®) over the sacrum (n = 50).  All participants 
were considered to be at “high” risk for PrU development.  Twenty-one covariates (such as 
HAPU rate, hours in the operating room, serum albumin levels, incontinence, and use of 
vasopressors) were measured.  No variable (including HAPU rate) differed significantly between 
the control and intervention groups.  The number of participants (by group) who developed at 
least one PrU was 4/35 (11%) for the controls, and 1/50 (2%) for the intervention group, p = 
.154.  Although researchers concluded a lack of statistical power, the difference between an 11% 
HAPU rate and a 2% HAPU rate would be significant to those who developed a HAPU, and 
those trying to prevent them. 
More recently, support for Mepilex® dressing use to prevent PrUs was presented in a 
literature review conducted by PrU prevention experts from Australia, Portugal, the U.K, and the 
U.S. (Black et al., 2014).  The purpose of this review was to present recommendations for wound 
45 
dressing use in PrU prevention.  Twenty-nine studies met inclusion criteria in that they 
considered wound dressing use in PrU prevention, were written in English or Spanish, and were 
published from 1998 to 2011.  Black and colleagues concluded that when used in conjunction 
with usual PrU prevention interventions, Mepilex® decreased PrU incidence; and should be 
applied (as early as upon arrival to the emergency department) to the sacrum, buttocks, and heels 
of those at risk for PrU development. 
Although Black and colleagues identified a specific dressing, no one dressing has been 
identified as the best dressing to decrease shear and HAPU rates.  Despite limitations, evidence 
supports minimizing shear in order to prevent PrU occurrence among all ages for those at risk for 
PrU development.  Pressure ulcer prevention experts recommend further research on wound 
dressings and shear (Black et al., 2014; NPUAP, 2013). 
Minimizing Pressure 
Pressure’s role in PrU development has been well-documented.  Kosiak’s 1959 article 
described the link between skin breakdown in dogs with the magnitude and time of exposure to 
pressure.  As early as 1930, mean arteriolar capillary pressure was determined to be 32 mm Hg 
(Landis, 1930).  Later, in 1976, Roaf (2006) reported this pressure to be the threshold below 
which tissues tolerate.  More recent research has focused on specific strategies to decrease 
pressure; such as body positioning, frequency of repositioning, and pressure-redistribution 
surfaces. 
Body position.  Defloor (2000) assessed interface pressure of 10 body positions on a 
standard mattress and a polyethylene-urethane pressure-redistribution mattress.  Interface 
pressure is the pressure on skin and underlying tissues due to the surface the patient is on.  Sixty-
two healthy adults volunteered for this study.  Defloor reported pressure on the sacrum and heels 
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was lowest in a semi-Fowler’s position—the head and the foot of the bed elevated 30º, while the 
lower legs are horizontal—relative to any supine position (the head of the bed flat; or raised 30º, 
60º, or 90º) on both mattresses.  In addition, a 30º (tilt) side lying position allowed for lower 
pressures than a 90º side lying position, which had the highest pressures of any position on either 
mattress.  A small (N = 46) RCT by Young (2004), however, found no difference in HAPU rates 
between a 30º tilt (3/23 = 13%) and 90º side-lying position (2/23 = 8.7%) among hospitalized 
elderly at risk for PrU development.  All PrUs (N = 5) were Stage I in the Young (2004) study; 
which was likely underpowered. 
A cross-sectional study by Moody, Gonzales, and Cureton (2004) was performed to 
measure interface pressures of four patient positions: when the head of the bed was elevated to 
45º, 60º, and 65º; and a 30º side lying with the head of the bed elevated 30º.  In addition, two 
mattresses were used; a polyethylene-urethane pressure-redistribution mattress and a dynamic air 
flow mattress.  Interface pressure was measured by the X-Sensor Pressure Mapping System.  
This system consists of a pad with pressure sensors throughout that is placed on the bed and 
displays pressure values along the body.  The sample included 20 adults with quadriplegia.  
Pressures increased—body location not specified but assumed bony prominences such as the 
sacral area—as the degrees of elevation of the head of the bed increased.  The 30º side lying 
position had the lowest pressures of all positions, on both mattresses.  This study supported 
Defloor’s (2000) findings that keeping the head of the bed as low as possible keeps pressure on 
tissues to a minimum. 
Heels are a common site of PrU development.  Fowler, Scott-Williams, and McGuire 
(2008) conducted a review of studies on interventions to prevent heel PrUs.  Among the eight 
studies included, all were published in 2007.  Key points were: (1) while evidence supports use 
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of pillows to offload heels, it is important pillows are used properly and actually keep pressure 
off heels; (2) heel offloading is the first step to prevent heel PrUs; (3) heel offloading decreased 
heel PrU incidence; and (4) heel padding devices are not the same as heel offloading devices, 
and therefore do not relieve heel pressure. 
Lyman (2009) reported on the effectiveness of a heel offloading device to decrease heel 
PrUs among 550 long-term care residents at risk for PrU development.  During the 6 months 
prior to the intervention, 39 facility-acquired heel PrUs occurred; with an incidence rate of 2.1% 
to 5% per month (3 to 13 heel PrUs/month).  The first 3 months after the intervention, the 
incidence of facility-acquired heel PrUs was 0% to 3.2% (0 to 15 heel PrUs/month).  No heel 
PrUs developed during the 4th, 5th, or 6th month post-intervention.  No information on statistical 
significance was reported. 
Evidence supports that offloading heels is associated with a decrease in heel PrU 
development.  The problem is doing it correctly.  If pillows are used, it is important to make sure 
they are firm enough and remain in place to properly offload heel pressure.  Care providers need 
to understand the difference between heel padding and offloading devices. 
Repositioning.  The effect of patient repositioning on PrU rates was examined by 
Defloor, De Bacquer, and Grypdonck (2005).  These investigators conducted an RCT that 
examined four different repositioning schedules among 838 long-term care patients, within 11 
facilities in Belgium.  The four schedules for repositioning were (a) every 2 hours on a standard 
mattress, (b) every 3 hours on a standard mattress, (c) every 4 hours on a pressure-redistribution 
(viscoelastic foam) mattress, and (d) every 6 hours on a pressure-redistribution (viscoelastic 
foam) mattress.  Within these facilities, 32 units were randomly assigned to perform one of the 
four repositioning schedules.  Each unit implemented the repositioning schedule for 4 weeks.  
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Then the randomization process was repeated and each unit implemented a different 
repositioning schedule for another 4 weeks.  Defloor and colleagues (2005) reported 
repositioning patients every 4 hours combined with the use of a viscoelastic foam mattress, 
significantly reduced HAPU2+ incidence, OR = 0.12, 95% CI [0.03 – 0.48], p = 0.003, when 
compared to the other repositioning schedules.  These data are difficult to interpret because the 
study design combined different repositioning schedules with different support surfaces. 
An RCT was conducted by Vanderwee, Grypdonck, De Bacquer, and Defloor (2007) 
from a sample of 235 nursing home residents among 84 units within 16 Belgian facilities.  All 
residents had viscoelastic foam (pressure-redistribution) mattresses.  Randomization was by 
ward.  The experimental group (n = 122) was alternated between a 2-hour lateral position, and a 
4-hour supine position.  The controls (n = 113) were repositioned every 4 hours.  The study 
continued for 21 months.  No statistically significant difference was found between the groups 
with regard to Stage II and higher PrU incidence (16.4% and 21.2% in the experimental and 
control groups respectively, p = .40), PrU severity (p = .65), and time to developing a PrU (p = 
.29).  With these high HAPU rates, one might argue that neither repositioning schedule was often 
enough.  In addition, many patients did not stay in the side-lying position, so results are difficult 
to interpret. 
Moore, Cowman, and Conroy (2011) conducted a cluster-RCT (by facility) to examine 
the effect of nighttime repositioning on PrU incidence among long-term care residents (N = 213) 
in 12 facilities in Ireland.  Study patients were repositioned from 8 p.m. to 8 a.m. in one of two 
ways: (1) using the 30º tilt (left, back, right, back) every 3 hours (experimental group, n = 99); or 
(2) using the 90º side lying position every 6 hours (control group, n = 114).  The routine daytime 
care of repositioning every 2 to 3 hours was maintained for all participants.  All study patients 
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were at risk for PrU, had no PrU at the start of the study, and were at least 65 years of age—53% 
were 81 to 90 years of age, and 13% were 91 to 100 years of age.  The researchers reported those 
in the experimental group (every 3 hours, 30º tilt) had lower odds of developing a PrU than those 
in the control group (every 6 hours, 90º side lying); OR = 0.234, 95% CI [0.067 – 0.879], p = 
.034.  All PrUs were Stage 1 (n = 7; 44%) or Stage II (n = 9; 56%) [total of 16 PrUs among 16 
patients].  Pressure ulcers developed in 3/99 (3%) participants repositioned every 3 hours using 
the 30º tilt group, and in 13/114 (11%) participants repositioned every 6 hours using the 90º side 
lying position; p = .035 95% CI [0.031 – 0.038].  Because this study randomized by facility 
(cluster randomization), an intra-class correlation (ICC = 0.001) by cluster was presented.  An 
ICC near zero is desirable and suggests in-cluster variance is greater than between-cluster 
variance.  In other words, variance in PrU rates can be attributed to the repositioning schedule, 
not the effect of being in a particular facility.  Unfortunately, findings do not reveal if the time 
between turning or the degree of tilt was responsible for improved HAPU rates. 
A secondary data analysis of data from a prospective cohort study (Baumgarten et al., 
2009) of 658 patients, from nine hospitals within Maryland and Pennsylvania, 65 years of age 
and older, and who underwent hip surgery, was performed by Rich et al. (2011a).  The purpose 
of this study was to examine the association between repositioning frequency and HAPU2+ 
incidence.  Secondary analysis included patients (n = 269) from the parent study who had their 
skin examined for PrUs at least once during the first five days of hospitalization, and were bed-
bound according to their Braden subscale score.  In the parent study, repositioning data were 
collected from the medical record, which counted how many times a patient was repositioned per 
day for the initial 5 days of hospitalization.  Also during the parent study, PrU status was 
assessed upon admission and on alternating days for 21 days—follow-up continued after 
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discharge from the hospital.  The analysis found no association between repositioning frequency 
and HAPU2+ rates.  This study is difficult to interpret because PrU incidence was determined 
over 21 days, while repositioning was assessed only the first 5 days of hospitalization.  In 
addition, the number of times someone is repositioned each day may not be associated with 
HAPU rates because time between repositioning is what matters.  For instance, someone may be 
repositioned 10 times over 3 hours, then left in the same position the rest of the day. 
Bergstrom et al. (2013) conducted a multi-site RCT to identify the best repositioning 
frequency for nursing home residents while on high-density foam (pressure-redistribution) 
mattresses.  The sample (N = 942) included residents 65 years of age and older (M = 85.1 years), 
from among 20 U.S. and 7 Canadian nursing homes, who were at moderate (n = 617) or high (n 
= 325; Braden Scale score ≤ 13) risk for PrU.  Participants were randomly assigned to a 2-hour 
(n = 321), 3-hour (n = 326), or 4-hour (n = 295) repositioning schedule for 3 weeks.  This 
random assignment was stratified according to the patient’s degree of risk for PrU (moderate or 
high risk).  The coccyx/sacrum, trochanters, and heels were examined weekly by blinded 
assessors.  Twenty-one PrUs (2 Stage I and 19 Stage II) on 19 participants developed.  There was 
no statistically significant difference in PrU incidence rates between the groups: 2-hour, 8/321 
(2.5%); 3-hour, 2/326 (0.6%); and 4-hour, 9/295 (3.1%); p = .68. 
The evidence suggests that repositioning every 4 hours while on a pressure-redistribution 
surface may be enough to prevent PrUs, but every 2-hour repositioning is typically considered 
the standard of care for those who cannot reposition themselves (AHRQ, n. d.b; Black et al., 
2011; Institute for Healthcare Improvement, 2011; NDNQI, 2013).  Routine repositioning is a 
mainstay of PrU prevention (NPUAP, EPUAP, & PPPIA, 2014).  The NPUAP acknowledges the 
need for further research on repositioning schedules (NPUAP, 2013). 
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Pressure-redistribution surface.  Pressure-redistribution surfaces (such as specialty 
mattresses or overlays that are filled with air, water, foam, gel, or a combination of these; 
dynamic surfaces such as alternating-pressure mattresses, and alternating-pressure overlays; and 
chair cushions) have been well-studied and found to reduce interface pressure (Chou et al., 2013; 
Reddy, Gill, & Rochon, 2006).  In fact, the large number of studies is “staggering and confusing” 
(Clancy, 2013, p. 58).  Randomized controlled trials on pressure-redistribution surfaces, 
however, are rare. 
Among the RCTs conducted, Nixon (2006) performed one to compare PrU development 
among those on an alternating-pressure mattress, to those on an alternating-pressure overlay.  
The sample (N = 1,972) included hospitalized persons at least 55 years of age (M = 75.2 years).  
Critical care admits and people considerably over or under weight were excluded.  No difference 
was found in HAPU rates between the two pressure-redistribution surfaces (10.3% and 10.7% 
for the mattress and overlay respectively).  Nixon (2006) found the only surfaces that 
consistently relieved sacral pressure were the low-air-loss and fluid-filled mattresses (not the 
overlays).  Unfortunately, the population most at risk for PrU, the critically ill and the 
underweight, were excluded from this study. 
Comfort’s (2008) meta-analysis began with a literature review to find studies that cited 
hospitals implementing the Braden Scale and subsequent use of a pressure-redistribution surface 
for those identified “at risk” for PrU.  Nine such hospitals/studies were found.  These studies 
were published from 1996 to 2000.  Each hospital measured HAPU prevalence before and after 
implementing the Braden Scale followed by best practices.  Although which prevention 
interventions were initiated varied across hospitals, all hospitals included some type of pressure-
redistribution surface in their PrU prevention protocol.  All hospitals reported improvement in 
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HAPU prevalence for patients who received the intervention (n = 2,593) compared to those who 
did not (n = 2,589), but the degree of improvement varied, OR = 0.335, 95% CI [0.22 – 0.508].  
The reviewers concluded that providing support surfaces after the appearance of a Stage I or II 
PrU was associated with failure of the surface to prevent PrUs advancing to a higher stage.  
Pressure-redistribution surfaces, therefore, should be provided to all at risk patients upon 
admission. 
A Cochran Review (McInnes, Jammali-Blasi, Bell-Syer, Dumville, & Cullum, 2012) of 
53 RCTs and quasi-randomized trials examined pressure-redistribution surfaces.  Reviewers 
concluded that: (1) foam alternative (pressure-redistribution) mattresses were associated with 
lower PrU occurrence than standard hospital mattresses, RR = 0.40, 95% CI [0.21 – 0.74]; (2) 
evidence is not clear as to the value of alternating- and constant-low pressure devices; (3) 
overlay use in the operating room decreased PrU occurrence for high-risk surgical patients and 
those with surgeries lasting > 3 hours; and (4) sheepskin use decreased PrU occurrence.  The 
reviewers recommended that those at risk for PrU development should be placed on any 
pressure-redistribution surface.  In addition, alternating-pressure mattresses may be more cost 
effective than alternating-pressure overlays. 
Using multivariate logistic regression, Schindler et al. (2011) identified prevention 
interventions associated with decreased HAPUs among 5,346 pediatric ICU patients; 545 
(10.2%) of who developed a PrU during hospitalization.  After controlling for age and risk of 
mortality, patients who were on a specialty bed had lower HAPU rates than patients not on a 
specialty bed, OR = 0.226, 95% CI [0.167 – 0.306], p < .001.  The type of specialty bed was not 
defined.  Also, PrU development was less likely for patients on a sheepskin, compared to patients 
not on a sheepskin, OR = 0.448, 95% CI [0.325 – 0.618], p < .001. 
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Different results were reported from Rich et al.’s (2011b) secondary analysis of data from 
a sample of 658 hospitalized persons who were at least 65 years of age (46.4% were ≥ 85 years) 
and had undergone hip fracture surgery at one of nine Baltimore area hospitals.  The purpose of 
this study was to determine the association between use of a pressure-redistributing surface and 
HAPU2+ incidence.  Upon admission and every other day for 21 days, patients were assessed for 
PrU presence, pressure-redistribution surface use, and bedbound status.  Because some patients’ 
hospital stay did not last 21 days, patient follow-up continued in the 105 post-acute care facilities 
to which these patients were discharged. 
The rate of HAPU2+ was compared between patients who had: (1) no pressure-
redistribution surface; (2) a powered pressure-redistribution surface (alternating-pressure 
mattresses, low-air-flow mattresses, or alternating-pressure overlays); and (3) a non-powered 
pressure-redistribution surface (high-density foam, static air, gel mattress, or overlay).  Because 
participants’ use of a pressure-redistribution surface was not necessarily consistent throughout 
the 21-day data collection period, HAPU2+ rates were presented per follow-up visit (versus per 
total patients).  In other words, a Stage II or higher PrU was found among (1) 195 of the 4,632 
visits (4.2% of visits) during which no pressure-redistribution surface was in use, (b) 28 of the 
623 visits (4.5% of visits) during which a powered pressure-redistribution surface was in use, 
and (c) 54 of the 1,496 visits (3.6% of visits) during which a non-powered pressure-redistribution 
surface was in use.  Analysis revealed no statistically significant difference in these rates (p = 
.52).  This data is difficult to interpret because it was cross-sectional and perhaps patients were 
put on a pressure-redistribution surface after they developed a PrU. 
A 2012 review of RCTs (N = 45) published from 2000 to 2010 was conducted by French 
investigators to determine which support surfaces should be used for PrU prevention and 
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treatment (Colin et al., 2012).  These RCTs compared different support surfaces to each other 
and/or to the standard hospital mattress.  The types of support surfaces examined varied widely 
across the studies.  Reviewers concluded (1) structured foam surfaces were more effective in 
preventing PrUs than standard hospital mattresses, (2) alternating-pressure mattresses were more 
effective in preventing PrUs than viscoelastic mattresses, (3) low-air loss mattresses were more 
effective at preventing heel PrUs than mixed-pulsating air mattresses, (4) some sheepskins 
decreased sacral PrU occurrence in orthopedic patients, and (5) the use of overlays in operating 
rooms decreased PrU occurrence among surgical patients. 
The AHRQ reviewed the evidence on the effectiveness of prevention interventions in 
decreasing PrU incidence or PrU severity (Chou et al., 2013).  Studies from 1946 to 2012 were 
searched for RCTs or cohort studies that examined the effect of prevention interventions on 
clinical outcomes (N = 120).  This review confirmed that use of a more advanced mattress or 
overlay is associated with fewer PrUs compared to standard mattress use; and that there is no 
clear evidence as to which pressure-redistribution surface is best to decrease PrU rates.  Other 
findings from this AHRQ efficacy study are presented within each intervention’s review that 
follows.  Similar conclusions regarding support surfaces were made by the NPUAP/EPUAP and 
the WOCN Society (NPUAP/EPUAP, 2009; Ratliff et al., 2010).  As clinicians and researchers, 
we can agree the standard hospital mattress should be replaced with one considered to 
redistribute pressure. 
Moisture Management and Skin Care 
An RCT with blinded assessors was conducted by Bates-Jensen, Alessi, Al-Samarrai, and 
Schnelle (2003a) to examine skin health outcomes (such as wetness, blanchable erythema, and 
PrUs) after an exercise and incontinence program.  The sample included 144 incontinent nursing 
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home residents (M = 87.5 years of age) among four nursing homes.  The intervention group (n = 
70) received exercise and incontinence care every 2 hours from 0800 to 1630, 5 days a week, for 
32 weeks.  The control group (n = 74) received usual care.  Twenty-two residents (15.3%) 
developed a Stage I or Stage II PrU: No PrUs higher than a Stage II occurred.  While those who 
received the intervention had better functional, incontinence, and skin wetness outcomes than the 
controls; there was no difference in PrU incidence rates between the intervention group (14.3%) 
and the controls (16.2%). 
Through retrospective chart review, Schindler et al. (2011) examined moisture 
management interventions associated with decreased HAPUs among 5,346 pediatric ICU 
patients; 545 of who developed a PrU during hospitalization.  After controlling for age and risk 
of mortality, decreased HAPU rates were associated with nursing care interventions to manage 
moisture that included: (a) use of dry-weave diapers, OR = 0.286, 95% CI [0.218 – 0.375], p < 
.001; (b) urinary catheter, OR = 0.441, 95% CI [0.347 – 0.559], p < .001; (c) use of disposable 
under pads, OR = 0.345, 95% CI [0.252 – 0.473], p < .001; and (d) application of body lotion, 
OR = 0.655, 95% CI [0.478 – 0.897], p = .008.  These two studies present different findings for 
two very different samples; the incontinent-elderly nursing home resident, and the critically-ill 
hospitalized pediatric patient.  Incongruent findings are likely due to the differences in sample 
characteristics, or that Schindler et al.’s (2011) study was so large even a small effect would be 
statistically significant. 
In addition to protection from excessive moisture, emollients should be used to hydrate 
dry skin (NPUAP, EPUAP, & PPPIA, 2014).  In a study of 286 hospitalized patients, 
multivariable Cox regression analysis revealed that those with dry skin were more likely to 
develop a HAPU than those without dry skin, RR = 2.31, 95% CI [1.02 – 5.21] (Allman, Goode, 
56 
Patrick, Burst, & Bartolucci, 1995).  The best emollient to prevent PrUs, however, has not been 
determined (NPUAP/EPUAP, 2009).  The  literature review performed by AHRQ (to examine 
the efficacy of PrU prevention interventions in reducing PrU rates) concluded evidence was 
meager and insufficient to form reliable conclusions as to the effectiveness of lotions, creams, 
and cleansers to prevent PrUs, compared to standard care (Chou et al., 2013). 
Nutritional Support 
For decades, low serum protein levels have been associated with poor wound healing 
(Thompson, Ravdin, & Frank, 1938) and pressure ulcer development (Mulholland, Tui, Wright, 
Vinci, & Shafiroff, 1943).  Current research confirms serum albumin is associated with PrU 
development.  A retrospective analysis of data from 9,409 persons 14 years of age and older, 
who were patients at a United Kingdom hospital (from April 2006 through November 2007), was 
conducted to compare subscale scores on the Waterlow Scale with serum albumin levels in 
predicting HAPU development (Anthony, Rafter, Reynolds, & Aljezawi, 2011).  One hundred 
and thirty-nine participants (1.5%) developed a HAPU.  Pair-wise testing (with a Bonferroni 
correction and revised p value of .05/25 = .002 for 25 pair-wise tests) determined that serum 
albumin levels < 3.2 g/dl (binary variable) were associated with increased PrU development, χ2 = 
47.8, df = 1, p < .001. 
Iizaka, Okuwa, Sugama, and Sanada (2010) conducted a case-control study to investigate 
the effect of nutritional status on PrU development and PrU severity in the home care setting.  
Two hundred and seven home health offices in Japan were randomly selected and stratified by 
region.  Participants with a PrU (n = 290) were matched to those without a current or previous 
PrU (n = 456).  Eleven nutritional risk factors for PrU development were measured.  After 
adjusting for non-nutritional risk factors: (a) the odds for PrU development were higher among 
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those with malnutrition than those without malnutrition, OR = 2.29, 95% CI [1.53 – 3.44]; and 
(b) malnutrition was associated with more severe PrUs, OR = 1.88, 95% CI [1.03 – 3.45].  
Malnutrition was widely defined as having (a) a body mass index ≤ 18.5, (b) serum albumin ≤ 
3.0 g/dl, (c) hemoglobin ≤ 11.0 g/dl, (d) weight loss, (e) presence of edema, or (f) inadequate 
nutritional intake. 
Other studies have examined nutritional supplements and HAPU occurrence.  
Researchers in France conducted a multi-site (19 wards) RCT that included 672 critically ill 
elderly (M = 83.3 years of age) patients (Bourdel-Marchasson et al., 2000).  The nutritional 
intervention group (n = 295) received two daily oral supplements of 200 kcal each, for 15 days, 
in addition to the standard hospital diet of 1800 kcal/day.  The control group (n = 377) received 
the hospital diet only.  At day 15, 40.6% of the intervention group developed a PrU, compared to 
47.2% of the controls.  Ninety percent (90%) of the PrUs were Stage I.  Multivariate analysis 
revealed: (a) those in the control group had a higher risk of developing a PrU than those 
receiving the supplements, RR = 1.57, 95% CI [1.03 – 2.38], p = .04; and (b) for every 1g/L 
decrease in serum albumin level on admission, there was a 5% increased risk of PrU 
development, RR = 1.05, 95% CI [1.02 – 1.07], p < .001. 
Houwing et al. (2003) conducted a double-blind RCT to investigate the effect of 
nutritional supplements on (new) PrU development.  The sample included 103 hip fracture 
patients (M = 81 years of age) among three facilities in the Netherlands.  Participants were 
randomized to receive either: (1) 400 ml of a supplement with protein, arginine, zinc, and 
antioxidants (n = 51); or (2) a zero-calorie water-based placebo (n = 52).  Pressure ulcer presence 
was assessed daily for 28 days or until discharge (median = 10 days).  There was no difference in 
HAPU rate between the intervention (55%) and placebo (59%) groups.  However, those 
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receiving the supplement had a longer time before PrU onset (3.6 +/- 0.9 days) relative to those 
who received the placebo (1.6 +/- 0.9 days).  No Stage III or higher PrUs developed.  These 
HAPU rates, however, are considerably higher than current U.S rates of 7.9% for those at risk for 
PrU reported by Bergquist-Beringer et al. (2013).  Certainly these participants were at risk for 
PrU due to advanced age and hip fracture, but overall body mass index (M ≈ 24 BMI) did not 
suggest malnutrition among either group; so perhaps participants had adequate nutritional intake 
without the supplement.  The study did not report information on changes in weight or other 
nutritional markers (NPUAP/EPUAP, 2009). 
A Cochran Review (Langer, Knerr, Kuss, Behrens, & Schlomer, 2008) to evaluate the 
effectiveness of parenteral and enteral nutrition on PrU prevention and treatment examined eight 
RCTs.  Reviewers reported difficulty in forming conclusions due to small sample sizes, high 
attrition rates, and variable interventions.  Implications for practice included only that “elderly 
people recovering from acute illness appear to develop fewer pressure ulcers when given two 
daily supplement drinks” (p. 8). 
Finally, from a sample of 5,346 critical care pediatric patients, those who received a 
nutritional consult had lower HAPU rates than those who did not have a consult (after 
controlling for age and risk of mortality), OR = 0.206, 95% CI [0.156 – 0.272], p < .001 
(Schindler et al., 2011).  It is likely the consult led to nutritional support not measured in the 
study as no other nutritional measures were collected. 
Studies on nutritional interventions typically have short follow-up periods, making it 
difficult to identify effects of the intervention on PrU development (NPUAP/EPUAP, 2009).  
Despite numerous studies, the NPUAP and the WOCN Society recognize a gap in knowledge 
with regard to the association between nutritional interventions and PrU development, and 
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recommend further research (NPUAP, 2013; Ratliff et al., 2010).  This is confirmed by the 
AHRQ’s recent efficacy review which concluded there is insufficient evidence to come to any 
reliable conclusions as to the effectiveness of nutritional support in preventing PrUs, when 
compared to standard care (Chou et al., 2013). 
Education 
Pressure ulcer prevention includes education.   Caregivers, the person at risk for PrU 
development and their family, and all levels of healthcare providers should be instructed about 
PrU prevention (Bryant & Rolstad, 2001).  The AHRQ recommends that PrU teaching focuses 
on risk factors, pathophysiology, and risk reduction (AHRQ, 2011b). 
Caregiver education.  While education has been shown to improve nurses’ knowledge 
of PU prevention, improved knowledge has not always been linked with improved care—let 
alone decreased HAPU rates (Armstrong et al., 2008; Athlin, Idvall, Jernfält, & Johansson, 2009; 
Levine, Ayello, Zulkowski, & Fogel, 2012; Moore, 2010; Pieper & Mattern, 1997; Zulkowski, 
Ayello, & Wexler, 2007).  Beeckman, Defloor, Schoonhoven, and Vanderwee (2011) conducted 
a study in Belgium to examine the relationships between nurses’ knowledge of PrU prevention, 
attitudes towards PrU prevention, and performance of PrU prevention.  This was a cross-
sectional study of 553 nurses and 625 patients at risk for PrU development among 14 hospitals.  
The participants and hospitals were randomly selected.  Researchers reported that education was 
positively correlated with knowledge scores (p = .003), but knowledge scores were not correlated 
with performance of prevention interventions (p = .198). 
Abel et al. (2005) measured PrU prevention process of care measures and PrU incidence, 
before and after an education intervention.  The sample of convenience included 34 nursing 
homes in Texas.  The intervention was a change in the process of care systems.  This change was 
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introduced via tools and intense education of care providers.  Findings showed there was a 
statistically significant improvement in eight out of ten quality indicators (risk assessment within 
2 days of admission, appropriate plan of care that triggered interventions, timely skin 
assessments, appropriate ulcer description, use of a pressure-redistribution surface, and 
orders/care plans reflect wound care policy) after the intervention.  However, even though 
facility-acquired PrU occurrence decreased from 13.6% to 10% after the intervention; this 
decrease was not statistically significant, χ2 MH = 3.66, p = .06 [there is a 60% chance that the 
difference in HAPU incidence was from chance alone (Chi-square test, n. d.)]. 
Patient education.  An RCT was conducted by Rintala, Garber, Friedman, and Holmes 
(2008) to determine if patient education and follow-up after PrU surgery decreased PrU 
recurrence.  The sample consisted of 41 veterans (all male) with spinal cord injury (n = 39) or 
multiple sclerosis (n = 2).  Participants were randomized into three groups (1) individualized PrU 
education and monthly phone follow-up (n = 20), (2) monthly mail or phone follow-up without 
the education portion (n = 11), and (3) quarterly mail or phone follow-up without the education 
portion (n = 10).  All follow-up continued for 2 years, or PrU recurrence, or death.  Patients who 
received the education (Group 1) had a lower rate of PrU recurrence relative to patients who did 
not (Groups 2 and 3) [33%, 60%, and 90%; p = .007].  Also, there was a longer time before PrU 
recurrence among those that received the education (Group 1) relative to those that did (Groups 2 
and 3) [19.6, 10.1, and 10.3 months; p = 002].  Limitations to this study include a small sample 
size.  Moreover, the groups differed with regard to type of PrU surgery, level of spinal cord 
injury, time since last PrU surgery for those who had a history of this, and self-reported health 
status at baseline.  Despite limitations, this study supports the use of education to decrease PrU 
recurrence.  While the literature differs as to the effect education has on PrU occurrence, 
61 
commonsense says one must have the knowledge before they can be expected to properly 
perform PrU prevention.  In other words, education is necessary but not sufficient to decrease 
PrU occurrence.  The NPUAP recommends further research on patient literacy and teaching 
(NPUAP, 2013). 
In summary, because numerous variables are associated with PrU development, it is 
challenging and often not feasible to apply the rigorous controls necessary to determine 
causality.  Evidence supports that while individually each intervention may be necessary to 
prevent PrUs, they may not be sufficient.  An interesting descriptive-cohort study was performed 
by Bates-Jensen et al. (2003b) to determine whether nursing homes (in California) that ranked 
among the extreme quartiles of PrU prevalence, provided different PrU prevention interventions 
than nursing homes in the other extreme quartile.  From among a total of 45 nursing homes in 
these upper and lower quartiles, 16 participated (upper quartile, n = 10; lower quartile, n = 6).  
Pressure ulcer prevalence rates were those reported as part of the Minimum Data Set PrU 
Indicator.  Data on 16 PrU care processes were collected from medical records, direct patient 
observation, interviews, and wireless thigh movement monitors to measure repositioning.  Nine 
of these indicators measured aspects of PrU prevention such as risk assessment, every 2-hour 
repositioning, pressure reduction, nutritional support, and moisture management; and seven 
indicators measured aspects of PrU treatment.  The only significant difference in PrU prevention 
between nursing homes with low PrU prevalence rates and high PrU prevalence rates, was that 
homes with low PrU prevalence were less likely to use pressure-redistribution surfaces (M = 
52%, SD = 38.7) than the high PrU prevalence homes (M = 68%, SD = 33.1); p < .001. This is 
contrary to what was expected.  Knowing their performance of PrU prevention would be 
examined, perhaps only nursing homes that performed well on PrU prevention interventions 
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agreed to participate.  Or perhaps what matters is what combination of prevention interventions 
is applied, such as with the combination of interventions implemented with a PrU prevention 
program.  There is still much to learn about PrU prevention. 
Pressure Ulcer Prevention Programs 
Pressure ulcer prevention programs use an interdisciplinary approach to implement a 
combination of PrU prevention strategies (AHRQ, 2011b).  Numerous studies have described the 
implementation of PrU prevention programs.  Three recent literature reviews have evaluated 
these PrU prevention studies.  Each review focused on programs of prevention; which is 
important because that is typically how PrU prevention is implemented, and immediate adoption 
of a multifaceted intervention program is among the top ten patient safety strategies 
recommended by an international panel of patient safety and quality care experts (Shekelle et al., 
2013).  Many of the studies reviewed, implemented a combination of similar PrU prevention 
strategies.  However, which strategies were included, how they were implemented, and how 
processes and outcomes were measured as they related to the intervention; varied widely among 
the studies. 
A meta-analysis was performed by Soban et al. (2011) to examine studies that 
implemented PrU prevention programs.  Of the 39 studies published from 1990 to 2009 that met 
inclusion criteria, 22 were U.S. studies.  Most used a pre-, post-intervention design at a single 
site.  Interventions implemented varied widely across the studies.  The number of studies in the 
review, and the interventions studied, were: (a) protocol developed/implemented, 29/39; (b) staff 
education, 28/39; (c) risk assessment tool, 21/39; (d) performance monitoring at least three times 
during the study, 20/39; (e) team assembled, 19/39; (f) beds/support surfaces, 14/39; (g) 
guideline implemented based on published guidelines specified in the study, 11/39; (h) feedback 
to nursing staff and/or nurse managers, 10/39; and (i) link/resource nurse, 9/39.  No standardized 
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measure of these interventions was available, however, and evidence as to the reliability of the 
measures was lacking. 
Most of the studies included in the meta-analysis found their PrU prevention initiatives 
were associated with improvement in at least one nursing care process or patient outcome 
measure.  Nearly all (37 out of 39) reported the effect of implementation on patient outcome 
measures.  From this, Soban and colleagues computed an overall risk ratio of -0.07; 95% CI [-
0.0976 to -0.418]; p < .0001, reflecting a decreased risk of developing a HAPU after 
implementation of at least one nurse-focused intervention.  However, only eight of the 39 studies 
reported the effect of implementation on nursing care processes.  Moreover, how these nursing 
care processes were measured, varied across studies.  Due to the lack of evidence for the 
reliability of data from these process measures, the credibility of the study findings must be 
questioned. 
A literature review was performed by Niederhauser et al. (2012) to examine the evidence 
for “comprehensive” PrU prevention programs in acute or long-term care settings.  Studies 
published from 1995 to 2010 were included in the review (N = 24) if their program had two or 
more interventions and involved a multidisciplinary team.  Similar to Soban et al.’s (2011) meta-
analysis, most of the studies (21/24) reported the effect of the prevention program on patient 
outcome measures, while only five studies considered how the program affected care processes 
(i.e. improved performance of repositioning). 
Overall, 17 of the 20 studies that reported the intervention’s effect on care process or 
patient outcome measures found improvement after the intervention.  Five of the six studies that 
measured facility-acquired PrU rates found a decrease in these rates after the intervention.  
Researchers reported post-intervention improvement in some care processes, but not others.  
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Also, interventions included in the prevention programs varied across studies, from repositioning 
and use of pressure-redistribution mattresses, to mentoring, initiation of a physician 
communication form, and organization of supplies. 
Results from this review suggest that a multifaceted program of prevention that includes 
repositioning, skin assessment, PrU risk assessment, heel protectors, and use of pressure-
redistribution surfaces such as new mattresses, are important to decreasing PrU rates.  This is 
significant because PrU prevention is usually delivered through a multifaceted approach.  
Unfortunately, due to the wide-variety (and various combinations) of interventions implemented, 
and the lack of standardized and reliable process measures, the relationship between a PrU 
prevention program and improvement in patient outcome measures is difficult to understand and 
imprecise. 
The third and most recent review was conducted by Sullivan and Schoelles (2013) to 
examine “multicomponent” PrU prevention programs.  Multicomponent was broadly defined as 
programs with more than one component, such as a skin champion and education.  Only studies 
that reported PrU rates as an outcome variable for at least 6 months after initiating the program 
were included.  Twenty-six studies, 18 acute care and 8 long-term care settings, published from 
2000 to 2012 met study criteria.  Components of the PrU prevention programs, and the number 
of studies including them, were: (a) risk assessment, 24/26; (b) repositioning, 23/26; (c) moisture 
management, 21/26; (d) support surfaces, 21/26; (e) nutrition, 17/26; (f) skin examinations, 
13/26; (g) reduce friction and shear, 12/26; (h) patient and family education, 2/26; and (i) use of 
the Agency for Health Care Policy and Research Clinical Practice Guidelines for PrU Prediction 
and Prevention, 1/26. 
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Findings from this review were similar to the previous literature reviews (Soban et al., 
2011; Niederhauser et al., 2012) in that 24 out of 26 studies reported improved PrU rates.  Eleven 
of those 24 studies had a statistically significant improvement, and out of the 13 studies not 
reaching statistical significance, five reported improvement in process of care measures (and PrU 
rates).  Once again, the care processes that were measured before and after initiation of the 
prevention program, and how they were measured, varied across studies: They were not 
standardized measures.  Also concerning is that no evidence to support the reliability of these 
process measures was presented.  Similar findings are not surprising because many studies were 
included in more than one review.  Only 11 of the 26 Sullivan and Schoelles (2013) studies had 
not been included in either the Niederhauser et al. (2012) or Soban et al. (2011) reviews: Nine 
studies were included in all three reviews. 
Sullivan and Schoelles’ (2013) review was unique because it reported on: (a) the models 
or theories that guided the research—most of which were quality improvement models such as 
Plan-Do-Study-Act, and failure mode and effects analysis; (b) the details of how initiatives were 
implemented—some very unique such as staff sitting on bedpans for 30 minutes (Young, 
Ernsting, Kehoe, & Holmes, 2010); (c) solutions to perceived barriers to PrU prevention 
intervention initiatives; and (d) cost-savings.  Four of the 26 studies that evaluated cost, reported 
savings, with two studies reporting an annual savings of $2.4 million (Courtney, Ruppman, & 
Cooper, 2006) and $6.7 million (McInerney, 2008) per facility. 
These three reviews, the NPUAP/ EPUAP/PPPIA (2014), and the WOCN Society 
(Ratliff et al., 2010); recommend further research be performed to better understand the effect of 
interventions on PrU occurrence.  But in order to link prevention interventions with decreased 
PrUs, we as nurse researchers must have standardized measures with empirically supported 
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reliability.  Only one study was found that used standardized measures of PrU prevention 
interventions to examine their association with HAPU rates (Bergquist-Beringer et al., 2013).  
The sample included 710,626 adult patients on the adult critical care, step-down, medical, 
surgical, and medical/surgical units who were surveyed for PrUs among 1,419 U.S. hospitals that 
participated in the NDNQI.  Data on PrU risk assessment and PrU prevention were gathered by 
chart review, and data on PrU identification and staging were gathered by direct patient 
examination. 
Of the 710,626 patients, 282,500 (40%) were considered “at risk” for PrU development.  
Among patients at risk for PrU, 7.9% (n = 22,317 patients) developed a PrU after hospital 
admission.  After controlling for hospital characteristics and nurse staffing, hierarchical logistic 
regression revealed a decreased odds of HAPU for those who: (a) received a skin assessment on 
admission, OR = 0.76, 95% CI [0.67 – 0.87], p < .001; (b) received a PrU risk assessment on 
admission, OR = 0.82, 95% CI [0.73 – 0.92], p < .001; (c) were reassessed for PrU risk during 
the 24 hours prior to the NDNQI PrU survey, OR = 0.87, 95% CI [0.81 – 0.92], p < .001; (d) 
received a daily skin assessment, OR = 0.82, 95% CI [0.72 – 0.94], p = .003; or (e) were 
repositioned as prescribed, OR = 0.86, 95% CI [0.81 – 0.92], p < .001.  Higher HAPU rates were 
reported for patients who: (a) received nutritional support, OR = 1.58, 95% CI [1.51 – 1.66], p < 
.001, compared to those who did not; (b) daily skin assessment was contraindicated, OR = 2.84, 
95% CI [1.64 – 4.95], p < .001, compared to those for whom it was not contraindicated; or (c) 
refused repositioning, OR = 1.78, 95% CI [1.43 – 2.20], p < .001, compared to those who did not 
refuse. 
Overall, findings support the use of PrU prevention interventions to decrease HAPU 
development.  However, a fundamental problem remains: the reliability of these PrU prevention 
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process measures was not reported.  The fact that a large number of hospitals use the same 
NDNQI structure, process, and outcome measures, makes NDNQI research especially 
newsworthy to any acute care facility’s administration and nursing staff.  This emphasizes the 
pressing need for establishing the reliability of the PrU prevention measures used in NDNQI 
research.  The literature highlights the need for, and value of, using standardized national quality 
indicators to improve the quality of patient care across the nation. 
Criteria for a Sound Measure 
While reliability is the focus of this proposed research, validity is a fundamental 
requirement of a psychometrically sound measure and therefore warrants a brief discussion. 
Validity 
Validity is “the degree to which the measures or observations are appropriate or 
meaningful in the way they claim to be” (Rosenthal & Rosnow, 2008, p. 763).  Systematic error 
is the central threat to validity (Salkind, 2006).  Systematic error is predictable; it does not 
fluctuate from one measuring condition to another (Waltz et al., 2010).  Validity assessment falls 
into three categories (1) content validity, (2) construct validity, and (3) criterion validity 
(Rosenthal & Rosnow, 2008). 
Content validity is the extent to which a test measures the content of the concept being 
tested, and is usually evaluated during instrument development through literature review, expert 
opinion, and qualitative research.  After the tool is developed, content validity may be supported 
by content validity indices calculated from experts’ opinions (DeVon et al., 2007).  This involves 
rating each item for relevance.  Face validity is the subjective evaluation that the tool measures 
what it claims to measure (DeVon et al., 2007). 
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The overarching validity of a measure is construct validity (DeVon et al., 2007).  
Construct validity refers to whether a measure accurately reflects the concepts as operationally 
defined (Waltz et al., 2010).  Methods to assess construct validity include contrasted groups, 
hypothesis testing, a multitrait-multimethod approach, and factor analysis (Waltz et al., 2010). 
Criterion validity refers to the relationship between the instrument and its performance on 
some other variable.  Three types of criterion validity exist: (a) predictive validity, which is the 
extent scores predict performance on a future measure; (b) concurrent validity, which reflects the 
amount scores are correlated to a related criterion at the same point in time; and (c) convergent 
and discriminant validity.  Convergence reflects a high correlation between theoretically similar 
constructs, while discriminant validity represents an instrument’s ability to distinguish between 
theoretically similar and different constructs (DeVon et al., 2007; Rosenthal & Rosnow, 2008). 
Reliability 
Reliability is “the degree to which observations or measures are consistent or stable” 
(Rosenthal & Rosnow, 2008, p. 757).  A reliable measure—whether it be a quantitative survey, 
an observation, or a subjective judgment—allows for replication of the same or similar results.  
Random error is the main threat to reliability (Salkind, 2006).  According to Classical 
Measurement Theory, every observed score is comprised of a true score and the influence 
random error has on that true score (Salkind, 2006; Waltz et al., 2010): 
Observed Score = True Score + Error Score 
It is not possible to measure the true score, as the true score is a theoretical representation of the 
actual amount of the trait being measured: A true score is 100% accurate (Salkind, 2006). 
Random error, therefore, is present (to some extent) in all measurement; but it too 
remains unknown, only the observed score is known (Waltz et al., 2010).  Random error can be 
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classified as trait error or method error (Salkind, 2006).  Trait error is error caused by the 
individual, such as filling out a survey while ill, being distracted, and motivation.  Method error 
is caused by the testing situation, such as unclear instructions or an uncomfortable testing 
environment.  In addition, random error can originate after data collection, such as with data 
entry mistakes (Wambach, 2012b).  Keeping random error to a minimum, therefore, is essential 
if a measure is to be reliable.  Random error results in higher and lower than expected scores.  If 
the measurement process is repeated enough times, therefore, random error cancels itself out and 
average scores will represent true values (Waltz et al., 2010). 
Reliability is mathematically defined as the proportion of variance in the distribution of 
the observed scores that is caused from true score differences (versus caused by random error).  
Waltz et al. (2010, p. 73) statistically defined reliability with the following steps: 
Reliability    =       True Variance 
Observed Variance 
Because unreliability is the result of random error causing variance in the observed score, 
unreliability can be statistically defined as 
Unreliability    =   Error Variance 
Observed Variance 
Applying the Classical Measurement Theory, variance (commonly displayed as a 95% 
confidence interval) is written as 
Observed Variance = True Variance + Error Variance 
Dividing both sides of the equation by the Observed Variance results in the equation 
1.0  =  True Variance  + Error Variance 
Observed Variance  Observed Variance 
 
Reliability of the observed score (True Variance /Observed Variance), therefore, is written as 
   True Variance  = 1.0 - Error Variance 
   Observed Variance    Observed Variance 
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Types of reliability include stability, internal consistency, and equivalence (Waltz et al., 2010). 
Stability reliability.  Stability assesses if the instrument measures the concept 
consistently over time.  It is evaluated by repeating the measure twice within an appropriate 
specified time.  This is called test-retest reliability (Portney & Watkins, 2009; Waltz et al., 2010). 
Internal consistency reliability.  Internal consistency reflects the homogeneity of the 
items in an instrument.  For example, internal consistency reflects the logic behind combining 
the items together to measure a single attribute (Salkind, 2006).  Internal consistency is 
commonly estimated by Cronbach’s alpha (α), which is based on correlations between an 
individual’s score on one item and their total score (Salkind, 2006), and therefore reflects the 
extent that performance on any single item predicts performance on any other item in the 
measure (Waltz et al., 2010). 
Equivalence reliability.  Equivalence means similar results are obtained from two 
equivalent forms of a test (DeVon et al., 2007).  When measurement involves observation, 
equivalence is assessed by inter-rater and intra-rater reliability.  Intra-rater reliability is the 
stability of the data when multiple observations by the same person, separated by a short interval, 
produce the same results.  The number of repeated observations depends on how much 
variability is expected (Portney & Watkins, 2009).  Intra-rater reliability is an assumption for 
inter-rater reliability testing (Gwet, 2012), and can be estimated by Pearson’s r correlations 
(Wambach, 2012a). 
Inter-rater reliability is the degree to which two or more observers (raters) agree on their 
judgments of an outcome (Rosenthal & Rosnow, 2008).  The best method for estimating inter-
rater reliability depends on the number of raters (two, or more than two), and whether all raters 
score the same participants or if multiple ratings per subject are done by different raters (Fleiss et 
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al., 2003).  Method selection also depends on if the ratings are dichotomous, nominal, ordinal, or 
ratio.  Finally, for inter-rater reliability, issues of prevalence, bias, and interdependence must be 
considered throughout analysis and interpretation of results (Sim & Wright, 2005).  These issues 
are discussed fully, later in this chapter.  Statistical tests to determine inter-rater reliability 
include percent agreement, kappa, intraclass correlation coefficient (ICC), and Pearson’s r or its 
non-parametric counterpart Spearman rho (Portney & Watkins, 2009). 
Percent agreement is the simplest agreement index, and is used when measurements are 
categorical.  It measures how often raters agree on the rating they give someone on a particular 
attribute, or how often test-retest scores agree.  Percent agreement is the proportion of 
observations on which raters agree and is written as (Portney & Watkins, 2009, p. 598):  
% Agreement  =  Number of Agreements  
   Number of Possible Agreements 
Its main limitation is that it does not account for agreement due to chance.  Although taken alone 
it has limitations, percent agreement is an important commonsense descriptive statistic 
(Uebersax, 2009). 
Kappa was first proposed by Cohen (1960).  Kappa takes into consideration that some 
agreement will occur by chance alone and corrects for this chance agreement (Fleiss et al., 2003).  
This correction, however, assumes statistical independence of raters.  Lack of independence will 
inflate kappa (Sim & Wright, 2005; Uebersax, 2010a).  For nominal and ordinal ratings, inter-
rater reliability is best estimated by Cohen’s kappa when there are two raters, and Fleiss’ kappa 
is best for more than two raters (Gwet, 2012; Salkind, 2006).  Fleiss’ kappa also allows for the 
number of raters to be more than the number of raters per subject (i.e. not every rater needs to 
evaluate every subject).  What matters is that each subject is evaluated the same number of times 
(Zaiontz, 2013).  Fleiss’ kappa, therefore, measures the overall agreement between all raters 
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(Uebersax, 2010b), and is based on the proportion of agreeing rater-rater pairs compared to the 
total number of rater-rater pairs (Zaiontz, 2013).  Kappa (k) can be mathematically written as 
k = (Po - Pe) / (1 - Pe) 
where Po is the proportion of observed total agreement (i.e. percent agreement), and Pe is the 
proportion of agreement that is expected by chance (Feinstein & Cicchetti, 1990, p. 544).  
When ratings have more than two choices, kappa can be “weighted”.  Weighted kappa 
considers the degree of agreement and will be higher for raters who are closer to agreement than 
those who are not (Fleiss et al., 2003).  For instance, raters who differ between completely agree 
and mostly agree will have a higher weighted kappa value than raters who differ between 
completely agree and completely disagree.  Different methods of weighting exist and will result 
in different kappa values (Sim & Wright, 2005). 
Kappa equals 1.0 when there is complete agreement.  If the observed agreement is greater 
than or equal to the agreement due to chance alone, kappa is ≥ 0.  If observed agreement is less 
than agreement expected from chance alone—which rarely occurs in clinical contexts (Sim & 
Wright, 2005)—then kappa is < 0 (Fleiss et al., 2003).  Researchers have categorized kappa’s 
strength of agreement as: 
Landis and Koch (1977, p. 165) Shrout (1998, p. 308)        Fleiss et al. (2003, p. 604) 
< 0.00  Poor   0.00 to 0.10 Virtually none  < 0.40  Poor 
0.00 to 0.20 Slight   0.11 to 0.40 Slight   0.40 to 0.75 Good 
0.21 to 0.40 Fair   0.41 to 0.60 Fair   > 0.75         Excellent 
0.41 to 0.60  Moderate  0.61 to 0.80 Moderate 
0.61 to 0.80 Substantial  0.81 to 1.00 Substantial 
0.81 to 1.00 Almost Perfect 
The classifications by Landis and Koch (1977) are most commonly used (Bergquist-Beringer, 
Gajewski, Dunton, & Klaus, 2011; Fleiss et al., 2003; Hart, Bergquist, Gajewski, & Dunton, 
2006).  What is considered the acceptable level of kappa, however, depends on the situation.  
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Nonetheless, for the current study, the recommended reliability level is ≥ .610, which is similar 
to Polit and Beck’s (2012) recommendation of > .60, but much lower than Salkind’s (2006) 
recommendation of .90.  Commonsense says inter-rater reliability should be better than 
“moderate” agreement. 
Prevalence-adjusted kappa (PAK) is an additional statistic to measure observer 
agreement, and is useful to adjust kappa values when prevalence may affect kappa values (Sim & 
Wright, 2005).  Prevalence is the difference between counts in cells of agreement (cells on the 
diagonal, or cells a and d in Table 1 below).  Similarly, bias-adjusted kappa (BAK) is useful to 
adjust kappa values when bias my affect kappa values (Sim & Wright, 2005).  Bias is the 
difference between counts in cells of disagreement (cells off the diagonal, or cells c and b in 
Table 1). 
Table 1. 
Illustration of Prevalence in a Distribution of 100 Subjects by Rater and Response Category 
     Rater 1 
       Yes      No 
 
       f1 = 99     f2 = 1       
The effect of prevalence on kappa can be explained by referring to the equation for 
kappa: 
k = (Po - Pe)/ (1 - Pe) 
If the proportion of expected by chance agreement (Pe) is large, even a large proportion of 
observed agreement (Po) can be reflected as a low kappa.  A prevalence index can be calculated 
a 
    98 
b 
     1 
c 
      1 
d 
      0 
Yes 
No 
g1 = 99 
g2 = 1 
n = 100 
Rater 2 
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to determine if prevalence may influence the kappa values.  The equation for calculating 
prevalence index is (Sim & Wright, 2005, p. 261): 
Prevalence index = │a – d │ 
          n 
The prevalence index has a possible value of 0 to 1.0.   A value at or near zero would reflect 
equiprobable (positive and negative) cases.  For the hypothetical data in Table 1 (above) showing 
a 98% “Yes” rating, agreement expected by chance alone is: 
 Pe  =  
  

  +  
  

 =  		 
 		

  +  
 
 

 = .98 
             
          n         100 
 
Observed agreement is: 
 
    Po = (a + d)/n = (98 + 0)/100 = .98 
and k = 0 even though the raters disagreed on only two out of 100 cases. 
    k = (Po – Pe) = (.98 - .98) = 0/.02 = 0 
                          1 – Pe   1 - .98 
Kappa values, therefore, are difficult to interpret unless prevalence is considered. 
In addition to prevalence, bias may be present and affect kappa.  Bias is the degree to 
which raters disagree on the proportion of positive and negative cases, and is reflected as 
unbalanced marginal totals.  Marginal homogeneity and/or a bias index can be used to identify 
and evaluate the degree of imbalance among marginal totals (Sim & Wright, 2005).  The bias 
index has a possible value of 0 to 1.0: 
    Bias index = │b – c │ 
           n 
 
Table 2 (from Feinstein & Cicchetti, 1990, p. 545) is an example of the effect unbalanced 
marginal totals may have on kappa.  The proportion of observed (Po) agreement is the same for 
both tables [Po Table 2A = (45 + 15)/100 = 60%; Po Table 2B = (25 + 35)/100 = 60%]; yet the 
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proportion of expected agreement (Pe) causes different kappa values [Pe Table 2A = (0.70)(0.60) + 
(0.30)(0.40) = 0.54, so k = (0.60 - 0.54)/(1 - 0.54) = 0.13; Pe Table 2B = (0.30)(0.60) + (0.70)(0.40) 
= 0.46, so k = (0.60 - 0.46)/(1 - 0.46) = 0.26]. 
Table 2. 
Illustration of the Influence of Bias on Kappa Value 
2A    Rater 2  2B   Rater 2   
   Yes No Total    Yes No Total  
  Yes 45 15 60   Yes 25 35 60 
Rater 1 
  No 25 15 40   No 5 35 40  
 
  Total 70 30 100   Total 30 70 100 
 
Compared to balanced marginal totals (in Table 2A), unbalanced totals (in Table 2B) will 
produce a higher kappa because Pe is smaller for unbalanced totals (Feinstein & Cicchetti, 1990). 
Kappa can be adjusted for prevalence (PAK), bias (BAK), or both (PABAK).  These 
adjustments use average cell counts instead of actual cell counts of agreement (prevalence-
adjustment), and average cell counts instead of actual cell counts of disagreement (bias-
adjustment), between raters (Sim & Wright, 2005).  An example of PAK is presented in Table 3 
below.  In this example, the actual cell counts in Table 3A produce a k of .52; and average cell 
counts of agreement in Table 3B produce a PAK of .72. 
Table 3. 
Example of Calculating Prevalence-Adjusted Kappa and Change in Kappa Value 
A   Rater 2   B  Rater 2  
  Yes No Pending Total  Yes No Pending Total 
  90 3 4  97  35 3 4  42 
Rater 1 7 10 2  19  7 35 2  44 
  3 5 5  13  3 5 35  43  
  100 18 11  129  45 43 41  129 
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While some believe PAK should not be used because the kappa calculated from average 
cell counts do not convey the circumstances in which the initial ratings were made (Hoehler, 
2000), others suggest reporting kappa with and without PAK in order to gain insight into how 
prevalence may have affected kappa values (J. Sim, personal communication, May 5, 2014; Sim 
& Wright, 2005).  Because prevalence was a concern for this study, PAK values were presented 
to better understand the effect high prevalence may have had on the Cohen’s kappa values (Sim 
& Wright, 2005). 
Intraclass correlation coefficients (ICCs) are widely used to estimate inter-rater 
reliability, and are appropriate for quantitative (continuous level) ratings regardless of the 
number of raters (Fleiss et al., 2003; Gwet, 2012; Salkind, 2006; Shrout, 1998; Uebersax, 
2010b).  When the same raters are used for the same subjects, ICCs are identical to kappa values 
(Fleiss et al., 2003).  The ICC is the ratio of between-subjects variance to total variance, and 
theoretically has a possible value of 0 to 1.0 with 1.0 representing perfect reliability (Portney & 
Watkins, 2009).  However, an ICC will be negative when the average covariance within subjects 
is negative (Nichols, 1999). 
There are six forms of ICCs, each giving different results with the same data.  Selecting 
the appropriate ICC model depends on if the subjects are rated by the same or different sets of 
raters, and if one wants to generalize findings to a larger population of raters (Portney & 
Watkins, 2009; Shrout & Fleiss, 1979).  According to Shrout and Fleiss (1979) three ICC models 
pertain to raters.  In the model that was used in this study (Model 1) participants are judged by 
different groups of raters.  The raters are considered randomly selected.  For this model, a one-
way analysis of variance (ANOVA) estimates the variance between participants, as well as error.  
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The error is the variation within a participant across raters; and is made up of true changes, rater 
error, and unexplained error.  The type of error, however, is not differentiated. 
In the inter-rater reliability of PrU identification, staging, and origin study by Hart et al. 
(2006), Model 1 was used to calculate the ICC to compare variability of responses within and 
between hospitals (B. Gajewski, personal communication, May 15, 2014).  Specifically, in Hart 
et al.’s (2006) study the ICC represented the ratio: 
(Variability of kappa’s between hospitals) 
(Variability of kappa’s between hospitals) + (Variability of kappa’s within hospitals) 
An ICC near zero, therefore, would reveal a large proportion of the variability on an item is 
within hospitals.  This equates to hospitals having similar inter-rater reliabilities.  Put another 
way, a hospital’s given data collectors identified, staged, and classified PrUs with the same 
amount of error as other hospitals’ data collectors.  This use of ICC was employed in this study 
to estimate inter-rater reliability between hospitals. 
Signal-to-noise ratio is another measure of reliability.  The National Quality Forum 
(NQF) recommended that measures used for value-based purchasing, such as CMS’s measure of 
Stage III or Stage IV PrUs, are evaluated using a signal-to-noise ratio (NQF, 2013d).  Signal-to-
noise ratio represents the ratio of useful information (signal) to irrelevant information (noise); 
and is a measure of precision (Adams, Mehrotra, Thomas, & McGlynn, 2010).  For value-based 
purchasing measures, this is the ratio of real variation in performance (signal), to variation due to 
imprecision of the measure (noise).  It is used for value-based payments to classify the provider’s 
level of performance in relation to another provider’s performance (Adams et al., 2010).  One 
can understand the value of assessing the signal-to-noise ratio because CMS payments are not 
determined in isolation, but instead relative to other providers’ level of performance (Tompkins, 
Higgins, & Ritter, 2009). 
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Reliability Studies of the NDNQI Measures 
A number of reliability studies on the NDNQI measures have been published (Table 4).  
They include: (a) PrU identification, staging, and origin (Bergquist-Beringer et al., 2011; 
Gajewski, Hart, Bergquist-Beringer, & Dunton, 2007; Hart et al., 2006); (b) Fall classification 
(Simon, Klaus, Gajewski, & Dunton, 2013); (c) Patient day (Simon, Yankovskyy, & Dunton, 
2010; Simon, Yankovskyy, Klaus, Gajewski, & Dunton, 2011); (d) RN Satisfaction survey 
(Taunton et al., 2004; Elliott, 2006); and (e) Nursing care hour (Klaus et al., 2013).  The purpose 
of reviewing these studies was to identify the research designs and methods that might be used in 
this study.  Three of these nine reliability studies (Bergquist-Beringer et al., 2011; Gajewski et 
al., 2007; Hart et al., 2006) were deemed relevant to this study, and therefore are discussed 
below.  These studies are closely related and (although somewhat dated) support the reliability of 
these PrU outcome measures. 
Hart, Bergquist, Gajewski, and Dunton (2006) investigated the inter-rater reliability of 
PrU identification, PrU staging, and PrU origination (nosocomial or community-acquired). 
A random selection of 48 hospitals (87% response rate) from among NDNQI hospitals 
participated in the study.  Each hospital was randomly assigned to take one of two versions of a 
criterion-referenced online test.  Both versions of the test included 20 photographs of PrUs and 5 
photographs of other wounds, but only one version included a short narrative describing the 
wound in the photograph.  Two hundred, fifty-six RN raters (69% response rate) [1 to 21 raters 
(M = 5.3) per hospital] completed the test. 
Cohen’s kappa values were computed by comparing responses from each hospital rater to 
the “correct” response as determined by an expert panel.  The overall kappa value for wound 
identification (yes PrU/no PrU) was 0.56.  The overall kappa value for PrU staging was 0.65 and 
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overall kappa value for PrU origin was 0.80.  These values demonstrated moderate to almost 
perfect reliability (Landis & Koch, 1977).  The ICC analysis revealed hospitals were equally 
reliable in identifying wound type, identifying PrUs (yes/no), staging PrUs, and determining PrU 
origin; ICC values = .19, .09, .16, and .21, respectively.  This study will calculate ICCs in order 
to examine rater agreement across hospitals. 
Bergquist-Beringer et al. (2011) expanded the previous study to evaluate the reliability of 
PrU staging by direct observation.  The sample of convenience included 31 NDNQI participating 
hospitals.  Two to ten raters per hospital (M = 5.3, Total = 180 raters) rounded on patients with a 
PrU.  Collectively, 591 PrUs were independently staged from I to IV or classified as unstageable 
(M = 3.3 PrUs per rater).  Among the raters at each hospital was one person who was the hospital 
expert on PrUs.  After PrU staging by direct observation was completed, 162 of the 180 raters 
(90% response rate) completed the 3-part criterion-referenced web-based test used in the Hart et 
al. (2006) study.  Each rater was randomly assigned to one of two versions of the online test; one 
with and one without the narrative descriptors. 
The kappa agreement among raters from direct observation of the wounds was 
determined by comparing the ratings of each rater to the expert rater.  For the online test, 
Cohen’s kappa values were computed by comparing responses from each hospital rater to the 
“correct” response determined by experts.  Finally, hierarchical linear modeling was used to 
examine the relationships between participant characteristics, hospital characteristics, and kappa 
values. 
Pressure ulcer staging by direct observation revealed moderate reliability (k = 0.60, SD = 
0.29).  The average kappa for PrU staging from direct observation of PrUs was significantly 
higher (p = .027) for hospitals whose raters where led by a wound certified nurse (k = 0.68, SD = 
85 
0.68) compared to those teams without a certified nurse (k = 0.57, SD = 0.22).  Overall 
agreement for PrU staging from photos was substantial (k = 0.69, SD = 0.20).  The reliability of 
PrU staging was significantly higher (p ≤ .001) for the test version with wound descriptors (k = 
0.81, SD = 0.16) compared to the version without (k = 0.59, SD = 0.18).  The overall kappa 
value for PrU identification (yes a PrU/not a PrU) using the online test was 0.83; and overall 
kappa for PrU origin (community- or hospital-acquired) was 0.79.  There was no difference in 
kappa values between certified and noncertified nurses (p = .241) after adjusting for test version. 
Kappa values for wound/skin care nurses were higher relative to nurses not recognized as 
wound/skin care nurses, but results were not statistically significant (p = .063). 
This study is similar to the Hart et al. (2006) study in that raters directly rated patients on 
the PrU risk and prevention measures.  Also, a reliability coefficient, Cohen’s kappa, was 
calculated in the same manner as the Bergquist-Beringer et al. (2011) and Hart et al. (2006) 
studies.  In these studies, the expert’s rating was the criterion and all other raters were compared 
to the expert. 
Gajewski et al. (2007) investigated the inter-rater reliability of PrU staging by secondary 
analysis of data on wound staging from direct observation of these wounds (Bergquist-Beringer 
et al., 2011) using a subsample of 20 NDNQI participating hospitals.  The overall purpose of 
Gajewski et al.’s (2007) study was to address the shortcomings of the traditional statistical 
approach typically used to estimate inter-rater reliability of PrU staging (a one-way Analysis of 
Variance random-effects model).  In addition, this study focused on dealing with unstageable 
PrUs during statistical analysis.  Specifically, whether or not unstageable PrUs should be 
classified as Stage III or Stage IV PrUs was considered because these ulcers are typically 
dropped from analysis.  Other shortcomings addressed were that PrU stage is incorrectly treated 
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as continuous level data, when they are actually ordinal level data, and with small samples, 
within-hospital variance in PrU classification may be estimated as zero, leading to an ICC of 1.0, 
95% CI [1.0 – 1.0], which is “scientifically unreasonable” (p. 4606). 
Three to nine raters (M = 7) per hospital independently staged PrUs within their facility.  
Collectively, 347 PrU had been staged, 6 to 108 PrUs per hospital.  Findings supported the inter-
rater reliability of PrU staging from direct observation (mean ICC = 0.57), however the Bayesian 
method presented the most accurate reliability estimates when compared to traditional analysis. 
These PrU incidence, staging, and origin studies (Gajewski et al., 2007; Bergquist-
Beringer et al., 2013; and Hart et al., 2006) provide support for the reliability of the NDNQI 
outcome measure on PrU.  Data on the reliability of PrU risk and prevention measures, however, 
is still needed to examine the reliability of the NDNQI pressure ulcer risk and prevention 
measures.  
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CHAPTER III:  METHODOLOGY 
 
The purpose of this study was to examine the reliability of the NDNQI® pressure ulcer 
risk and prevention measures.  Although more than 1,400 hospitals collect the NDNQI pressure 
ulcer data, no studies have evaluated the reliability of this database’s PrU risk and prevention 
measures.  In Chapter III, the research design is presented, followed by a discussion of the 
setting and sample, study variables and their measures, and data collection procedures.  Human 
Subject Committee review, data analysis, and the pilot study are described.  Lastly, the study 
timeline is presented. 
Research Design 
A descriptive design was used to accomplish the aims of this study.  The study is a multi-
site, two-part, inter-rater reliability study.  In Part 1, participants collected NDNQI PrU risk and 
prevention data from patient records.  In Part 2, these same participants completed an online 
survey asking them about the methods and processes they use to rate patients on these measures.  
Participants completed Part 1 before beginning Part 2.  Advantages of the study design include 
(a) data collection procedures reflected actual PrU data collection procedures that are performed 
in hospitals or clinical settings, (b) data collection from a large geographical area, (c) a multi-
faceted approach of using chart reviews with data extraction, and online survey provided more 
insight than a single approach, (d) methods were useful for identifying future areas of research in 
areas not well studied, and (e) data were easily quantified in that they did not require complex 
statistical analysis (Grimes & Schultz, 2002; Polit & Beck, 2012).  Disadvantages of this design 
include (a) causal relationships cannot be determined, (b) lack of control over study variables, 
and (c) the survey response options may not have accurately captured how respondents wanted to 
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respond (Grimes & Schultz, 2002; Polit & Beck, 2012).  Study limitations are discussed in 
Chapter V. 
Setting and Sample 
Participation in the NDNQI is voluntary, and participating hospitals are not required to 
collect data on all the indicators, although they are encouraged to do so.  While not all 
participating hospitals submit PrU data, most do: As of January 2014, more than 1,400 out of the 
1,986 hospitals that participated in the NDNQI submitted PrU data (NDNQI, 2014b).  Hospitals 
are encouraged to submit PrU data quarterly, but can elect to submit less frequently. 
Sample of Hospitals 
The NDNQI classifies hospital type as General Acute Care, Critical Access, Non-USA, 
and Specialized (NDNQI, 2013).  In order to eliminate the bias that may occur if hospital types 
vary widely (among each other), only General Acute Care Hospitals were included in this study, 
which by definition are located in the U.S.  A General Acute Care Hospital “primarily offers 
services for medical-surgical patients and may or may not also include services for obstetrics, 
pediatrics, rehabilitation and psychiatry” (NDNQI, 2013, p. 11). 
Following usual NDNQI recruitment procedures for participation in research studies, 750 
randomly selected General Acute Care Hospitals that (1) submitted PrU data at least two of the 
last four quarters, and (2) had at least two adult medical-surgical, medical, or surgical units, were 
invited to participate in the study.  Considering the NDNQI has had hospital response rates of 
10% to 15% for reliability studies (S. Bergquist-Beringer, personal communication, March 24, 
2014), it was anticipated that approximately 75 to 112 hospitals would agree to participate. 
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Sample of Units and Patients 
The NDNQI classifies unit type based on patient population characteristics (i.e. acuity 
level, age, and type of care provided).  For this study, it was planned that data on PrU risk and 
prevention would be obtained from the records of 50 patients who were located on adult 
medical-surgical, adult medical, and /or adult surgical unit types in the hospital.  Much of the 
NDNQI data on PrUs is submitted by these unit types.  Of the 15,400 units that submitted PrU 
data for the 2nd Quarter of 2014, 7,471 (49%) units were classified as medical-surgical (n = 
1,774), medical (n = 2,468), or surgical (n = 3,229) (NDNQI Statistical Analyst, personal 
communication, November 21, 2014).  At least 90% of the patients on these units receive the 
level of care appropriate for the unit type (NDNQI, 2013). 
Critical care units were excluded from the study for consistency in the type of 
documentation system from which data were retrieved.  For example, critical care units 
sometimes have significantly different flow sheets for documentation than non-critical care units.  
Moreover, the rapid turnover of patients in critical care units could have confounded study 
procedures. 
Study Variables and Measures 
NDNQI Pressure Ulcer Risk and Prevention Variables and Measures 
NDNQI pressure ulcer risk and skin assessment variables.  There are 11 NDNQI PrU 
risk and prevention measures.  These measures include (1) Skin assessment within 24 hours of 
admission, (2) PrU risk assessment within 24 hours of admission, (3) Time since last PrU risk 
assessment, (4) Last PrU risk assessment scale and score, (5) PrU risk status, (6) PrU 
prevention use within the last 24 hours, (7) Skin assessment within the last 24 hours, (8) 
Pressure-redistribution surface use within the last 24 hours, (9) Routine repositioning as 
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prescribed within the last 24 hours, (10) Nutritional support within the last 24 hours, and (11) 
Moisture management within the last 24 hours (NDNQI, 2013). 
The NDNQI requires hospitals follow specific guidelines to collect data on PrUs 
(NDNQI, 2013).  Specifically, data on PrU risk and prevention are collected by staff at each 
hospital who have received training in PrUs—the NDNQI Pressure Ulcer Survey Team.  
According to the NDNQI guidelines, the NDNQI Pressure Ulcer Survey Team should be led by a 
person who is certified in wound/skin care, or has received additional training in PrU 
identification and staging, and is knowledgeable of the NDNQI PrU data collection guidelines.  
Training for new PrU team members includes: (a) the NDNQI guidelines on PrU prevalence 
indicators; (b) skin assessment; (c) NPUAP pressure ulcer staging definitions; (d) PrU stage 
appearance; (e) other wound types; (f) ability to differentiate between community-, hospital-, and 
unit-acquired PrUs; and (g) data extraction from the patient record (Bergquist-Beringer & 
Davidson, 2014).  Prior to each subsequent skin survey, team members should review data 
collection guidelines, skin assessment, and PrU identification and staging.  Chart reviewers are 
members of the NDNQI Pressure Ulcer Survey Team who collect data on the PrU risk and 
prevention measures, and should demonstrate competence in the performance of skin and risk 
assessments and data abstraction from the patient record.  Team members are supposed to be 
assigned to units other than the ones where they usually work in order to discourage biased 
reporting. 
For this study, data on PrU risk and prevention were recorded by participant raters on the 
Data Collection Form (Appendix B).  Each variable is discussed as follows, and the conceptual 
and operational definitions and level of analyses are listed in Table 5.  
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Pressure ulcer risk assessment.  Pressure ulcer risk assessment is the evaluation of the 
patient’s risk for PrU development.  Use of a validated scale to determine risk status is 
recommended by AHRQ (AHRQ, 2011b) and the Wound Ostomy and Continence Nurses 
Society (WOCN) (Ratliff et al., 2010).  The Institute for Healthcare Improvement (IHI) 
recommends PrU risk be assessed within 4 hours of admission, and reassessed at least daily 
(NDNQI, 2013).  For the NDNQI, members of the PrU data collection team review each patient 
record to determine if a PrU risk assessment was documented within 24 hours of admission.  
“Pending” is selected if the patient was admitted within the last 24 hours and risk assessment is 
in process.  According to 2010 NDNQI data, “Pending” was selected for only 0.7% of patients 
(Bergquist-Beringer et al., 2013).  Documentation in the patient record is also reviewed to 
determine how long before the NDNQI PrU Survey the last risk assessment was performed.  
Risk assessments performed at the time of the survey should not be counted.  The method used to 
assess PrU risk is identified as well as the score if risk was determined by the Braden, Norton, 
Braden Q, or Neonatal Skin Risk Assessment Scales.  Risk status is then identified. 
Skin assessment.  Skin assessment is the head-to-toe evaluation of the patient’s skin, 
focusing on bony prominences and other at risk areas of the body.  The goal of the skin 
assessment is to assess skin integrity and early identification of PrUs.  A skin assessment should 
be done on admission to detect and document any PrUs present on admission.  Ideally the skin of 
those at risk for PrU is inspected frequently, such as every shift or each time the patient is turned 
(NDNQI, 2013).  For the NDNQI, members of the PrU data collection team review patient 
records to determine if a skin assessment was documented within 24 hours of admission.  
“Pending” is selected if the patient was admitted within the last 24 hours and skin assessment is 
95 
in process.  According to 2010 NDNQI data, “Pending” was selected for only 0.5% of patients 
(Bergquist-Beringer, 2011). 
Documentation in the patient record is also reviewed to determine how long before the 
NDNQI PrU survey the last skin assessment was performed.  If no documentation for skin 
assessment is found, the chart should be reviewed for documentation of a reason why a skin 
assessment is contraindicated.  Documented contraindication can be any reason recorded in the 
patient record as to why a particular PrU prevention intervention is contraindicated, such as 
hemodynamic instability, spinal cord injury, or increased intracranial pressure. 
NDNQI pressure ulcer prevention defined.  For NDNQI, PrU prevention is defined as 
the performance of any PrU prevention intervention for “at risk” patients within the 24-hour 
period before the NDNQI Pressure Ulcer Survey (NDNQI, 2013).  Prevention interventions 
include skin assessment, pressure redistribution surface use, routine repositioning, nutritional 
support, and moisture management. 
Pressure ulcer prevention use.  If the patient is considered to be “at risk”, their patient 
record is reviewed for documentation of the performance of PrU prevention within the previous 
24 hours.  Documentation of only one PrU prevention intervention is sufficient to select “Yes” to 
the indicator of Pressure ulcer prevention within the last 24 hours.  “Pending” is selected if the 
patient was admitted within the last 24 hours and intervention implementation is in process.  If 
pending is selected, then no interventions will have been implemented.  According to 2010 
NDNQI data, “Pending” was selected for only 0.7% of patients (Bergquist-Beringer, 2011). 
Pressure-redistribution surface use.  Pressure-redistribution surface use is the use of a 
special support surface that redistributes pressure on skin and underlying subcutaneous tissue or 
other parts of the body exposed to pressure.  These surfaces can be special mattresses or seat 
96 
cushions, such as overlay mattresses or surfaces with air, gel, water, or high density foam.  
Pressure-redistribution also includes pressure relief of heels, such as suspending heels off the bed 
with pillows (NDNQI, 2013).  For the NDNQI, members of the PrU data collection team review 
each patient record to determine if any pressure-redistribution surface was in use within the 24 
hours prior to PrU data collection.  Direct observation of pressure-redistribution surface use is 
sufficient evidence of use—documentation of use in this case is not required if the patient is 
observed on the surface. 
Routine repositioning.  Routine repositioning reduces the duration and amount of 
pressure on tissues.  Repositioning frequency should be determined by individual patient 
characteristics (e.g. degree of immobility, body mass index, age, disease process) and the support 
surface being used.  The commonly accepted frequency of repositioning is every 2 hours while in 
bed; and every 1 hour while in a chair (NDNQI, 2015).  Routine repositioning is determined by 
reviewing the patient’s record for documentation of prescribed frequency of repositioning.  
Prescribed frequency is the frequency of repositioning prescribed in the patient’s plan of care.  
For the NDNQI, members of the PrU data collection team review each patient record to 
determine if routine repositioning was documented for the 24 hours prior to PrU data collection. 
Nutritional support.  Adequate nutritional intake helps the skin tolerate pressure.  The 
recommended intake to prevent PrUs is ≥ 30 kcal/kg of body weight per day, and 1.25 to 1.5 
grams/kg/day of protein.  Nutritional support may be achieved by providing assistance with 
meals, nutritional consults, nutritional supplements, enteral or parenteral nutrition, and adequate 
hydration (NDNQI, 2013).  For the NDNQI, members of the PrU data collection team review 
each patient record to determine if nutritional support was provided within the 24 hours prior to 
PrU data collection.  Dietary consults not yet performed are adequate documentation of 
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nutritional support only for a patient who has been admitted for less than 24 hours.  Direct 
observation of the patient receiving parenteral or enteral feedings is sufficient evidence of 
nutritional support—documentation of nutritional support is not required if the patient is 
observed receiving parenteral or enteral feedings. 
Moisture management.  Because excessive moisture may lead to skin breakdown when 
exposed to pressure, keeping patient skin clean and dry prevents PrU development.  Use of 
absorbent pads or moisture barrier creams; management of urinary incontinency, fecal 
incontinence, and draining wounds; are examples of moisture management (NDNQI, 2013).  
Evidence of moisture management includes documentation of such interventions in the patient’s 
record.  Incontinence products or barrier creams at the bedside are not adequate evidence of their 
use.  For the NDNQI, members of the PrU data collection team review each patient record to 
determine if moisture management was documented within the 24 hours prior to PrU data 
collection. 
Pressure ulcer risk and prevention data collection form.  The student investigator 
developed a data collection form, (the Data Collection Form), that was derived from forms used 
by NDNQI to capture the ratings on PrU risk and prevention for its PrU indicator (Appendix B).  
The investigator-developed form captures these data in the same order and was worded like the 
data collection form typically used during the NDNQI PrU Skin Survey (NDNQI, 2013).  The 
investigator-developed form also included the date and time of data collection, participant rater 
number and corresponding Survey ID, patient room/bed number, patient age and gender, and unit 
ID.  As before, data were collected only from nursing units that the NDNQI has classified as an 
adult medical-surgical, adult medical, or adult surgical unit. 
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The Data Collection Form was created in Excel.  Prior to the study, face validity was 
established by two NDNQI staff members.  Feasibility of use was determined during pilot study 
work by the participant raters and the skin survey team leader at the pilot site (see Pilot Study). 
The Pressure Ulcer Risk and Prevention Reliability Survey 
An online survey was developed by this student researcher to collect data about 
participant rater characteristics and information about the methods and processes used to rate the 
NDNQI pressure ulcer risk and prevention measures (Appendix C).  This survey, the Pressure 
Ulcer Risk and Prevention Reliability Survey, is a survey that was formatted into REDCap 
(http://project-redcap.org/).  REDCap allows for forward and backward navigation.  Alerts were 
in place to notify participants of missing or incomplete answers, but allowed respondents to 
submit incomplete surveys.  The survey could be accessed from any computer with internet 
access.  The University of Kansas Medical Center supports the use of REDCap, and information 
collected on REDCap is considered secure. 
Survey items #1 - #8 – Participant rater characteristics.  The first eight items of the 
survey collected self-reported participant rater characteristics.  Specifically, there are eight 
forced-choice questions on participant rater characteristics: (1) job title, (2) highest level of 
education, (3) review of the NDNQI Guidelines for Data Collection and Submission of Pressure 
Ulcers, and/or completion of the NDNQI Pressure Ulcer Training program, (4) education on PrU 
data collection other than the NDNQI Guidelines for Data Collection and Submission on 
Pressure Ulcers or the NDNQI Pressure Ulcer Training program, (5) years collecting NDNQI 
PrU data, (6) other role(s) in the NDNQI PrU survey, (7) who leads the PrU team, and (8) 
certifications.  These characteristics reflect those collected by NDNQI in the past.  Each 
participant rater characteristic is discussed below (Table 6) and the conceptual 
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and operational definitions and level of analyses are listed. 
Job title reflects the position participants fulfill, are paid for, and that they were hired to 
perform.  Because some participant raters may not be nurses, highest education level included 
nursing and non-nursing degrees, as well as high school graduate/GED.  The NDNQI Guidelines 
for Data Collection and Submission on Pressure Ulcers provides specific instructions to 
participating hospitals on how to collect data for the PrU measures (NDNQI, 2015).  Participant 
raters were asked if they reviewed these guidelines within the last 12 months.  The NDNQI 
Pressure Ulcer Training program has been shown to be an effective and easily accessible 
education method (Bergquist-Beringer et al., 2009).  This online program has four modules that 
provide a comprehensive overview of PrU staging and origin, other wound types, PrU 
prevention, and guidelines to data collection (Bergquist-Beringer & Davidson, 2014). 
Participant raters were asked if they completed all or some of the four modules of the 
NDNQI Pressure Ulcer Training program.  Ongoing pressure ulcer training and review helps 
ensure data integrity.  Participant raters were asked if they received any education for data 
collection on PrUs other than reviewing the NDNQI Guidelines for Data Collections and 
Submission on Pressure Ulcers or completing the NDNQI Pressure Ulcer Training program.  The 
NDNQI data collection guidelines state team members should receive PrU training or review 
prior to each skin survey (NDNQI, 2015). 
Years as an NDNQI pressure ulcer chart abstractor and other roles in the NDNQI 
Pressure Ulcer Survey helped capture the level of experience participant raters have in NDNQI 
PrU data collection.  Participant raters were asked how many years that they have been collecting 
NDNQI pressure ulcer risk and prevention data, and other roles they have had in NDNQI PrU 
data collection.  Wound and skin care expertise identifies participant raters who have advanced 
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knowledge and expertise in the area of wound and skin care management.  Participant raters 
were asked about current certifications.  Pressure ulcer data collection team characteristics were 
the wound/skin care certification status and the wound/skin care expertise of the leader of the 
PrU data collection team. 
Survey items #9 - #35 – Methods used to collect NDNQI pressure ulcer data.  The 
remaining survey items included 27 Likert-type questions (categorical-level) about the methods 
and processes used to gather information needed in order to rate the NDNQI PrU risk and 
prevention measures.  This information is helpful to better understand how data are collected, 
and if reported methods reflect the NDNQI data collection guidelines.  Prior to the study, face 
validity of the survey was established by two NDNQI staff members.  Feasibility was verified by 
the participant raters and the skin survey team leader at the pilot site during pilot work (see Pilot 
Study). 
Hospital Characteristics 
Hospital characteristics of interest to this study included hospital bed size, Magnet status, 
teaching status, and metropolitan status.  Hospitals self-classify this information using the 
NDNQI Hospital Demographic Summary (NDNQI, 2013).  Characteristics are determined 
before hospitals are enrolled in the NDNQI and verified by the site coordinator each quarter.  
Although no validity studies have been conducted on these hospital variables, quarterly 
verification lends support to their accuracy.  Information on these hospital characteristics were 
provided by the NDNQI staff for the 2nd Quarter of 2014, which is the quarter before data 
collection took place. 
Hospital size.  Hospital size is based on the number of staffed beds (AHRQ, 2011a), and 
is categorized as < 50, 50 – 74, 75 – 99, 100 – 199, 200 – 299, 300 – 399, 400 – 499, and 500 or 
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more beds.  Staffed beds include those that are occupied and those that are vacant and available, 
regardless of if they are included in NDNQI reporting (NDNQI, 2013). 
Magnet status.  Magnet status is recognition given to hospitals by the American Nurses 
Credentialing Center (ANCC), and signifies the hospital has achieved excellence in nursing 
(American Nurses Credentialing Center, 2013).  The NDNQI categorizes Magnet status as (1) 
have applied, (2) intend to apply, (3) Magnet recognition, (4) no plans to apply, and (5) 
unsuccessful application.  However, for this study, Magnet status available to the student 
researcher included “Magnet” or “Non-Magnet”.  Magnet recognition is verified by the NDNQI 
staff using information available on the ANCC website.  Hospitals that have applied for Magnet 
status but not yet received the result verify this information by sending the NDNQI (via 
facsimile) their ANCC application letter. 
Hospital teaching status.  Hospitals can identify themselves as an academic medical 
center, a teaching hospital, or a non-teaching hospital.  An academic medical center is the 
primary clinical site for a medical school; a teaching hospital has medical interns or residents; 
and a non-teaching hospital does not have interns or residents (NDNQI, 2013). 
Metropolitan status.  Metropolitan status is based on the U.S. Census Bureau’s 
definitions (United States Census Bureau, 2013) and refers to the location of the hospital in a 
metropolitan area, a micropolitan area, or neither a metropolitan area or micropolitan area.  A 
metropolitan area is a single county or group of adjacent counties that has a core urban 
population of at least 50,000 residents.  A micropolitan area is a county or group of adjacent 
counties that has a core urban population of greater than 10,000 but less than 50,000 residents.  A 
non-metropolitan area is defined as a county that is not metropolitan or micropolitan (NDNQI, 
2014a). 
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Procedures 
Recruitment and Enrollment 
Before the study, approval by the Human Subjects Committee (HSC) at the University of 
Kansas Medical Center (KUMC) was obtained.  On August 1, 2014, 750 randomly selected 
General Acute Care Hospitals that submitted PrU data at least two of the last four quarters, and 
had at least two adult medical-surgical, medical, or surgical units; were invited to participate in 
the study via email (Invitation to Participate presented in Appendix D).  The study’s original 
recruitment procedure was to exclude hospitals with < 100 staffed beds.  This exclusion was 
inadvertently not put in place during random selection of the hospitals.  Subsequently, hospitals 
with < 100 staffed beds were sent an Invitation to Participate.  This email invitation was 
reviewed by the NDNQI staff, and was sent from NDNQI.  The invitation described the study, 
identified each hospital’s eligible units, and included a link to a REDCap survey for site 
coordinator response.  Site coordinators (n = 124) replied to the Invitation to Participate by 
accessing the Reply to Invitation to Participate (Yes; No; or I’m not sure, I need more 
information) and provided their NDNQI hospital code and name and email address (Appendix 
E).  The deadline to reply to the invitation was August 19, 2014.  However, a few site 
coordinators asked to participate after the deadline, and the survey was reopened until August 25. 
Before Data Collection 
Study researchers mainly communicated with each hospital through the hospital’s 
NDNQI site coordinator.  On occasion, hospital personnel other than the site coordinator (but 
still persons who were involved in the study) initiated and established communication with study 
researchers.  Each site coordinator, however, served as the contact person, distributed study-
related materials, and managed the study at their hospital.  This reflects usual NDNQI practice in 
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that site coordinators are the primary point of contact between the hospital and the NDNQI 
(NDNQI, 2013).  Site coordinators are responsible for quarterly NDNQI data collection and 
submission.  Site coordinators are also those with whom NDNQI communicates for optional 
research projects. 
Study materials.  Site coordinators of hospitals who indicated their interest in study 
participation received study materials via email on August 27, 2014.  These materials included: 
an Overview of the Pressure Ulcer Risk and Prevention Reliability Study, (Appendix F), Site 
Coordinator Instructions (Appendix G), Participant Rater Instructions (Appendix H), the Data 
Collection Form (Appendix B), list of their eligible units (Unit List), and the Teleconference 
Instructions (Appendix I).  The email that accompanied the study materials is presented in 
Appendix I.  The Overview of the Pressure Ulcer Risk and Prevention Reliability Study was 
distributed to site coordinators and participant raters, and provided both with an overview of the 
study procedures. 
The Site Coordinator Instructions provided step-by-step instructions for the study 
including selection of the participant raters, data collection procedures, access to and completion 
of the online survey, and data submission.  The Participant Rater Instructions provided step-by-
step directions for the study including collecting data (Part 1 and Part 2), accessing and 
completing the online survey, and submitting the completed Data Collection Form. 
The Data Collection Form was used by participant raters to record data on patient PrU 
risk and prevention measures.  Prior to the study, this Excel file form was reviewed and approved 
by NDNQI staff. 
A list of each hospital’s eligible medical-surgical, medical, and surgical units from which 
study data were to be collected, (the Unit List), was provided as a separate document among 
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initial study materials.  These units were listed in the order from which data were to be collected.  
The Unit List included unit name, and each unit’s corresponding unit type and unit identification 
number. 
The student researcher hosted a 1-hour teleconference session on September 9, 2014 for 
site coordinators and participant raters from hospitals who agreed to participate in the study.  The 
purpose of the teleconference was to explain the study and data collection procedures, and 
answer questions.  The Teleconference Instructions provided information about the 
teleconference’s time and date, how to attend, and how to obtain an audio-recording of the 
teleconference.   During the conference, the study instructions were reviewed and attendees were 
able to ask (and have answered) their questions.  One week before the teleconference, site 
coordinators received an email from the student researcher reminding them of the teleconference 
date, time, and access information.  The audio-recording was emailed to those who requested it.  
Thereafter, the student researcher was available within NDNQI office space at routine intervals 
to answer pre-study and during-study questions. 
Participant raters.  It was planned that each site coordinator would identify one expert 
and two or three non-expert raters (participant raters).  At one hospital, however, one expert and 
four non-experts were identified to collect data.  Site coordinators selected participant raters from 
their hospital’s established PrU data collection team, i.e. team of staff who usually collect these 
data for the quarterly NDNQI Pressure Ulcer Survey.  Site coordinators first selected the expert 
rater, defined as the PrU team member with the most experience and/or skill in patient record 
review for the quarterly PrU survey.  Site coordinators then selected non-expert raters, defined as 
any PrU team members (other than the identified expert) who usually review patient records.  
The number of expert and non-expert raters was selected because it is reasonable to expect that 
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hospitals would have at least three persons who usually review patient records.  The number of 
two or three non-expert raters was selected to better capture variability between the expert and 
non-expert ratings than if there were only two non-expert raters per hospital. 
Site coordinators distributed the Participant Rater Instructions (Appendix H) and a print-
copy the Data Collection Form (Appendix B) to each participant rater.  The site coordinator 
assigned each participant rater a rater number.  The site coordinator recorded this number on 
each Data Collection Form prior to distributing the form to the participant rater.  The “expert” 
was “Rater 1”, and the non-experts were “Rater 2” and “Rater 3”.  If a third non-expert rater was 
available, this rater was assigned to be “Rater 4”.  The hospital with a fourth non-expert rater 
identified this rater as “Rater 5”.  Each rater number had a corresponding Survey ID.  The Survey 
ID is a unique anonymous code comprised of the hospital’s NDNQI alphanumeric identifier code 
(hospital code) followed by the number “1”, “2”, “3”, or “4”.  Specifically, the expert (“Rater 1”) 
was assigned the Survey ID that was their hospital code followed by the number “1”.  Each of the 
non-experts was assigned a Survey ID that was their hospital code followed by the number “2” or 
“3”.  If a third non-expert was available, their Survey ID was their hospital code followed by the 
number “4”.  The Survey ID for the fourth non-expert rater (from the single hospital with four 
non-experts) was their hospital code followed by the number “5”.  Site coordinators also 
distributed the Participant Rater Instructions (Appendix H) to each participant rater. 
Study day.  It was planned that the data collection period for the study would be 
September 29 to October 13, 2014.  The site coordinator and participant raters chose what day 
during the study data collection period they would conduct the study.  Specifically, the site 
coordinator and participant raters were to agree on a single day within this period to collect the 
study data.  The goal across hospitals was to have data collected within 14 days of the study 
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period start, and have data submitted within 14 days after the data collection period ended.  
However, the data collection period was extended to the data submission deadline of October 27, 
2014 in order to accommodate hospital schedules. 
Participant raters were instructed to collect the data on the study day during a 5-hour time 
period beginning at 7:00 a.m. and ending at 12 noon.  They were directed to review the patient 
record for care provided in the 24 hour period between 7:00 a.m. the day before data collection 
to 7:00 a.m. the day of data collection.  Although participant raters collected data on the same 
morning, they were instructed to collect data independently. 
On the morning of data collection, each participant rater was to receive a list of patients 
(from the site coordinator) that included patient name and the room/bed numbers of those who 
were on each eligible unit at 7:00 a.m. (the Patient List).  Participant raters were asked to collect 
PrU risk and PrU prevention data only for patients on this list that were still in the room/bed 
number at the time of data collection.  Participant raters were directed not to seek or find the 
patients who had moved. 
Data Collection 
Part 1.  Participant raters were asked to independently review patient records and 
independently rate (the same) 50 patients on the NDNQI pressure ulcer risk and prevention 
measures.  They were asked not to collect data together, not to ask others for help, and not to 
share or compare their data with the others after collecting it.  A 15 to 30 minute staggered data 
collection start time was suggested in the Site Coordinator Instructions and the Participant Rater 
Instructions to minimize the risk of participant raters sharing information with each other.  
Participant raters were to begin data collection on the first unit identified in the Unit List, and 
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then proceed by unit in the order listed.  Units were listed starting with adult medical-surgical 
unit(s), then adult medical unit(s), and lastly adult surgical unit(s). 
Working from the 7:00 a.m. Patient Lists generated for each unit, participant raters were 
to start collecting patient data from the patient in the lowest room/bed number on the first unit in 
the Unit List.  For example, if the first unit on the Unit List was 6-East, data collection was to 
begin on 6-East; and the Patient List for 6-East was to be used to guide data collection on this 
unit.  Data collection was to continue in chronological order to the patient in the highest 
room/bed number on that unit.  Next, participant raters were to move to the next unit on the Unit 
List and collect data in the same manner; starting with the patient in the lowest room/bed number 
on that unit, and continuing in chronological order to the patient in the highest room/bed number.  
Data collection was to continue in this manner until the records of 50 patients were rated.  
However, some smaller hospitals reported that they may not have 50 patients.  These hospitals 
were instructed to choose their data collection day to be a day when they expected to have the 
highest patient census, and then collect data on however many patients were available. 
If the patient in the room/bed was different than the patient reported to be in that 
room/bed (according to the 7:00 a.m. Patient List), then data were not to be collected from this 
patient.  This was necessary to ensure that participant raters collected data on the same patients, 
and because some NDNQI PrU measures may be rated by direct observation.  This is consistent 
with usual NDNQI PrU data collection in that data are not collected on discharged patients.  
While collecting data, participant raters were to include only patient data for the 24-hour period 
beginning 7:00 a.m. the day before data collection to 7:00 a.m. the day of data collection.  It was 
not necessary for the patient to have been in that room/bed for the entire 24-hour period. 
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Participant raters used the Data Collection Form (Appendix B) to: (a) record the date and 
time data collection began; (b) record each patient’s room/bed number, age, and gender; and (c) 
record the unit ID.  As data were collected, participant raters could enter patient data onto their 
print-copy of the Data Collection Form, or enter data directly into their electronic version of the 
Data Collection Form.  Those who recorded data onto a print-copy then transcribed their data 
into their electronic Data Collection Form after data collection was completed.  Participant raters 
were to personally enter the data they collected into the electronic Data Collection Form in order 
to minimize the risk of results being changed to reflect agreement among participant raters.  
Participant raters were to check the accuracy of their data entry. 
Part 2: Online REDCap survey.  After data collection, participant raters logged into 
REDCap (http://project-redcap.org/) in order to (a) upload their completed Data Collection Form 
Excel file (Appendix B), and (b) complete the Pressure Ulcer Risk and Prevention Reliability 
Survey (Appendix C).  Only participant raters whose patient data were included in kappa value 
calculations, (Part I of the study), were included in the analysis of survey data (N = 120 
participant raters).  The Participant Rater Instructions (Appendix H) provided participant raters 
with the link to the REDCap survey.  The deadline for uploading completed Data Collection 
Forms, and completing the survey was October 27, 2014.  However, participant raters from three 
hospitals submitted their Data Collection Forms and completed the survey after the deadline 
(October 28 through October 31). 
Access to the online survey was by a common URL address.  The Data Collection Form 
Excel file upload process was presented as a survey item, with a direct upload (single click) link.  
REDCap provided step-by-step instructions to complete the file upload.  In addition, REDCap 
automatically tracked and recorded user activities, and did not allow for changes to the survey 
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after data collection began.  In essence, REDCap kept its own audit trail, code key, and data log.  
Site coordinators were responsible to make sure all Data Collection Forms were submitted, and 
to encourage participant raters to complete the online survey.  The student researcher sent emails 
to site coordinators notifying them of the status of their participant raters’ data submission. 
NDNQI personnel extracted the hospital characteristics of interest (size, Magnet status, 
teaching status, and metropolitan status) for the 2nd Quarter of 2014: the quarter before the study 
data collection period.  The student researcher received this information from NDNQI. 
Human Subject Review 
Approval for NDNQI activities was granted by the KUMC Institutional Review Board 
(IRB).  For this study (including the pilot study), approval was obtained from the Human 
Subjects Committee (HSC) at KUMC.  Specifically, a change in protocol to the NDNQI study 
was submitted.  The student researcher completed KUMC Human Subjects Protection training 
and Health Insurance Portability and Accountability Act (HIPAA) training, signed a conflict-of-
interest form, completed the NDNQI Confidentiality Form, and was added as student personnel 
to the NDNQI study.  The student conducted the study within assigned NDNQI office space. 
Data on hospitals within the NDNQI dataset received for this study were de-identified.  
Patient data recorded on the Data Collection Form by participant raters was de-identified.  
REDCap is a secure web-based application that provided a secure link to the survey.  Respondent 
anonymity was maintained by a de-identified number that was assigned to them.  Only members 
of the investigation team had access to the responses.  De-identified datasets were stored on a 
password-protected computer or secured KUMC drive.  All data are presented without 
identifiers. 
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Data Analysis 
Preparation of the Data for Analysis 
Hospital characteristics were extracted by NDNQI staff for the 2nd Quarter of 2014: the 
quarter before the study data collection period.  These data were sent to the student researcher 
who transferred the data into the Statistical Package for the Social Services (SPSS) version 22 
for analysis.  After participant raters uploaded their completed Data Collection Form onto 
REDCap, the student researcher also transferred these files into (SPSS).  Because each hospital 
had one expert and two, three, or four non-expert participant raters; three, four, or five Data 
Collection Forms were submitted per hospital.  Data from the online survey (Pressure Ulcer Risk 
and Prevention Reliability Survey) was also retrieved and electronically transferred into SPSS.  
All KUMC email is considered “secure” within KUMC, including REDCap.  The student 
researcher maintained a code book, data log, and audit trail throughout data analysis. 
Data cleaning and data exploration.  Data collected from patient record review (the 
Data Collection Forms), and data collected on REDCap (Pressure Ulcer Risk and Prevention 
Reliability Survey) was examined for errors.  Specifically, data entry errors on the Data 
Collection Forms (i.e. patient data) were identified and site coordinators were contacted as 
needed.  Most Data Collection Forms were submitted to and retrieved from REDCap the day 
patient data were collected.  This meant that site coordinators were contacted regarding data 
entry errors soon after data were collected.  Most of the time, therefore, the student researcher 
was successful in resolving data entry errors. 
Review of data missing from the Data Collection Forms suggested the patient was 
transferred, discharged, or died between the time the list was generated and data collection was 
completed by the three (four, or five) participant raters.  Data on patient age and gender were 
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examined by hospital to make sure that patient room/bed number, age and gender matched across 
participant raters within that hospital.  Only patients who had data collected on them by all of the 
participant raters at that hospital were included in the analysis.  Data were also examined to 
identify outliers.  The only outlier identified was a patient age of “5 years”, and this patient’s 
data was not included in the analysis because it did not match patient age recorded by the other 
participant raters. 
The data from The Pressure Ulcer Risk and Prevention Reliability Survey were examined 
for missing data.  The number of missing cases is presented by item in the survey data analysis 
results. 
Descriptive statistics.  Descriptive statistical analysis was performed to summarize 
patients by age and gender, the hospitals (size, Magnet status, teaching status, and metropolitan 
status), and the units (type).  For continuous level data (patient age), the mean and standard 
deviation (SD) were calculated.  For categorical level data (all other variables), frequencies and 
percentages were obtained. 
Descriptive statistics were also used to describe the participant raters (expert status, job 
title, highest level of education, review of the NDNQI Guidelines for Data Collection and 
Submission of Pressure Ulcers within the last 12 months, completion of the NDNQI Pressure 
Ulcer Training program within the last 12 months, education for data collection on PrUs other 
than review of the NDNQI Guidelines for Data Collection and Submission of Pressure Ulcers or 
completion of the NDNQI Pressure Ulcer Training program, years collecting NDNQI PrU data, 
other role(s) in the NDNQI PrU survey, certification status of the PrU data collection team 
leader, and certifications).  Frequencies and percentages were obtained.  Responses to the option 
“Other (please specify)”, were grouped into conceptually similar categories.  These items and 
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their item number were (#1) “What is your job title?”  (#6) “In addition to chart abstractor, what 
other role(s) in the NDNQI Pressure Ulcer Survey do you hold?” and (#8) “Which of the 
following active certifications do you hold?”  The frequencies and percentages of responses for 
each of these categories were determined. 
Data Analysis by Study Aim and Research Question 
Aim 1:  Examine the reliability of the NDNQI pressure ulcer risk and prevention 
measures within and across NDNQI hospitals.  For this aim, Cohen’s kappa, prevalence-
adjusted kappa (PAK), percent agreement, intraclass correlation coefficient (ICC), and 
agreement matrices/descriptive statistics were performed. 
Question 1: What is the agreement between expert participant ratings and non-
expert participant ratings for each of the 11 NDNQI pressure ulcer risk and prevention 
measures within each hospital?  Agreement was assessed by Cohen’s kappa, PAK, and percent 
agreement in order to obtain one Cohen’s kappa value for each of the 11 NDNQI risk and 
prevention measures per hospital, one PAK value for each of the 11 NDNQI risk and prevention 
measures per hospital, and a single percent agreement value for each of the 11 NDNQI risk and 
prevention measures per hospital.  It was planned that SPSS would be used to compute Cohen’s 
kappa values, and that Excel would be used to calculate PAK values.  However, two issues 
became apparent: (1) the frequency tables were very sparse (i.e. many cells had very small 
counts or values of zero), and (2) many participant raters’ ratings were considered constants (i.e. 
many participant raters rated all 50 patients as having received the intervention).  These two 
issues meant that neither SPSS nor Excel would compute a large percentage of Cohen’s k values.  
In order to produce Cohen’s k values, it was necessary to add 0.0001 to each cell.  This 
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adjustment was made to every cell regardless of its value, and it was kept in place during the 
PAK calculations.  Therefore, Excel was used to calculate Cohen’s kappa (and PAK) values. 
A frequency table was formulated in Excel to calculate all Cohen’s k and PAK values.  
Percent agreement was calculated by hand from each frequency table.  Accuracy of this Excel 
formula table was verified by hand calculations of Cohen’s k and PAK values for use as a 3 x 3 
table, 4 x 4 table, 5 x 5 table, and 7 x 7 table (i.e. all possible frequency tables that were used in 
this study). 
When SPSS is used to calculate Cohen’s kappa, a frequency table representing agreement 
(and disagreement) is constructed and presented in the output.  Each of the 11 measures had 84 
expert to non-expert pairs, across 36 hospitals.  Therefore, for each measure, 84 frequency tables 
were constructed (in SPSS) representing agreement (and disagreement) between each expert to 
non-expert pair (Total = 924 frequency tables).  Cell counts from each frequency table (plus 
0.0001) were then entered (by this student researcher), into an Excel frequency formula table.  
For each table, Excel calculated a Cohen’s k value and a PAK value for that expert/non-expert 
pair.  In other words, for each measure, 84 Cohen’s kappa values were calculated to estimate the 
agreement between each of the 84 expert to non-expert pairs, and 84 PAK values were calculated 
to estimate the agreement between each of the 84 expert to non-expert pairs.  These calculations 
were completed in Excel, but the cell counts (that were used for these calculations) were 
identified in SPSS. 
Risk for error while entering the cell counts into the Excel frequency table was 
minimized by:  (1) reconciling the marginal totals as identified in the SPSS table with the 
marginal totals identified in Excel table; (2) ensuring the Cohen’s k value calculated in the Excel 
table equaled the Cohen’s k value calculated in SPSS, when available; and (3) verifying that, 
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within each hospital, the expert’s margin totals were identical across all expert/non-expert pairs 
for that measure (because the expert’s ratings for each measure should be the same across all 
expert/non-expert pairs within that hospital).  No weighting of Cohen’s k or PAK values was 
performed.  This was because the measures had categorical-level response options, and the loss 
of information that would have resulted from weighting kappa. 
Cohen’s kappa.  For every hospital, ratings of each NDNQI PrU risk measure (Skin 
assessment on admission, Risk assessment on admission, Time since last risk assessment, Risk 
assessment scale, and Risk status) for the 23 – 50 patients, made by the 2 – 4 non-expert raters; 
were compared to the expert’s ratings.  Similarly, (for every hospital), ratings of each NDNQI 
PrU prevention measure (Any PrU prevention, Skin assessment, Pressure-redistribution surface 
use, Routine repositioning, Nutritional support, and Moisture management) for the 5 – 37 “at 
risk” patients, made by the 2 – 4 non-expert raters; were compared to the expert’s ratings.  In 
other words, at each hospital, there was two, three, or four expert to non-expert comparisons 
(kappa values) per patient (Figure 2) for each measure. 
Figure 2.  Expert to Non-Expert Pairs 
      Non-expert “Rater 2” 
   
  
 Expert “Rater 1”    Non-expert “Rater 3” 
 
      Non-expert “Rater 4” 
      
     Non-expert “Rater 5” 
 
 
One hundred twenty raters (36 “experts” and 84 “non-experts”, M = 3.3 raters/hospital) rated a 
total of 1,637 patients (M = 45.5 patients/hospital, SD = 6.4).  Of these 1,637 patients, 553 
(33.8%) were identified by the “expert” to be “at risk” for PrU.  However, not all non-experts 
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agreed with the expert on risk status, and 528 to 530 patients were rated on each of the 
prevention measures (5 – 37 “at risk” patients per hospital, M = 14.7, SD = 7.0).  To answer 
Question 1, the 2 – 4 kappa coefficients for each measure were averaged to yield a single kappa 
value for each risk and prevention measure per hospital.  Corresponding standard deviations 
were computed for each hospital’s per measure kappa value. 
Comparing pairs of expert/non-expert agreement evaluated the “correctness” (or validity) 
of the ratings; it is assumed the expert correctly rated the study PrU risk and prevention 
measures.  The equation for Cohen’s kappa is (Sim & Wright, 2005): 
k = (observed agreement) – (chance agreement) 
1 – (chance agreement) 
Table 7 below illustrates how observed agreement and chance agreement were calculated for 
Routine repositioning as prescribed.  The response options for Routine repositioning as 
prescribed include “Yes”, “No”, “Documented contraindication”, “Unnecessary for pt.”, and “Pt. 
refused”. 
Observed agreement (Po) is: 
Po = (a + f + l + r + x) 
n 
Chance agreement (Pe) is: 
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Table 7. 
Illustration for Calculating Observed Agreement and Expected Agreement 
      Non-Expert Rater 
 
a 
 
b 
 
c 
 
d 
 
e 
 
e 
 
f 
 
g 
 
h 
 
i  
 
j 
 
k 
 
l 
 
m 
 
n 
 
o 
 
p 
 
q 
 
r 
 
s 
 
t 
 
u 
 
v 
 
w 
 
x 
 
 
Note.  Contrain. = Contraindicated; Unnec. and Unnecessary = Unnecessary for the patient; 
Pt. = Patient 
 
The main diagonal cells (in bold outline) represent agreement, and the off-diagonal cells 
represent disagreement.  Landis and Koch’s (1977) classifications (< 0 = “poor”, 0 – .20 = 
“slight”, .21 – .40 = “fair”, .41 – .60 = “moderate”, .61 – .80 = “substantial”, and .81 – 1.0 = 
“almost perfect”) were used to categorize kappa values’ strength of agreement.  For this study, 
the recommended reliability level for the study measures is ≥ .610. 
Prevalence-adjusted kappa (PAK).  For the NDNQI PrU risk and prevention measures, a 
large proportion of patients receive appropriate PrU risk and prevention interventions (e.g. 
98.4% of “at risk” patients received a skin assessment within 24 hours of admission in Bergquist-
Beringer, 2011).  Therefore, the proportion of agreement by chance was expected to be large (i.e. 
high prevalence of “Yes” responses were expected).  Cohen’s kappa values decrease as chance 
for agreement increases. 
Yes 
No 
Contraindicated 
Unnecessary 
Pt. Refused 
Expert 
Rater 
Yes       No       Contrain.   Unnec.     Pt. Refused 
g1 
g2 
g3 
g4 
g5 
n f1      f2  f3         f4  f5 
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In order to evaluate the effect of prevalence on the Cohen’s kappa values, prevalence-
adjusted kappa (PAK) values were computed.  High (or low) prevalence decreases estimated 
kappa values (Sim & Wright, 2005).  Prevalence-adjusted kappa values were calculated from 
average cell counts of agreement (mean of cell counts on the diagonal).  Table 8 below illustrates 
how cell counts were calculated for PAK from cell counts for Routine repositioning as 
prescribed. 
Table 8. 
Illustration of Cell Counts used to calculate PAK from Actual Cell Counts 
     Non-Expert Rater 
 
a  
100.0001  
24.0001 
b  
10.0001     
c  
0.0001 
 
d  
10.0001 
 
e  
2.0001 
 
e  
10.0001 
 
f   
5.0001 
24.0001 
g  
5.0001 
 
h  
0.0001 
 
i  
0.0001 
 
j   
0.0001 
 
k  
5.0001 
 
l  
10.0001 
24.0001 
m  
10.0001 
 
n  
3.0001 
 
o   
8.0001 
 
p  
2.0001 
 
q  
6.0001 
 
r  
5.0001 
24.0001 
s  
0.0001 
 
t   
2.0001 
 
u  
3.0001 
 
v  
4.0001 
 
w  
0.0001 
 
x  
0.0001 
24.0001 
 
 
Note.  Contrain. = Contraindicated; Unnec. and Unnecessary = Unnecessary for the patient; 
Pt. = Patient 
 
Using the same formula that was used to calculate Cohen’s kappa values—only this time using 
the revised cell counts—a PAK value (and corresponding standard deviation) was calculated for 
each of the 11 NDNQI PrU risk and prevention measures per hospital.  Just as with the 
Yes 
 
No 
 
Contraindicated 
 
Unnecessary 
 
Pt. Refused 
Yes       No           Contrain.    Unnec. Pt. Refused 
g1= 122.0005 
46.0005 
g2= 20.0005 
39.0005 
g3= 28.0005 
42.0005 
g4= 21.0005 
40.0005 
g5= 9.0005 
33.0005 
n = 200.0025  f1=120.0005     f2=25.0005    f3=25.0005  f4=25.0005  f5=5.0005 
         44.0005   44.0005          39.0005   44.0005       29.0005 
Expert 
Rater 
121 
calculations for Cohen’s kappa values, 0.0001 was added to each cell (i.e. nothing changed 
except averaging the cells of agreement).  Landis and Koch’s (1977) classifications (< 0 = 
“poor”, 0 – .20 = “slight”, .21 – .40 = “fair”, .41 – .60 = “moderate”, .61 – .80 = “substantial”, 
and .81 – 1.0 = “near perfect”) were used to categorize PAK values’ strength of agreement.  For 
this study, the recommended reliability level for the study measures is ≥ .610. 
 Percent agreement.  Using the 2 – 4 frequency tables that were presented by SPSS, 
percent agreement was calculated for each expert/non-expert pair, per measure.  These are the 
same frequency tables that were used to calculate each expert/non-expert pair’s Cohen’s k and 
PAK values, only this time without the addition of 0.0001 to each cell.  These 2 – 4 percent 
agreement values for each measure were averaged to yield a single percent agreement for each 
risk and prevention measure per hospital.  Corresponding standard deviations were computed for 
each hospital’s per measure percent agreement value. 
Question 2: What is the overall agreement between expert participant ratings and 
non-expert participant ratings for the five NDNQI PrU risk measures per hospital, and the 
overall agreement between expert participant ratings and non-expert participant ratings 
for the six NDNQI PrU prevention measures per hospital?  For each hospital, the average 
Cohen’s kappa value obtained for each measure in Question 1 was used to answer Question 2.  
For each hospital, the average PAK value obtained in Question 1 for each measure, was used to 
answer Question 2. 
Cohen’s kappa.  The average Cohen’s kappa value obtained from the expert and non-
expert comparisons for each PrU risk measure (Skin assessment on admission, Risk assessment 
on admission, Time since last risk assessment, Risk assessment scale, and Risk status) was 
averaged to obtain one overall Cohen’s kappa value for PrU risk per hospital.  Similarly, the 
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average Cohen’s kappa value obtained from the expert and non-expert comparisons for each PrU 
prevention measure (Any PrU prevention, Skin assessment, Pressure-redistribution surface use, 
Routine repositioning, Nutritional support, and Moisture management) was averaged to obtain 
one overall Cohen’s kappa value for PrU prevention per hospital.  Corresponding standard 
deviations were computed for each of these per hospital Cohen’s k values for the PrU risk 
measures, and similarly for the per hospital Cohen’s k values for the PrU prevention measures. 
Prevalence-adjusted kappa.  The average PAK value obtained from the expert and non-
expert comparisons for each PrU risk measure (Skin assessment on admission, Risk assessment 
on admission, Time since last risk assessment, Risk assessment scale, and Risk status) was 
averaged to obtain one overall PAK value for PrU risk per hospital.  Similarly, the average PAK 
value obtained from the expert and non-expert comparisons for each PrU prevention measure 
(Any PrU prevention, Skin assessment, Pressure-redistribution surface use, Routine 
repositioning, Nutritional support, and Moisture management) was averaged to obtain one 
overall PAK value for PrU prevention per hospital.  Corresponding standard deviations were 
computed for each of these per hospital PAK values for the PrU risk measures, and similarly for 
the per hospital PAK values for the PrU prevention measures. 
Question 3: What is the average of the within hospital agreement between expert 
participant ratings and non-expert participant ratings for each of the 11 NDNQI pressure 
ulcer risk and prevention measures across hospitals?  Each hospital’s average Cohen’s kappa 
value that was obtained for each measure to answer Question 1 was used to answer Question 3.  
Similarly, each hospital’s average PAK value and percent agreement that was obtained for each 
measure in Question 1, was used to answer Question 3. 
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Cohen’s kappa.  The average Cohen’s kappa value that was computed for each pressure 
ulcer risk and prevention measure per hospital (to answer Question 1) was used to calculate an 
average Cohen’s kappa value for each pressure ulcer risk and prevention measure across 
hospitals.  For example, the average Cohen’s kappa value for Risk status that was obtained at 
each hospital was used to compute an average Cohen’s kappa value for Risk status across 
hospitals.  This was repeated for each of the other 10 NDNQI measures.  Therefore, there are 11 
across hospital Cohen’s kappa values (one for each of the 11 measures).  Corresponding 95% CIs 
were computed for each of these 11 Cohen’s kappa values. 
Prevalence-adjusted kappa (PAK).  In the same manner, the average PAK value that was 
computed for each pressure ulcer risk and prevention measure per hospital (to answer Question 
1) was used to calculate an average PAK value for each pressure ulcer risk and prevention 
measure across hospitals.  For example, the average PAK value for Risk status that was obtained 
at each hospital was used to compute an average PAK value for Risk status across hospitals.  
This was repeated for each of the other 10 NDNQI measures.  Therefore, there are 11 across 
hospital PAK values (one for each of the 11 measures).  Corresponding 95% CIs were computed 
for each of these 11 PAK values. 
Percent agreement.  In the same manner, the average percent agreement that was 
computed for each pressure ulcer risk and prevention measure per hospital (to answer Question 
1) was used to calculate an average percent agreement for each pressure ulcer risk and 
prevention measure across hospitals.  For example, the average percent agreement for Risk status 
that was obtained at each hospital was used to compute an average percent agreement for Risk 
status across hospitals.  This was repeated for each of the other 10 NDNQI measures.  Therefore, 
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there are 11 across hospital percent agreements (one for each of the 11 measures).  
Corresponding 95% CIs were computed for each of these 11 percent agreements. 
Question 4: What is the ICC (agreement) between expert participant ratings and 
non-expert participant ratings for each of the 11 NDNQI PrU risk and prevention 
measures across hospitals?  To answer this question, the Cohen’s kappa value obtained for each 
of the first two expert to non-expert comparisons (expert-to-Rater 1, and expert-to-Rater 2) per 
risk and prevention measure at each hospital, were used to calculate an ICCkappa for each of the 
11 NDNQI risk and prevention measures across hospitals.  Similarly, the PAK value from each 
of the first two expert to non-expert comparisons (expert-to-Rater 1, and expert-to-Rater 2) per 
risk and prevention measure at each hospital were used to calculate an ICCPAK for each of the 11 
NDNQI risk and prevention measures across hospitals. 
The choice for two rater pairs (expert to Rater 1 and expert to Rater 2) was because not 
all hospitals had three or more rater pairs.  Inclusion of all rater pairs in the analysis resulted in 
the listwise exclusion of all hospitals but one.  This is because the analysis method used requires 
that each hospital has the same number of raters, or data are excluded.  Therefore, when all rater 
pairs were included in the analysis (N = 84 kappa values from N = 36 hospitals), the analysis 
listwise excluded all but the single hospital that had 4 rater pairs.  Likewise, when only hospitals 
with 2 or 3 rater pairs (n = 35 hospitals) were included, the analysis listwise excluded 25 (69.4%) 
hospitals.  An alternative statistical approach to calculating ICCs was considered, such as linear 
mixed model analysis, but this method did not allow for the calculation of 95% CIs.  Although 
the ICC calculations did not include all 84 rater pairs, such as were used to calculate agreement 
estimates for the NDNQI risk and prevention measures (k, PAK, and percent agreement), the 
number of values that were included is comparable (N = 72).  Using two rater pairs per hospital 
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(to calculate ICCs) may be justified because the Cohen’s kappa values, PAK values, and percent 
agreements that were calculated for each measure are conceptually different than the ICCs.  The 
ICCs examined if participant raters across hospitals rated the study items with similar reliability.  
In contrast, the Cohen’s kappa values, PAK values, and percent agreements examined agreement 
within hospitals. 
Intraclass correlation coefficient (ICC).  Intraclass-correlation coefficients (ICCs) were 
used to examine inter-rater reliability across hospitals.  The sample size for ICCs was two kappa 
values per hospital, across 36 hospitals.  This translates to 72 kappa values per measure that were 
used to calculate ICCs. 
Intraclass correlation coefficients (ICCs) were calculated as in Hart et al. (2006): 
(Variability of kappa’s between hospitals) 
(Variability of kappa’s between hospitals) + (Variability of kappa’s within hospitals) 
Specifying Model 1 (Shrout & Fleiss, 1979), a one-way random ANOVA, 11 ICCskappa—one for 
each PrU risk and prevention measure—were calculated across hospitals.  The ICC reported is 
the “Single Measure” value.  This is because in practice, data on the study measures are collected 
by a single rater (B. Gajewski, personal communication, May 15, 2014).  Corresponding 95% 
CIs are reported for each ICCkappa. 
The choice for a one-way random model to calculate ICC values was based on previous 
research (Hart et al., 2006) that used this analysis to examine the reliability of PrU staging (B. 
Gajewski, personal communication, May 15, 2014).  The assumptions for a one-way ANOVA 
were addressed.  The assumptions include (1) the dependent variable is normally distributed for 
the population, (2) variances of the dependent variables are the same for all populations, and (3) 
the cases represent random samples from the populations and the scores are independent of each 
other (Green & Salkind, 2008).  According to Green and Salkind (2008), violation of the 
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normality assumption may have been tempered by requesting that an equal number of patients be 
rated per hospital, and  that  a random sample of hospitals meeting inclusion criteria were invited 
to participate in the study. 
An ICCPAK for each measure was calculated in the same way using the same formula 
from PAK values.  Specifying Model 1, a one-way random ANOVA, 11 ICCsPAK—one for each 
PrU risk and prevention measure—was calculated across hospitals.  The “Single Measure” ICC 
was reported.  Corresponding 95% CIs were calculated for each ICCPAK. 
An ICC close to zero (i.e. < .22) is desirable and suggests within-hospital variance is 
much greater than between-hospital variance (Hart et al., 2006); an ICC < .50 suggests within-
hospital variability was greater than between-hospital variability.  This means that the variance 
among the agreement between the expert and non-experts within hospitals, was greater than the 
variance in kappa values (agreement) across hospitals.  In other words, an ICC near zero 
suggests participant raters across hospitals rated the study items with similar reliability. 
Question 5: Where is the lack of agreement between expert and non-expert 
participant ratings on the 11 NDNQI pressure ulcer risk and prevention measures 
occurring?  (Agreement matrices/Descriptive statistics) 
Descriptive statistics.  Descriptive statistics were used to evaluate where the lack of 
agreement between experts’ ratings and non-experts’ ratings on each of the study measures 
occurred.  This included constructing “confusion” or agreement matrices in order to evaluate 
where the lack of agreement occurred (Bakeman & Gottman, 1997; Lloyd, n. d.).  These matrices 
are identical to the distribution table (Table 8) above in that cell counts on the diagonal indicate 
agreement between two raters, while cell counts off the diagonal identify disagreement.  The 
number of columns/rows equals the number of response categories.  Data used to construct these 
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matrices were the same as that were used to calculate Cohen’s kappa values (frequencies of 
agreement and disagreement between expert and non-expert participant ratings); data were 
presented in a matrix in order to visually identify areas of “confusion”.  Data were aggregated to 
present one matrix for each NDNQI PrU risk and prevention measure across hospitals.  These 
matrices give important insight into where the disagreement occurred in order to target efforts at 
improving reliability (as needed). 
Table 9 below is an example of an agreement matrix with hypothetical data.  From this 
table, areas of disagreement can be identified.  For instance, most disagreement occurred when 
one rater believed routine repositioning was performed (“Yes”), and the other rater thought 
repositioning was “Unnecessary”. 
Table 9. 
Illustration of an Agreement Matrix for Hypothetical Data: Routine Repositioning 
    Non-Expert Rater 
 
 
546 
 
28 
 
7 
 
73 
 
4 
 
25 
 
115 
 
11 
 
18 
  
7 
 
1 
 
21 
 
52 
 
10 
 
2 
 
53 
 
22 
 
4 
 
35 
 
0 
 
1 
 
30 
 
1 
 
2 
 
18 
 
Note.  Contrain. = Contraindicated; Unnec. and Unnecessary = Unnecessary for the patient; 
Pt. = Patient  
Yes 
No 
Contraindicated 
Unnecessary 
Pt. Refused 
Expert 
Rater Yes       No       Contrain.   Unnec.     Pt. Refused 
g1= 658 
g2 =176 
g3 =86 
g4 =114 
g5=52 
n = 1086 f1=626      f2=216 f3=75     f4=138    f5=31 
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 Aim 2: Examine the methods and processes used by participant raters to gather 
data on the NDNQI PrU risk and prevention measures.  (Descriptive statistics) 
Descriptive statistics.  Descriptive statistics were used to describe the methods and 
processes used to collect information needed to rate the study indicators, as self-reported on the 
online REDCap survey, Pressure Ulcer Risk and Prevention Reliability Survey (Appendix C).  
Frequencies and percentages are presented for each item on the survey.  For analysis of the open-
ended responses describing participant rater characteristics [(#1) What is your job title?—Other 
(please specify); (#6) In addition to chart abstractor, what other role(s) in the NDNQI Pressure 
Ulcer Survey do you hold?—Other (please specify); (#8) Which of the following active 
certifications do you hold?—Other (please specify)], responses were grouped into conceptually 
similar categories.  If a participant rater accessed the survey more than once, only survey data 
submitted during the first login was included in the data analysis.  Frequencies and percentages 
of responses for each of these categories are reported. 
Pilot Study 
A pilot study using a single NDNQI participating hospital was performed to assess the 
feasibility of the study and of the Data Collection Form, and test REDCap use.  Purposive 
sampling was used to identify a Midwestern hospital for the pilot study.  Except for recruitment 
and pre-study teleconference, the study protocol was followed during the pilot study.  Using the 
operational definitions specified in the study protocol, one expert and three non-experts were 
identified by the site coordinator.  After IRB approval at the pilot hospital, data were collected on 
August 7, 2014.  Participant raters did not submit their data and complete the online survey, 
however, until August 26.  After this date, pilot study participant raters and the skin survey team 
leader were asked to provide feedback on the Overview of the Pressure Ulcer Risk and 
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Prevention Study, the Site Coordinator Instructions, the Participant Rater Instructions, the Data 
Collection Form, and the Pressure Ulcer Risk and Prevention Reliability Survey—including 
feedback on the process of uploading their Excel file, and any issues or difficulties they 
encountered during the pilot study.  A REDCap survey was developed by this student researcher 
that was used to solicit anonymous feedback from these individuals (Appendix K).  In addition, 
the pilot study gave the student researcher experience with REDCap. 
Anonymous feedback on the study from pilot participants (N = 4) was received on 
August 27, 2014.  This feedback (Appendix K) identified some technical issues with the Data 
Collection Form, which were addressed before the start of the study.  No other issues were 
identified.  Other feedback from pilot participants included (a) it took approximately 3 to 4 hours 
to rate 50 patients on these measures, and (b) survey completion and file upload took ≤ 15 to 30 
minutes.  No pilot data were included in the study.  The hospital that participated in the pilot 
study was not eligible to participate in the study. 
Study Timeline 
Table 10. 
Study Timeline 
JUNE 
2014 
JULY 
2014 
AUG 2014 SEPT-OCT 
2014 
NOV-DEC 
2014 
JAN-MAR 
2015 
KUMC 
HSC & 
NDNQI 
approval 
 
 
 
 
Pilot 
hospital 
recruited 
Study 
materials 
sent to 
pilot site. 
(July 27) 
 
 
 
Pilot IRB 
approval 
(July 30) 
Sent Invitation to 
Participate (Aug. 1) 
& selected hospitals 
 
Pilot study  
(Aug. 7 – Aug. 27) 
 
Study materials sent 
to participating 
hospitals  
(Aug. 27) 
Teleconference 
(Sept. 9) 
 
 
 
 
 
Data collection 
& submission 
(Sept. 29 – Oct. 
31) 
Data 
clarification 
& cleaning 
 
 
 
 
Data 
analysis 
Write 
Results, 
Discussion, 
& 
Conclusion 
 
Results to 
participating  
hospitals 
(Feb.) 
Note. KUMC = Kansas University Medical Center; HSC = Human Subjects Committee. 
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CHAPTER IV:  RESULTS 
 
The purpose of this study was to examine the reliability of the NDNQI® pressure ulcer 
risk and prevention measures.  Specific study aims were to (1) Aim 1:  examine the reliability of 
the NDNQI pressure ulcer risk and prevention measures within and across NDNQI hospitals, and 
(2) Aim 2: examine the methods and processes used by participant raters to gather data on the 
NDNQI PrU risk and prevention measures.  In Chapter IV, the hospital, unit, patient, and 
participant rater characteristics are described.  Next, results by study aim and question are 
presented. 
Descriptive Statistics 
Participant raters from among 41 hospitals rated patients on the 11 NDNQI PrU risk and 
prevention measures.  Of these 41 hospitals, data from five hospitals were removed from the 
analysis because (a) only a single participant rater scored patients (1 hospital), (b) only two 
participant raters scored patients (3 hospitals), and (c) three participant raters collected data on 
different patients (1 hospital), see Figure 3 below.  Among the final sample of 36 hospitals, 120 
participant raters collected data on 1,637 patients.  These patients were located on 92 units; 
specifically on 62 (67%) adult medical-surgical units, 19 (21%) adult medical units, and 11 
(12%) adult surgical units. 
Hospitals (N = 36) 
Most of the hospitals were a Non-Teaching Facility [n = 21 (58.3%)], located in a 
metropolitan area [n = 31 (86.1%)], and Non-Magnet [n = 27 (75%)].  The majority were 100 – 
299 staffed beds in size [n = 26 (72.2%)].  Two hospitals were < 100 staffed beds.  The decision 
to include these two smaller hospitals in the final analysis was based on visual (box-and-whisker  
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Figure 3.  Derivation of the Hospital Sample 
750 Hospitals Invited to Participate 
 
124 (16.5%) Replied 
 
 61 (8.4%) Accepted     60 (8%) Regretted 
 (+2)       (+1) 
 = 63 Hospitals 3 (0.1%) “I’m not sure, I need more information” 
  
• 18 (28.6%) Withdrew: 
o 7 lack of time/resources 
o 8 non-specified reasons 
o 2 organizational or job change/transition 
o 1could not get IRB approval until after the study period 
 
• 5 (7.9%) Submitted data that were not usable: 
o 1 had only one participant rater 
o 3 had only two participant raters 
o 1 had three participant raters collect data on different  
patients 
 
• 4 (6.3%) Did not participate or respond. 
        [= 42.9% attrition rate] 
 
  36 Hospitals Included in the Study 
 
plots) and statistical inspection of the Cohen’s kappa and PAK values that were generally within 
the range of all the other hospitals’ kappa values.  Additional support for including these small 
hospitals came from the fact that the number of patients rated at each of these two small hospitals 
was similar to the number of patients rated at the other hospitals.  Hospital characteristics are 
presented in Table 11 below.  
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Table 11. 
Hospital Characteristics (N = 36):  Size, Teaching Status, Magnet Status, and Metropolitan 
Status              
 
       n (%)       
Number of Staffed Beds 
 50 – 74     1 (2.8%) 
 75 – 99     1 (2.8%) 
 100 – 199     13 (36.1%) 
 200 – 299     13 (36.1%) 
 300 – 399     5 (13.9%) 
 400 – 499     3 (8.3%) 
 ≥ 500      0 
Teaching Status 
 Academic Medical Center   3 (8.3%) 
 Teaching Facility    12 (33.3%) 
 Non-Teaching Facility   21 (58.3%) 
Magnet Status 
 Magnet     9 (25%) 
 Non-Magnet     27 (75%) 
Metropolitan Status 
 Non-Metropolitan/Non-Micropolitan  1 (2.8%) 
 Micropolitan     4 (11.1%) 
 Metropolitan     31 (86.1%) 
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Patients (N = 1,637) 
Among the 36 hospitals, data were collected on a total of 1,737 patients.  Of these 1,737 
patients, data from 100 patients were removed from analysis because patient age, patient gender, 
and patient room number did not agree across raters within that particular hospital.  The final 
sample has 1,637 patients, for an average of 45.5 patients per hospital (SD = 6.4).  All 1,637 
patients were rated on the PrU risk measures.  Of these, 553 (33.8%) patients were considered by 
the expert rater to be “at risk” for PrU development.  However, not all non-experts agreed with 
the expert on risk status, so the sample of patients for each of the prevention measures was 528 
to 530. Therefore, 528 to 530 patients were rated on both the risk and the prevention measures.  
This is an average of 14.7 “at risk” patients per hospital (range = 5 to 37; SD = 7.0). 
Patient age ranged from 17 – 102 years, with a mean age of 63.3 years (SD = 18.4).  A 
majority of patients were female, n = 893 (55%).  Of the 1,637 patients; 905 (55.3%) were on a 
medical-surgical unit, 619 (37.8%) were on a medical unit, and 113 (6.9%) were on a surgical 
unit.  These frequencies are logical because data collection was to begin on medical-surgical 
units, and then proceed to medical units, followed by surgical units.  Adult medical-surgical, 
medical, and surgical unit types represent the units from where nearly half (49%) of NDNQI PrU 
reporting is derived (NDNQI Statistical Analyst, personal communication, November 21, 2014). 
Participant raters at 30 (83.3%) of the 36 hospitals, each collected data on 50 patients.  
Table 12 below presents patient age and gender, the number of participant raters, the total 
number of patients rated, the number of patients included in the statistical analysis, and the 
number of patients considered to be “at risk” by the “expert”.  For instance, Table 12 shows that 
Hospital 1 had three participant raters who each collected data on 50 patients.  However, only 42  
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of those patients were rated by all three of these participant raters, and therefore, only these 42 
patients were included in the statistical analysis of the NDNQI PrU risk measures.  Of those 42 
patients, 12 (28.6%) were considered to be “at risk” for PrU development by the “expert”.  Only 
these 12 patients, therefore, were included in the data analysis for the NDNQI PrU prevention 
measures. 
Participant Raters (N = 120) 
Among the 36 hospitals, 120 raters participated in the study (36 experts—one at each 
hospital—and 84 non-experts), which is on average 3.3 participant raters per hospital.  
Specifically, 25 (69%) hospitals had 3 participant raters (1 expert, 2 non-experts), 10 (28%) 
hospitals had 4 participant raters (1 expert, 3 non-experts), and 1 (3%) hospital had 5 participant 
raters (1 expert, 4 non-experts).  Participant rater characteristics (job title, education, and 
certifications) are presented in Table 13. 
Most of the experts reported being a Wound/Skin Care Nurse [n = 17 (47.2%)] or Staff 
RN [n = 8 (22.2%)], with a Bachelor’s [n = 18 (50%)] or Master’s [n = 12 (33.3%)] Degree in 
Nursing.  Conversely, most of the non-expert participant raters reported being a “Staff RN” [n = 
44 (52.8%)], with a Bachelor’s [n = 37 (44%)] or Associate’s [n = 21 (25%) Degree in Nursing. 
Fourteen (38.9%) experts reported having “no certifications in wound care”, while 62 (73.8%) 
non-experts reported the same.  Among the experts, 16 (44.4%) were Certified Wound, Ostomy, 
Continence Nurses (CWOCN), 4 (11.1%) were Wound Care Certified (WCC), 1 (2.8%) was a 
Certified Wound Care Nurse (CWCN), and 1 (2.8%) was a Certified Wound Ostomy Nurse 
(CWON).  Overall, fewer non-experts were certified in wound care (8 [9.5%] CWOCNs, 2 
[2.4%] WCC, 2 [2.4%] CWCNs, and 1 [1.2%] CWON).  Five (13.9%) experts and 9 (10.7%) 
non-experts identified certification in areas other than wound care.  
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Table 13. 
Participant Rater (N = 120) Characteristics:  Job Title, Education, and Certifications 
           Total 
     Expert   Non-Expert       Participant Raters 
     (n = 36)  (n = 84)  (N = 120) 
     n (%)   n (%)   n (%)   
What is your job title? a 
 
 Staff RN   8 (22.2)  44 (52.4)  52 (43.3) 
 CNL    4 (11.1)  2 (2.4)   6 (5.0) 
 APN    1 (2.8)   2 (2.4)   3 (2.5) 
 Nurse Manager  3 (3.8)   3 (3.6)   6 (5.0) 
 Nursing Administrator      −   1 (1.2)   1 (0.8)  
 Quality Improvement       −   4 (4.8)   4 (3.3) 
 Wound/Skin Care Nurse 17 (47.2)  15 (17.9)  32 (26.7) 
 NDNQI Site Coordinator 1 (2.8)   4 (4.8)   5 (4.2) 
 Other, specify 
      Clinical Educator  1 (2.8)   2 (2.4)   3 (2.5) 
      Infection Prevention 1 (2.8)        −   1 (0.8) 
      Certified Nurse Aid      −   2 (2.4)   2 (1.7) 
      Research Council       −   1 (1.2)   1 (0.8) 
      Dietitian        −   1 (1.2)   1 (0.8) 
      LPN        −   1 (1.2)   1 (0.8) 
      Clinical Supervisor      −   1 (1.2)   1 (0.8) 
 
Registered Nurse (RN) nursing education. b 
 
 Yes    33 (91.7)  72 (85.7)  105 (87.5) 
 No    3 (8.3)   11 (13.1)  14 (11.7) 
              
a Missing values = 1 (0.8%) 
b Missing values = 1 (0.8%)  
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Table13 (continued). 
Participant Rater (N = 120) Characteristics:  Job Title, Education, and Certifications 
           Total 
     Expert   Non-Expert       Participant Raters 
     (n = 36)  (n = 84)  (N = 120) 
     n (%)   n (%)   n (%)   
Select highest RN education level. c 
 
 Associate’s Degree Nursing 3 (8.3)   21 (25)  24 (20) 
 Bachelor’s Degree Nursing 18 (50)  37 (44)  55 (45.8) 
 Master’s Degree Nursing 12 (33.3)  12 (14.3)  24 (20) 
 Doctorate Degree Nursing      −        −        − 
  
Select highest non-RN education level. d 
 
 High School Graduate/GED      −   2 (2.4)   2 (1.7) 
 Associate’s Degree  2 (5.6)   4 (4.8)   6 (5.0) 
  Non-nursing 
 Bachelor’s Degree  1 (2.8)   4 (4.8)   5 (4.2) 
  Non-nursing 
 Master’s Degree       −   1 (1.2)   1 (0.8) 
  Non-nursing 
 Doctorate Degree       −        −        − 
  Non-Nursing 
              
c Missing values = 2 (1.7%) 
d Missing values = 0 
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Table 13 (continued). 
Participant Rater (N = 120) Characteristics:  Job Title, Education, and Certifications 
           Total 
     Expert   Non-Expert       Participant Raters 
     (n = 36)  (n = 84)  (N = 120) 
     n (%)   n (%)   n (%)   
Which of the following active certifications do you hold? e (Select all that apply.) 
 CWOCN   16 (44.4)  8 (9.5)   24 (20) 
 CWCN   1 (2.8)   2 (2.4)   3 (2.5) 
 COCN         −        −        − 
 CCCN         −        −        − 
 CWON        −        −        − 
 WCC    4 (11.1)  2 (2.4)   6 (5.0) 
 No certifications in wound care 
     14 (38.9)  62 (73.8)  76 (63.3) 
 Other Certifications (please describe) 
• CIC   1 (2.8)        −   1 (0.8) 
• Adult Health CNS 1 (2.8)        −   1 (0.8) 
• CCRN   1 (2.8)   1 (1.2)   2 (1.7) 
• CNRN   1 (2.8)   1 (1.2)   2 (1.7) 
• Medical-Surgical 1 (2.8)   3 (3.6)   4 (3.3) 
• ONC        −   2 (2.4)   2 (1.7) 
• CNL        −   1 (1.2)   1 (0.8) 
• CWCA       −   1 (1.2)   1 (0.8) 
              
e Totals do not equal the number of raters because respondents were to select “all that apply”. 
 
Note. 
CWOCN = Certified Wound, Ostomy, Continence Nurse 
CWCN = Certified Wound Care Nurse 
COCN = Certified Ostomy Care Nurse 
CCCN = Certified Continence Care Nurse 
CWON = Certified Wound Ostomy Nurse 
CWS = Certified Wound Specialist 
WCC = Wound Care Certified 
CIC = Certified Infection Control 
CNS = Clinical Nurse Specialist 
CCRN = Critical Care Registered Nurse 
CNRN = Certified Neuroscience RN 
ONC = Oncology/Chemotherapy Administrator 
CNL = Clinical Nurse Leader 
CWCA = Certified Wound Care Associate 
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Results by Study Aim 
Aim 1 
Aim 1 was to examine the reliability of the NDNQI pressure ulcer risk and prevention 
measures within and across NDNQI hospitals.  Results are reported by question. 
Question 1.  What is the agreement between expert participant ratings and non-
expert participant ratings for each of the 11 NDNQI pressure ulcer risk and prevention 
measures within each hospital?  To address this question, each hospital’s Cohen’s kappa value, 
PAK value (see discussion p. 119 – 121), and percent agreement are presented by measure 
below.  Altogether, 396 Cohen’s kappa values, 396 PAK values, and 396 percent agreement 
values are reported (36 hospitals x 11 measures = 396).  Overall, the level of agreement for 
Cohen’s kappa values was more varied than the PAK values, and ranged from “poor” [n = 15 
(3.8%)] to “near perfect” [n = 34 (8.6%)].  More than 40% of the Cohen’s kappa values indicate 
“moderate” [n = 170 (42.9%)] agreement.  Another 40% indicate “fair” [n = 74 (18.7%)] or 
“slight” agreement [n = 83 (21%)].  Only 84 of the 396 (21.2%) Cohen’s kappa values reflect at 
least “substantial” agreement.  Hospital PAK values across the 11 measures ranged from “poor” 
[n = 1 (0.3%)] to “near perfect” [n = 265 (66.9%)], with 309 of the 396 (78.0%) PAK values 
reflecting at least “substantial” agreement. 
Risk measure – Skin assessment within 24 hours of admission.  Cohen’s kappa values 
for the PrU risk measure, Skin assessment within 24 hours of admission (Table 14), ranged from 
-.014 “poor” to 1.0 “near perfect” agreement between the expert and non-expert raters.  For 2 
(5.6%) hospitals, Cohen’s kappa values indicate “substantial” to “near perfect” agreement.  In 17 
(47.2%) hospitals, Cohen’s kappa values indicated “moderate” agreement; in 11 (30.6%) 
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Table 14. 
Aim 1 Question 1: “Skin Assessment within 24 hours of Admission”—Number of Expert/Non-
Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital 
(N = 36 Hospitals) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .236 (.356)   .911 (.025)   94.05 (1.68) 
2 2   .500 (0) 1.00 (0) 100 (0) 
3 2   .500 (0) 1.00 (0) 100 (0) 
4 3   .334 (.288)   .989 (.019)   99.26 (1.28) 
5 2   .001 (0.00)   .963 (0.00)   97.56 (0.00) 
6 2 -.014 (.021)   .939 (.043)   95.92 (2.89) 
7 3   .500 (0) 1.00 (0) 100 (0) 
8 3 1.00 (0) 1.00 (0) 100 (0) 
9 2   .500 (0) 1.00 (0) 100 (0) 
10 2   .250 (.354)   .968 (.046)   97.83 (3.08) 
11 2   .500 (0) 1.00 (0) 100 (0) 
12 3   .772 (.197)   .975 (.022)   98.33 (1.44) 
13 3   .500 (0) 1.00 (0) 100 (0) 
14 2   .500 (0) 1.00 (0) 100 (0) 
15 2   .500 (0) 1.00 (0) 100 (0) 
16 2   .500 (0) 1.00 (0) 100 (0) 
17 2   .154 (.218)   .854 (.023)   90.22 (1.53) 
18 3   .334 (.288)   .989 (.019)   99.26 (1.28) 
19 2   .251 (.353)   .985 (.021)   99.00 (1.41) 
20 2   .219 (.310)   .919 (.023)   94.57 (1.53) 
21 2   .001 (.001)   .952 (.023)   96.81 (1.51) 
22 2   .500 (0) 1.00 (0) 100 (0) 
23 3   .334 (.577)   .979 (.018)   98.61 (1.20) 
24 4   .375 (.250)   .992 (.016)   99.48 (1.04) 
25 2   .500 (0) 1.00 (0) 100 (0) 
26 3   .334 (.288)   .990 (.018)   99.32 (1.18) 
27 2   .500 (0) 1.00 (0) 100 (0) 
28 3   .500 (0) 1.00 (0) 100 (0) 
29 2   .250 (.354)   .882 (.168)   92.00 (11.31) 
30 2 -.010 (.015)   .955 (.021)   97.00 (1.41) 
31 3   .333 (.289)   .977 (.039)   98.48 (2.63) 
32 2   .500 (0) 1.00 (0) 100 (0) 
33 2   .001 (0.00)   .966 (0.00)   97.73 (0.00) 
34 2   .500 (0) 1.00 (0) 100 (0) 
35 2   .500 (0) 1.00 (0) 100 (0) 
36 2   .500 (0) 1.00 (0) 100 (0) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa  
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hospitals there was “fair” agreement; in 4 (11.1%) hospitals, there was “slight” agreement; and in 
2 (5.6%) hospitals, Cohen’s kappa values indicate “poor” agreement between the expert and non-
expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .854 – 1.0, indicating “near 
perfect” agreement between expert and non-expert ratings on Skin assessment within 24 hours of 
admission.  Percent agreement ranged from 90.22% – 100% across hospitals for this measure. 
Risk measure – Risk assessment within 24 hours of admission.  Cohen’s kappa values 
for the PrU risk measure, Risk assessment within 24 hours of admission (Table 15), ranged from 
-.027 “poor” to 1.0 “near perfect” agreement between the expert and non-expert raters.  For 4 
(11.1%) hospitals, Cohen’s kappa values indicate “near perfect” agreement; and in 1 (2.8%) 
hospital, there was “substantial” agreement.  In 22 (61.1%%) hospitals, Cohen’s kappa values 
indicate “moderate” agreement; in 4 (11.1%) hospitals, there was “fair” agreement; in 4 (11.1%) 
hospitals, there was “slight” agreement; and in 1 (2.8%) hospital, the Cohen’s kappa value 
indicates “poor” agreement between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .822 – 1.0, indicating “near 
perfect” agreement between expert and non-expert ratings on Risk assessment within 24 hours of 
admission.  Percent agreement ranged from 87.76% – 100% across hospitals for this measure. 
Risk measure – Time since last pressure ulcer risk assessment.  Cohen’s kappa values 
for the PrU risk measure, Time since last pressure ulcer risk assessment (Table 16), ranged from 
-.052 “poor” to .826 “near perfect” agreement between the expert and non-expert raters.  For 1 
(2.8%) hospital, the Cohen’s kappa value indicates “near perfect” agreement; and in 3 (8.3%) 
hospitals, there was “substantial” agreement.  In 13 (36.1%) hospitals, Cohen’s kappa values 
indicate “moderate” agreement; in 7 (19.4%) hospitals, there was “fair” agreement; in 8 (22.2%)  
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Table 15. 
Aim 1 Question 1: “Risk Assessment within 24 hours of Admission”—Number of Expert/Non-
Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital 
(N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .251 (.353)   .982 (.025)   98.81 (1.68) 
2 2   .500 (0) 1.00 (0) 100 (0) 
3 2   .500 (0) 1.00 (0) 100 (0) 
4 3   .500 (0) 1.00 (0) 100 (0) 
5 2   .500 (0) 1.00 (0) 100 (0) 
6 2   .250 (.354)   .822 (.252)   87.76 (17.32) 
7 3   .500 (0) 1.00 (0) 100 (0) 
8 3   .913 (.151)   .985 (.025)   99.02 (1.70) 
9 2   .001 (0.00)   .969 (0.00)   97.92 (0.00) 
10 2   .556 (.128)   .903 (.046)   93.48 (3.08) 
11 2   .251 (.353)   .985 (.022)   98.98 (1.44) 
12 3   .658 (.296)   .950 (.043)   96.67 (2.89) 
13 3   .500 (0) 1.00 (0) 100 (0) 
14 2   .500 (0) 1.00 (0) 100 (0) 
15 2   .001 (0.00)   .970 (0.00)   98.00 (0.00) 
16 2   .500 (0) 1.00 (0) 100 (0) 
17 2   .151 (0.00)   .828 (0.00)   90.22 (1.53) 
18 3 1.00 (0) 1.00 (0) 100 (0) 
19 2   .500 (0) 1.00 (0) 100 (0) 
20 2   .501 (.706)   .984 (.023)   98.92 (1.53) 
21 2 -.027 (.008)   .904 (.045)   93.62 (3.01) 
22 2 1.00 (0) 1.00 (0) 100 (0) 
23 3   .914 (.149)   .990 (.018)   99.32 (1.18) 
24 4   .581 (.501)   .977 (.030)   98.44 (2.00) 
25 2   .500 (0) 1.00 (0) 100 (0) 
26 3   .334 (.288)   .990 (.018)   99.32 (1.18) 
27 2   .500 (0) 1.00 (0) 100 (0) 
28 3   .500 (0) 1.00 (0) 100 (0) 
29 2   .500 (0) 1.00 (0) 100 (0) 
30 2   .500 (0) 1.00 (0) 100 (0) 
31 3   .167 (.288)   .977 (.020)   98.49 (1.31) 
32 2   .500 (0) 1.00 (0) 100 (0) 
33 2   .500 (0) 1.00 (0) 100 (0) 
34 2   .500 (0) 1.00 (0) 100 (0) 
35 2   .500 (0) 1.00 (0) 100 (0) 
36 2   .500 (0) 1.00 (0) 100 (0) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa  
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Table 16. 
Aim 1 Question 1: “Time since Last Pressure Ulcer Risk Assessment”—Number of Expert/Non-
Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital 
(N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .001 (.001)   .791 (.055)   80.95 (3.37) 
2 2   .002 (.041)   .658 (.382)   69.39 (34.63) 
3 2 -.052 (.074)   .257 (.075)   35.87 (1.54) 
4 3   .270 (.036)   .827 (.065)   85.18 (5.59) 
5 2   .039 (.028)   .570 (.078)   64.64 (5.17) 
6 2   .188 (.035)   .454 (.063)   54.08 (4.33) 
7 3   .500 (0) 1.00 (0) 100 (0) 
8 3   .426 (.328)   .717 (.163)   76.19 (13.51) 
9 2   .299 (.493)   .902 (.069)   91.67 (5.89) 
10 2 -.020 (.033)   .924 (.036)   93.48 (3.08) 
11 2   .705 (.127)   .834 (.067)   85.72 (5.78) 
12 3   .500 (0) 1.00 (0) 100 (0) 
13 3   .315 (.595)   .548 (.415)   58.98 (38.72) 
14 2   .252 (.351)   .988 (.018)   98.94 (1.51) 
15 2   .004 (0)   .977 (0)   98.00 (0.00) 
16 2   .729 (0)   .953 (0)   96.00 (0.00) 
17 2   .305 (.412)   .500 (.491)   53.27 (47.66) 
18 3   .664 (.364)   .871 (.112)   88.89 (9.69) 
19 2   .430 (.308)   .849 (.147)   87.00 (12.73) 
20 2   .455 (.643)   .899 (.107)   91.31 (9.23) 
21 2   .389 (.548)   .913 (.052)   92.55 (4.51) 
22 2   .826 (.016)   .953 (0)   91.00 (7.07) 
23 3   .506 (.111)   .726 (.059)   76.98 (4.81) 
24 4   .397 (.079)   .647 (.048)   70.22 (3.88) 
25 2   .004 (0.00)   .976 (0.00)   97.92 (0.00) 
26 3   .504 (.449)   .944 (.036)   95.24 (3.12) 
27 2   .500 (0) 1.00 (0) 100 (0) 
28 3 -.014 (.103)   .487 (.188)   57.41 (15.88) 
29 2   .497 (.023)   .638 (.016)   69.00 (1.41) 
30 2   .525 (0.00)   .766 (0.00)   80.00 (0.00) 
31 3   .061 (.106)   .713 (.086)   75.17 (6.12) 
32 2   .500 (0) 1.00 (0) 100 (0) 
33 2   .470 (.274)   .668 (.206)   71.59 (17.68) 
34 2 -.040 (.059)   .765 (.260)   80.00 (22.01) 
35 2   .513 (.204)   .952 (.034)   95.92 (2.89) 
36 2   .001 (.001)   .791 (.065)   82.00 (5.66) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
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hospitals, there was “slight” agreement; and in 4 (11.1%) hospitals, Cohen’s kappa values 
indicate “poor” agreement between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .257 “fair” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 30 (83.3%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement.  In 5 (13.9%) hospitals, PAK values indicate 
“moderate” agreement; and in 1 (2.8%) hospital, the PAK value indicates “fair” agreement 
between expert and non-expert ratings for the measure Time since last pressure ulcer risk 
assessment.  Percent agreement ranged from 35.87% – 100% across hospitals for this measure. 
Risk measure – Risk assessment scale.  Cohen’s kappa values for the PrU risk measure, 
Risk assessment scale (Table 17), ranged from .319 “fair” to .500 “moderate” agreement between 
the expert and non-expert raters.  For 35 (97.2%) hospitals, Cohen’s kappa values indicate 
“moderate” agreement; and for 1 (2.8%) hospital, the Cohen’s kappa value indicates “fair” 
agreement between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .829 – 1.0, indicating “near 
perfect” agreement between expert and non-expert ratings on Risk assessment scale.  Percent 
agreement ranged from 91.90% – 100% across hospitals for this measure. 
Risk measure – Risk status.  Cohen’s kappa values for the last PrU risk measure, Risk 
status (Table 18), ranged from .314 “fair” to 1.0 “near perfect” agreement between the expert 
and non-expert raters.  For 23 (63.9%) hospitals, there was “near perfect” agreement; and in 9 
(25.0%) hospitals, there was “substantial” agreement.  In 3 (8.3%) hospitals, Cohen’s kappa 
values indicate “moderate” agreement; and in 1 (2.8%) hospital, there was “fair” agreement 
between the expert and non-expert raters.  
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Table 17. 
Aim 1 Question 1: “Risk Assessment Scale”—Number of Expert/Non-Expert Pairs, Cohen’s 
Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2 .500 (0) 1.00 (0) 100 (0) 
2 2 .500 (0) 1.00 (0) 100 (0) 
3 2 .500 (0) 1.00 (0) 100 (0) 
4 3 .500 (0) 1.00 (0) 100 (0) 
5 2 .500 (0) 1.00 (0) 100 (0) 
6 2 .500 (0) 1.00 (0) 100 (0) 
7 3 .500 (0) 1.00 (0) 100 (0) 
8 3 .500 (0) 1.00 (0) 100 (0) 
9 2 .500 (0) 1.00 (0) 100 (0) 
10 2 .500 (0) 1.00 (0) 100 (0) 
11 2 .500 (0) 1.00 (0) 100 (0) 
12 3 .500 (0) 1.00 (0) 100 (0) 
13 3 .500 (0) 1.00 (0) 100 (0) 
14 2 .500 (0) 1.00 (0) 100 (0) 
15 2 .500 (0) 1.00 (0) 100 (0) 
16 2 .500 (0) 1.00 (0) 100 (0) 
17 2 .500 (0) 1.00 (0) 100 (0) 
18 3 .500 (0) 1.00 (0) 100 (0) 
19 2 .319 (.451)   .892 (.040)   91.90 (2.97) 
20 2 .500 (0) 1.00 (0) 100 (0) 
21 2 .500 (0) 1.00 (0) 100 (0) 
22 2 .500 (0) 1.00 (0) 100 (0) 
23 3 .500 (0) 1.00 (0) 100 (0) 
24 4 .500 (0) 1.00 (0) 100 (0) 
25 2 .500 (0) 1.00 (0) 100 (0) 
26 3 .500 (0) 1.00 (0) 100 (0) 
27 2 .500 (0) 1.00 (0) 100 (0) 
28 3 .500 (0) 1.00 (0) 100 (0) 
29 2 .500 (0) 1.00 (0) 100 (0) 
30 2 .500 (0) 1.00 (0) 100 (0) 
31 3 .500 (0) 1.00 (0) 100 (0) 
32 2 .500 (0) 1.00 (0) 100 (0) 
33 2 .500 (0) 1.00 (0) 100 (0) 
34 2 .500 (0) 1.00 (0) 100 (0) 
35 2 .500 (0) 1.00 (0) 100 (0) 
36 2 .500 (0) 1.00 (0) 100 (0) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
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Table 18. 
Aim 1 Question 1: “Risk Status”—Number of Expert/Non-Expert Pairs, Cohen’s Kappa, 
Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .914 (.037)   .947 (.025)   96.43 (1.68) 
2 2   .970 (.043)   .985 (.022)   98.98 (1.44) 
3 2   .905 (.047)   .951 (.023)   96.74 (1.54) 
4 3   .659 (.217)   .746 (.169)   82.96 (11.41) 
5 2   .429 (.035)   .711 (.053)   80.49 (3.45) 
6 2   .788 (.015)   .849 (.002)   89.90 (0.14) 
7 3   .609 (.066)   .633 (.062)   75.51 (4.08) 
8 3   .961 (.067)   .985 (.026)   98.99 (1.75) 
9 2   .314 (.039)   .443 (.030)   60.42 (2.95) 
10 2   .947 (.076)   .968 (.046)   97.83 (3.08) 
11 2   .947 (.008)   .969 (0.00)   97.94 (0.03) 
12 3   .723 (0.00)   .884 (0.00)   92.31 (0.00) 
13 3   .918 (.143)   .943 (.099)   96.15 (6.66) 
14 2   .713 (.038)   .748 (.001)   82.98 (0.00) 
15 2   .924 (.107)   .926 (.105)   95.00 (7.07) 
16 2   .917 (0.00)   .940 (0.00)   96.00 (0.00) 
17 2 1.00 (0) 1.00 (0) 100 (0) 
18 3   .573 (.139)   .646 (.142)   75.56 (10.64) 
19 2   .839 (.152)   .924 (.065)   94.92 (4.36) 
20 2   .915 (.060)   .935 (.046)   95.66 (3.08) 
21 2   .851 (.211)   .888 (.059)   92.50 (10.61) 
22 2   .794 (.023)   .835 (.021)   89.00 (1.41) 
23 3   .786 (.331)   .838 (.254)   88.65 (17.84) 
24 4   .889 (.127)   .921 (.095)   94.68 (6.38) 
25 2   .950 (.071)   .969 (.045) 100 (0) 
26 3   .636 (.111)   .786 (.081)   85.72 (5.40) 
27 2   .957 (0.00)   .969 (0.00)   97.96 (0.00) 
28 3   .969 (.054)   .986 (.024)   99.07 (1.61) 
29 2   .944 (0.00)   .970 (0.00)   98.00 (0.00) 
30 2   .618 (.017)   .866 (.021)   91.00 (1.41) 
31 3   .831 (.094)   .871 (.073)   91.42 (4.82) 
32 2   .935 (.030)   .955 (.021)   97.00 (1.41) 
33 2   .848 (.215)   .885 (.163)   92.39 (10.76) 
34 2   .683 (.322)   .821 (.206)   87.78 (14.14) 
35 2   .912 (0.00)   .939 (0.00)   95.92 (0.00) 
36 2   .937 (.089)   .955 (.064)   97.00 (4.24) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
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Prevalence-adjusted kappa (PAK) values ranged from .443 “moderate” to 1.0 “near 
perfect” agreement between the expert and non-expert raters.  For 35 (97.2%) hospitals, PAK 
values indicate “substantial” to “near perfect” agreement.  For 1 (2.8%) hospital, the PAK value 
indicates “moderate” agreement between expert and non-expert ratings on Risk status.  Percent 
agreement ranged from 60.42% – 100% across hospitals for this measure. 
Prevention measures – Any prevention within the last 24 hours.  Cohen’s kappa values 
for the PrU prevention measure, Any prevention within the last 24 hours (Table 19), ranged from 
-.133 “poor” to .855 “near perfect” agreement between the expert and non-expert raters.  For 2 
(5.6%) hospitals, Cohen’s kappa values indicate “near perfect” agreement.  In 20 (55.6%) 
hospitals, there was “moderate” agreement; in 6 (16.7%) hospitals, there was “fair” agreement; 
in 7 (19.4%) hospitals, there was “slight” agreement; and in 3 (8.3%) hospitals, Cohen’s kappa 
values indicate “poor” agreement between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from -.089 “poor” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 31 (86.1%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement. In 1 (2.8%) hospital, the PAK value indicates 
“moderate” agreement; in 2 (5.6%) hospitals, there was “fair” agreement; in 1 (2.8%) hospital 
there was “slight” agreement; and in 1 (2.8%) hospital, the PAK value indicates “poor” 
agreement between expert and non-expert ratings on Any prevention within the last 24 hours.  
Percent agreement ranged from 13.26% – 100% across hospitals for this measure. 
Prevention measure – Skin assessment documented within the last 24 hours.  Cohen’s 
kappa values for the PrU prevention measure, Skin assessment documented within the last 24 
hours (Table 20), ranged from .000 “slight” to .501 “moderate” agreement between the expert 
and non-expert raters.  For 29 (80.6%) hospitals, Cohen’s kappa values indicate “moderate”  
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Table 19. 
Aim 1 Question 1: “Any Prevention within the Last 24 hours”—Number of Expert/Non-Expert 
Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital (N = 
36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2 -.133 (.046) -.089 (.012)   13.26 (6.97) 
2 2   .500 (0) 1.00 (0) 100 (0) 
3 2   .500 (0) 1.00 (0) 100 (0) 
4 3   .333 (.289)   .746 (.441)   80.00 (34.64) 
5 2   .500 (0) 1.00 (0) 100 (0) 
6 2   .500 (0) 1.00 (0) 100 (0) 
7 3   .334 (.288)   .976 (.041)   97.41 (4.48) 
8 3   .848 (.263)   .902 (.170)   93.33 (11.55) 
9 2   .500 (0) 1.00 (0) 100 (0) 
10 2   .500 (0) 1.00 (0) 100 (0) 
11 2   .500 (0) 1.00 (0) 100 (0) 
12 3   .500 (0) 1.00 (0) 100 (0) 
13 3   .500 (0) 1.00 (0) 100 (0) 
14 2   .500 (0) 1.00 (0) 100 (0) 
15 2   .500 (0) 1.00 (0) 100 (0) 
16 2   .500 (0) 1.00 (0) 100 (0) 
17 2   .380 (.095)   .858 (.001)   90.48 (0.00) 
18 3   .063 (.188)   .303 (.190)   54.86 (9.84) 
19 2   .855 (.205)   .932 (.096)   95.46 (6.43) 
20 2 0 (0)   .777 (0.00)   85.00 (0.00) 
21 2   .171 (.168)   .369 (.165)   54.17 (17.68) 
22 2   .500 (0) 1.00 (0) 100 (0) 
23 3   .500 (0) 1.00 (0) 100 (0) 
24 4   .500 (0) 1.00 (0) 100 (0) 
25 2   .500 (0) 1.00 (0) 100 (0) 
26 3   .500 (0) 1.00 (0) 100 (0) 
27 2   .001 (0.00)   .917 (0.00)   94.44 (0.00) 
28 3   .167 (.289)   .835 (.143)   88.89 (9.62) 
29 2   .500 (0) 1.00 (0) 100 (0) 
30 2 0 (0)   .180 (.081)   32.50 (10.61) 
31 3   .107 (.189)   .524 (.180)   67.46 (13.35) 
32 2   .250 (.354)   .956 (.062)   97.06 (4.16) 
33 2   .500 (0) 1.00 (0) 100 (0) 
34 2   .250 (.354)   .763 (.335)   83.34 (23.57) 
35 2   .319 (.451)   .869 (.062)   91.18 (4.16) 
36 2   .500 (0) 1.00 (0) 100 (0) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
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Table 20. 
Aim 1 Question 1: “Skin Assessment Documented within the Last 24 hours”—Number of 
Expert/Non-Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement 
by Hospital (N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
 mean (SD) 
1 2 .250 (.354)   .644 (.503)   72.73 (38.57) 
2 2 .500 (0) 1.00 (0) 100 (0) 
3 2 .500 (0) 1.00 (0) 100 (0) 
4 3 .334 (.288)   .944 (.096)   97.92 (3.61) 
5 2 .500 (0) 1.00 (0) 100 (0) 
6 2 .250 (.354)   .886 (.161)   92.31 (10.88) 
7 3 .500 (0) 1.00 (0) 100 (0) 
8 3 .500 (0) 1.00 (0) 100 (0) 
9 2 .500 (0) 1.00 (0) 100 (0) 
10 2 .500 (0) 1.00 (0) 100 (0) 
11 2 .500 (0) 1.00 (0) 100 (0) 
12 3 .500 (0) 1.00 (0) 100 (0) 
13 3 .500 (0) 1.00 (0) 100 (0) 
14 2 .500 (0) 1.00 (0) 100 (0) 
15 2 .500 (0) 1.00 (0) 100 (0) 
16 2 .500 (0) 1.00 (0) 100 (0) 
17 2 .501 (.706)   .965 (.050)   97.62 (3.37) 
18 3 .500 (0) 1.00 (0) 100 (0) 
19 2 .500 (0) 1.00 (0) 100 (0) 
20 2 .500 (0) 1.00 (0) 100 (0) 
21 2 .251 (.353)   .970 (.042)   98.00 (2.83) 
22 2 .500 (0) 1.00 (0) 100 (0) 
23 3 .500 (0) 1.00 (0) 100 (0) 
24 4 .500 (0) 1.00 (0) 100 (0) 
25 2 .500 (0) 1.00 (0) 100 (0) 
26 3 .500 (0) 1.00 (0) 100 (0) 
27 2 .500 (0) 1.00 (0) 100 (0) 
28 3 .333 (.289)   .918 (.143)   94.44 (9.62) 
29 2 .500 (0) 1.00 (0) 100 (0) 
30 2 0 (0)   .107 (.022)   22.50 (3.54) 
31 3 .334 (.288)   .972 (.048)   98.15 (3.21) 
32 2 .500 (0) 1.00 (0) 100 (0) 
33 2 .500 (0) 1.00 (0) 100 (0) 
34 2 .500 (0) 1.00 (0) 100 (0) 
35 2 .500 (0) 1.00 (0) 100 (0) 
36 2 .500 (0) 1.00 (0) 100 (0) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
151 
agreement.  In 6 (16.7%) hospitals, Cohen’s kappa values indicate “fair” agreement; and in 1 
(2.8%) hospital, there was “slight” agreement between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .107 “slight” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 35 (97.2%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement; and in 1 (2.8%) hospital, the PAK value 
indicates “slight” agreement between expert and non-expert ratings on Skin assessment 
documented within the last 24 hours.  Percent agreement ranged from 22.50% – 100% across 
hospitals for this measure. 
Prevention measure - Pressure-redistribution surface use within the last 24 hours.  
Cohen’s kappa values for the PrU prevention measure, Pressure-redistribution surface use 
within the last 24 hours (Table 21), ranged from .002 “slight” to .828 “near perfect” agreement 
between the expert and non-expert raters.  For 1 (2.8%) hospital, the Cohen’s kappa value 
indicates “near perfect” agreement.  In 17 (47.2%) hospitals, Cohen’s kappa values indicate 
“moderate” agreement; in 8 (22.2%) hospitals, there was “fair” agreement; and in 10 (27.8%) 
hospitals, Cohen’s kappa values indicate “slight” agreement between expert and non-expert 
ratings on Pressure-redistribution surface use within the last 24 hours. 
Prevalence-adjusted kappa (PAK) values ranged from .252 “fair” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 28 (77.8%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement.  In 5 (13.9%) hospitals, PAK values indicate 
“moderate” agreement; and in 3 (8.3%) hospitals, there was “fair” agreement between expert and 
non-expert ratings on Pressure-redistribution surface use within the last 24 hours.  Percent 
agreement ranged from 29.37% – 100% across hospitals for this measure.  
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Table 21. 
Aim 1 Question 1: “Pressure-Redistribution Surface Use within the Last 24 hours”—Number 
of Expert/Non-Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent 
Agreement by Hospital (N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2 .500 (0) 1.00 (0) 100 (0) 
2 2 .500 (0) 1.00 (0) 100 (0) 
3 2 .500 (0) 1.00 (0) 100 (0) 
4 3 .500 (0) 1.00 (0)   97.92 (3.61) 
5 2 .500 (0) 1.00 (0) 100 (0) 
6 2 .002 (0.00)   .904 (0.00)   92.31 (0.00) 
7 3 .167 (.288)   .795 (.234)   83.13 (19.42) 
8 3 .500 (0) 1.00 (0) 100 (0) 
9 2 .251 (.353)   .905 (.135)   92.31 (10.88) 
10 2 .040 (.053)   .522 (.384)   58.33 (35.36) 
11 2 .251 (.353)   .917 (.117)   93.34 (9.43) 
12 3 .500 (0) 1.00 (0) 100 (0) 
13 3 .500 (0) 1.00 (0) 100 (0) 
14 2 .500 (0) 1.00 (0) 100 (0) 
15 2 .376 (.040)   .517 (.062)   60.81 (5.73) 
16 2 .500 (0) 1.00 (0) 100 (0) 
17 2 .251 (.352)   .970 (.042)   97.62 (3.37) 
18 3 .500 (0) 1.00 (0) 100 (0) 
19 2 .390 (.031)   .607 (.018)   68.34 (2.35) 
20 2 .368 (.237)   .624 (.097)   70.00 (7.07) 
21 2 .190 (.203)   .284 (.206)   36.00 (22.63) 
22 2 .500 (0) 1.00 (0) 100 (0) 
23 3 .500 (0) 1.00 (0) 100 (0) 
24 4 .006 (.007)   .501 (.475)   53.22 (46.08) 
25 2 .500 (0) 1.00 (0) 100 (0) 
26 3 .167 (.289)   .511 (.426)   56.67 (37.86) 
27 2 .002 (0.00)   .934 (0.00)   94.74 (0.00) 
28 3 .168 (.288)   .862 (.120)   88.89 (9.62) 
29 2 .500 (0) 1.00 (0) 100 (0) 
30 2 .159 (.058)   .362 (.071)   45.00 (7.07) 
31 3 .103 (.091)   .252 (.345)   29.37 (36.53) 
32 2 .251 (.353)   .891 (.155)   91.08 (12.47) 
33 2 .251 (.352)   .974 (.037)   97.92 (2.95) 
34 2 .500 (0) 1.00 (0) 100 (0) 
35 2 .828 (.082)   .890 (.052)   91.18 (4.16) 
36 2 .500 (0) 1.00 (0) 100 (0) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
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Prevention measure – Routine repositioning as prescribed within the last 24 hours.  
Cohen’s kappa values for the PrU prevention measure, Routine repositioning as prescribed 
within the last 24 hours (Table 22), ranged from -.242 “poor” to .750 “substantial” agreement 
between the expert and non-expert raters.  For 4 (11.1%) hospitals, Cohen’s kappa values 
indicate “substantial” agreement.  In 4 (11.1%) hospitals, Cohen’s kappa values indicate 
“moderate” agreement; in 6 (16.7%) hospitals, there was “fair” agreement; in 19 (52.8%) 
hospitals, there was “slight” agreement; and in 3 (8.3%) hospitals, Cohen’s kappa values indicate 
“poor” agreement between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .069 “slight” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 16 (44.4%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement.  In 10 (27.8%) hospitals, PAK values indicate 
“moderate” agreement; in 8 (22.2%) hospitals, there was “fair” agreement; and in 2 (5.6%) 
hospitals, PAK values indicate “slight” agreement between expert and non-expert ratings on 
Routine repositioning as prescribed within the last 24 hours.  Percent agreement ranged from 
10.00% – 100% across hospitals for this measure. 
Prevention measure – Nutritional support within the last 24 hours.  Cohen’s kappa 
values for the PrU prevention measure, Nutritional support within the last 24 hours (Table 23), 
ranged from -.050 “poor” to 1.0 “near perfect” agreement between the expert and non-expert 
raters.  For 1 (2.8%) hospital, the Cohen’s kappa value indicates “near perfect” agreement; and in 
2 (5.6%) hospitals, there was “substantial” agreement.  In 4 (11.1%) hospitals, Cohen’s kappa 
values indicate “moderate” agreement; in 11 (30.6%) hospitals, there was “fair” agreement; in 15 
(41.7%) hospitals, there was “slight” agreement between expert and non-expert ratings. 
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Table 22. 
Aim 1 Question 1: “Routine Repositioning as Prescribed within the Last 24 hours”—Number 
of Expert/Non-Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent 
Agreement by Hospital (N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .047 (.167)   .412 (.102)   51.89 (9.11) 
2 2   .001 (.001)   .644 (.327)   70.00 (28.28) 
3 2   .197 (.076)   .375 (.088)   47.78 (11.00) 
4 3   .188 (.099)   .464 (.073)   56.79 (4.98) 
5 2   .001 (0.00)   .650 (0.00)   71.43 (0.00) 
6 2   .010 (.185)   .122 (.160)   30.77 (10.88) 
7 3   .051 (.087)   .574 (.148)   64.87 (13.45) 
8 3   .681 (.276)   .815 (.163)   85.00 (13.23) 
9 2   .002 (.001)   .874 (.042)   99.91 (3.40) 
10 2 -.242 (.061)   .444 (.171)   58.34 (11.79) 
11 2   .377 (.457)   .672 (.230)   73.34 (18.86) 
12 3 0 (0)   .254 (.101)   33.33 (11.55) 
13 3 -.188 (.184)   .244 (.195)   42.86 (14.29) 
14 2   .501 (.705)   .963 (.052)   97.06 (4.16) 
15 2   .130 (.031)   .290 (.029)   40.54 (0.00) 
16 2   .002 (0.00)   .930 (0.00)   94.44 (0.00) 
17 2   .380 (.095)   .881 (.001)   90.48 (0.00) 
18 3   .296 (.273)   .522 (.270)   59.72 (25.71) 
19 2   .664 (.131)   .834 (.058)   86.67 (4.72) 
20 2   .264 (.136)   .596 (.220)   67.50 (17.68) 
21 2   .669 (.289)   .723 (.236)   78.00 (19.80) 
22 2 0 (0)   .709 (.045)   76.32 (3.73) 
23 3   .500 (0) 1.00 (0) 100 (0) 
24 4   .058 (.102)   .384 (.154)   47.26 (15.23) 
25 2   .750 (.353) 1.00 (0) 100 (0) 
26 3   .167 (.288)   .835 (.143)   86.67 (11.55) 
27 2   .061 (.024)   .390 (.107)   52.63 (7.44) 
28 3   .168 (.288)   .862 (.120)   88.89 (9.62) 
29 2   .427 (.226)   .700 (.063)   81.82 (12.86) 
30 2   .084 (.118)   .069 (.098)   10.00 (14.14) 
31 3   .192 (.330)   .363 (.354)   49.21 (28.05) 
32 2   .334 (.055)   .412 (.044)   50.00 (4.16) 
33 2   .379 (.172)   .459 (.170)   56.25 (14.74) 
34 2   .529 (.313)   .593 (.284)   66.67 (23.57) 
35 2 -.021 (.029)   .425 (.115)   52.94 (8.32) 
36 2   .107 (.067)   .300 (.054)   43.56 (2.04) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
155 
Table 23. 
Aim 1 Question 1: “Nutritional Support within the Last 24 hours”—Number of Expert/Non-
Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital 
(N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .015 (.021)   .135 (.061)   21.59 (4.82) 
2 2 0 (0)   .266 (.065)   35 (7.07) 
3 2   .250 (.354)   .569 (.610)   60.00 (56.57) 
4 3   .020 (.059)   .152 (.110)   22.81 (12.04) 
5 2   .001 (.001)   .515 (.434)   57.14 (40.40) 
6 2   .340 (.265)   .511 (.161)   61.54 (10.88) 
7 3   .347 (.264)   .459 (.333)   52.57 (33.31) 
8 3   .388 (.235)   .585 (.239)   65.00 (21.79) 
9 2   .434 (.482)   .525 (.451)   59.14 (40.11) 
10 2   .001 (.001)   .297 (.420)   33.34 (47.14) 
11 2   .015 (.021)   .341 (.358)   40.00 (37.72) 
12 3   .333 (.289)   .771 (.397)   80.00 (34.64) 
13 3 -.040 (.169)   .072 (.173)   23.81 (16.49) 
14 2   .001 (0.00)   .842 (.016)   87.30 (1.33) 
15 2   .271 (.106)   .454 (.105)   55.41 (9.55) 
16 2   .100 (0.00)   .595 (0.00)   66.67 (0.00) 
17 2   .393 (.141)   .645 (.081)   71.43 (6.73) 
18 3   .362 (.324)   .685 (.087)   74.31 (7.31) 
19 2 1.00 (.001) 1.00 (0) 100 (0) 
20 2   .260 (.342)   .502 (.269)   60.00 (21.21) 
21 2 -.009 (.096)   .079 (.054)   28.00 (0.00) 
22 2   .001 (.001)   .773 (.136)   81.58 (11.17) 
23 3   .179 (.104)   .354 (.082)   45.24 (8.25) 
24 4 0 (0)   .361 (.165)   44.17 (16.50) 
25 2   .566 (.093)   .956 (.063)   96.43 (5.05) 
26 3   .159 (.273)   .737 (.228)   89.63 (0.64) 
27 2   .522 (.004)   .600 (.001)   68.42 (0.00) 
28 3   .616 (.375)   .735 (.298)   77.78 (25.46) 
29 2   .666 (.471)   .780 (.311)   81.82 (25.71) 
30 2   .383 (.244)   .502 (.269)   57.50 (24.75) 
31 3   .119 (.063)   .343 (.091)   46.48 (8.43) 
32 2 -.050 (.103)   .040 (.053)   14.71 (4.16) 
33 2   .211 (.124)   .620 (.151)   69.74 (12.54) 
34 2   .139 (.087)   .199 (.038)   33.33 (0.00) 
35 2   .017 (.033)   .362 (.081)   47.06 (8.32) 
36 2   .449 (.320)   .628 (.154)   64.21 (5.95) 
Total Expert to Non-Expert pairs = 84         
Note. SD = standard deviation; PAK = prevalence-adjusted kappa   
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Prevalence-adjusted kappa (PAK) values ranged from .040 “slight” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 12 (33.3%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement.  In 11 (30.6%) hospitals, PAK values indicate 
“moderate” agreement; in 7 (19.4%) hospitals, there was “fair” agreement; and in 6 (16.7%) 
hospitals, PAK values indicate “slight” agreement between expert and non-expert ratings on 
Nutritional support within the last 24 hours.  Percent agreement ranged from 14.71% – 100% 
across hospitals for this measure. 
Prevention measure – Moisture management within the last 24 hours.  Cohen’s kappa 
values for the last PrU prevention measure, Moisture management within the last 24 hours 
(Table 24), ranged from -.111 “poor” to .848 “near perfect” agreement between the expert and 
non-expert raters.  For 1 (2.8%) hospital, the Cohen’s kappa value indicates “near perfect” 
agreement.  In 6 (16.7%) hospitals, Cohen’s kappa values indicate “moderate” agreement; in 12 
(33.3%) hospitals, there was “fair” agreement; in 16 (44.4%) hospitals, there was “slight” 
agreement; and in 1 (2.8%) hospital, the Cohen’s kappa value indicates “poor” agreement 
between the expert and non-expert raters. 
Prevalence-adjusted kappa (PAK) values ranged from .000 “slight” to 1.0 “near perfect” 
agreement between the expert and non-expert raters.  For 14 (38.9%) hospitals, PAK values 
indicate “substantial” to “near perfect” agreement.  In 14 (38.9%) hospitals, PAK values indicate 
“moderate” agreement; in 3 (8.3%) hospitals, there was “fair” agreement; and in 5 (13.9%) 
hospitals, PAK values indicate “slight” agreement between expert and non-expert ratings on 
Moisture management within the last 24 hours.  Percent agreement ranged from 0.00% – 100% 
across hospitals for this measure.  
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Table 24. 
Aim 1 Question 1: “Moisture Management within the Last 24 hours”—Number of Expert/Non-
Expert Pairs, Cohen’s Kappa, Prevalence-Adjusted Kappa, and Percent Agreement by Hospital 
(N = 36) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2   .069 (.097)   .155 (.060)   21.97 (7.50) 
2 2 0 (0)   .473 (.227)   55.00 (21.21) 
3 2   .096 (.206)   .223 (.258)   36.11 (19.64) 
4 3 0 (0)   .192 (.041)   26.65 (4.94) 
5 2   .001 (.001)   .581 (.342)   64.29 (30.30) 
6 2 0 (0)   .250 (0.00)   33.33 (0.00) 
7 3   .275 (.344)   .758 (.144)   80.60 (11.52) 
8 3   .848 (.262)   .917 (.143)   93.33 (11.55) 
9 2   .013 (.226)   .588 (.250)   67.55 (19.37) 
10 2   .357 (.505)   .588 (.332)   66.67 (23.57) 
11 2   .125 (.177)   .671 (.002)   73.33 (0.00) 
12 3   .500 (0) 1.00 (0) 100 (0) 
13 3   .382 (.544)   .496 (.446)   57.14 (37.80) 
14 2   .247 (.347)   .841 (.018)   87.30 (1.33) 
15 2   .143 (.243)   .424 (.169)   51.35 (15.29) 
16 2   .500 (0) 1.00 (0) 100 (0) 
17 2   .280 (.042)   .537 (.082)   61.91 (6.74) 
18 3   .429 (.245)   .638 (.156)   71.53 (11.85) 
19 2   .573 (.002)   .771 (.031)   81.67 (2.35) 
20 2   .078 (.134)   .179 (.153)   32.50 (10.61) 
21 2   .253 (.121)   .405 (.182)   52.00 (16.97) 
22 2   .002 (.001)   .902 (.046)   92.11 (3.73) 
23 3   .334 (.288)   .970 (.051)   97.62 (4.12) 
24 4   .176 (.108)   .451 (.258)   52.26 (26.17) 
25 2   .470 (.042)   .911 (.126)   92.86 (10.10) 
26 3   .057 (.095)   .683 (.321)   72.96 (28.55) 
27 2   .248 (.169)   .476 (.093)   57.90 (7.45) 
28 3   .168 (.288)   .862 (.120)   88.89 (9.62) 
29 2 -.111 (.158)   .471 (.429)   59.09 (32.15) 
30 2 0 (0) 0 (0) 0 (0) 
31 3   .268 (.266)   .458 (.372)   53.97 (34.03) 
32 2   .316 (.126)   .400 (.129)   50.00 (12.47) 
33 2   .461 (.083)   .633 (.075)   70.84 (5.89) 
34 2   .143 (0.00)   .181 (.098)   25.00 (11.78) 
35 2   .308 (.033)   .444 (.039)   55.88 (4.16) 
36 2   .313 (.250)   .522 (.211)   61.84 (16.74) 
Total Expert to Non-Expert pairs = 84          
Note. SD = standard deviation; PAK = prevalence-adjusted kappa  
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Question 2.  What is the overall agreement between expert participant ratings and 
non-expert participant ratings for the NDNQI PrU risk measures per hospital, and the 
overall agreement between expert participant ratings and non-expert participant ratings 
for the NDNQI PrU prevention measures per hospital?  Average Cohen’s kappa value for the 
5 risk measures (Skin assessment within 24 hours of admission, Risk assessment within 24 hours 
of admission, Time since last PrU risk assessment, Risk assessment scale, and Risk status) are 
presented by hospital in Table 25, as are the average PAK value and the average percent 
agreement for these risk measures.  Likewise, the average Cohen’s kappa value for all 6 
prevention measures (Any prevention, Skin assessment documented, Pressure-redistribution 
surface use, Routine repositioning as prescribed, Nutritional support, and Moisture 
management) are presented in Table 26 by hospital, as are the average PAK value and the 
average percent agreement for these prevention measures. 
Overall agreement for the (five) PrU risk measures.  Cohen’s kappa values representing  
the overall agreement between the expert and non-expert raters on the five NDNQI PrU risk 
measures (Table 25) ranged from “fair” (.294) to “substantial” (.760) agreement, (M = .498, 95% 
CI [.463 – .533]).  Specifically, for 6 (16.7%) hospitals, Cohen’s kappa values ranged from .608 
to .760, indicating “substantial” agreement; for 23 (63.9%) hospitals, Cohen’s kappa values 
ranged from .422 to .591, indicating “moderate” agreement; and for 7 (19.4%) hospitals, Cohen’s 
kappa values ranged from .294 to .387, indicating “fair” agreement. 
Prevalence-adjusted kappa (PAK) values representing the overall agreement on the five 
NDNQI PrU risk measures ranged from .812 – .994, (M = .924, 95% CI [.910 – .939]), 
indicating “near perfect” agreement between expert and non-expert ratings on this overall risk  
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Table 25. 
Aim 1 Question 2: Overall Agreement for the Five Pressure Ulcer Risk Measures by Hospital  
(N = 36 Hospitals) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2 .380 (.347) .926 (.083) 94.05 (7.67) 
2 2 .494 (.342) .923 (.151) 93.67 (13.58) 
3 2 .471 (.341) .842 (.327) 86.52 (28.35) 
4 3 .453 (.154) .912 (.119) 93.48 (8.63) 
5 2 .294 (.252) .849 (.197) 88.54 (15.65) 
6 2 .342 (.309) .812 (.213) 85.53 (18.24) 
7 3 .522 (.049) .927 (.164) 95.10 (10.95) 
8 3 .760 (.274) .937 (.124) 94.84 (10.44) 
9 2 .323(.204) .863 (.238) 90.00 (16.89) 
10 2 .445 (.361) .952 (.039) 96.52 (2.92) 
11 2 .580 (.260) .957 (.070) 96.53 (6.10) 
12 3 .631 (.126) .962 (.048) 97.46 (3.19) 
13 3 .546 (.222) .898 (.197) 91.03 (17.99) 
14 2 .493 (.163) .947 (.112) 96.38 (7.51) 
15 2 .386 (.390) .975 (.031) 98.20 (2.05) 
16 2 .629 (.189) .979 (.030) 98.40 (2.19) 
17 2 .422 (.353) .838 (.204) 86.74 (19.34) 
18 3 .614 (.247) .901 (.153) 92.74 (10.70) 
19 2 .468 (.229) .930 (.063) 94.56 (5.33) 
20 2 .518 (.251) .947 (.043) 96.09 (3.49) 
21 2 .343 (.367) .931 (.045) 95.09 (3.26) 
22 2 .724 (.219) .958 (.071) 96.00 (5.52) 
23 3 .608 (.236) .907 (.121) 92.71 (9.94) 
24 4 .548 (.207) .907 (.149) 92.56 (12.66) 
25 2 .491 (.335) .989 (.015) 99.58 (0.93) 
26 3 .461 (.129) .942 (.090) 95.95 (6.01) 
27 2 .591 (.204) .994 (.014) 99.59 (0.91) 
28 3 .491 (.348) .895 (.228) 91.30 (18.95) 
29 2 .538 (.251) .898 (.153) 91.80 (13.16) 
30 2 .427 (.249) .917 (.101) 93.60 (8.44) 
31 3 .379 (.303) .908 (.120) 92.71 (10.36) 
32 2 .587 (.194) .991 (.020) 99.40 (1.34) 
33 2 .464 (.302) .904 (.140) 92.34 (12.01) 
34 2 .429 (.273) .917 (.115) 93.56 (9.24) 
35 2 .585 (.183) .978 (.030) 98.37 (2.23) 
36 2 .488 (.332) .949 (.091) 95.8 (7.82) 
Note.  SD = standard deviation; PAK = prevalence-adjusted kappa  
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Table 26. 
Aim 1 Question 2: Overall Agreement for the Six Pressure Ulcer Prevention Measures by 
Hospital (N = 36 Hospitals) 
 
Hospital 
# Of Expert to  
Non-Expert Pairs 
Cohen’s kappa 
mean (SD) 
PAK 
mean (SD) 
Percent Agreement 
mean (SD) 
1 2 .125 (.221) .376 (.396) 46.91 (34.37) 
2 2 .250 (.274) .730 (.319) 76.67 (27.87) 
3 2 .340 (.182) .694 (.352) 73.98 (29.49) 
4 3 .229 (.197) .583 (.370) 63.68 (33.76) 
5 2 .251 (.273) .791 (.233) 82.14 (20.08) 
6 2 .184 (.213) .612 (.372) 68.38 (31.10) 
7 3 .279 (.155) .760 (.215) 79.77 (18.41) 
8 3 .628 (.195) .870 (.156) 89.44 (13.19) 
9 2 .283 (.232) .815 (.208) 84.82 (17.33) 
10 2 .193 (.305) .637 (.295) 69.44 (26.18) 
11 2 .295 (.200) .767 (.257) 80.00 (23.09) 
12 3 .389 (.202) .837 (.300) 85.56 (26.81) 
13 3 .276 (.309) .635 (.422) 70.64 (33.86) 
14 2 .375 (.209) .941 (.079) 95.28 (6.28) 
15 2 .320 (.166) .614 (.308) 68.02 (25.65) 
16 2 .350 (.234) .921 (.162) 93.51 (13.34) 
17 2 .364 (.089) .809 (.178) 84.92 (14.81) 
18 3 .358 (.165) .691 (.273) 76.74 (19.41) 
19 2 .663 (.228) .857 (.153) 88.69 (12.40) 
20 2 .245 (.184) .613 (.275) 69.17 (22.95) 
21 2 .254 (.225) .472 (.321) 57.70 (26.21) 
22 2 .250 (.273) .897 (.129) 91.67 (10.45) 
23 3 .419 (.135) .887 (.262) 90.48 (22.18) 
24 4 .207 (.236) .616 (.301) 66.15 (26.43) 
25 2 .548 (.104) .978 (.037) 98.21 (2.99) 
26 3 .258 (.192) .794 (.191) 84.32 (16.85) 
27 2 .222 (.241) .719 (.263) 78.02 (20.85) 
28 3 .270 (.182) .846 (.606) 87.96 (5.46) 
29 2 .414 (.269) .825 (.217) 87.12 (16.37) 
30 2 .104 (.151) .203 (.192) 27.92 (21.53) 
31 3 .187 (.096) .485 (.256) 57.44 (23.43) 
32 2 .267 (.180) .616 (.390) 67.16 (34.32) 
33 2 .384 (.127) .781 (.239) 82.46 (19.17) 
34 2 .343 (.187) .623 (.369) 68.06 (32.67) 
35 2 .325 (.316) .665 (.284) 73.04 (23.49) 
36 2 .395 (.159) .742 (.302) 78.27 (24.86) 
Note.  SD = standard deviation; PAK = prevalence-adjusted kappa  
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measure.  Percent agreement ranged from 85.5% - 99.6%, (M = 94.1%, 95% CI [92.9% - 
95.3%]) across hospitals on this measure. 
Overall agreement for the (six) PrU prevention measures.  Whether considering 
Cohen’s kappa, PAK, or percent agreement; overall agreement for the prevention measures was 
uniformly lower than the overall agreement for the risk measures.  Cohen’s kappa values 
representing the overall agreement between the expert and non-expert raters on the six NDNQI 
PrU prevention measures (Table 26) ranged from “slight” (.104) to “substantial” (.628), (M = 
.312, 95% CI [.273 – .352]).  Specifically, for 2 (5.6%) hospitals, Cohen’s kappa values ranged 
from .628 to .633 indicating “substantial” agreement; for 3 (8.3%) hospitals, Cohen’s kappa 
values ranged from .414 to .548, indicating “moderate” agreement; for 26 (72.2%%) hospitals, 
Cohen’s kappa values ranged from .207 to .395, indicating “fair” agreement; and for 5 (13.9%) 
hospitals, Cohen’s kappa values are .104 or .187, indicating “slight” agreement between expert 
and non-expert ratings on this overall prevention measure. 
Prevalence-adjusted kappa (PAK) values for the overall agreement on the six NDNQI 
PrU prevention measures ranged from “slight” (.203) to “near perfect” (.978) agreement between 
expert and non-expert ratings on this overall prevention measure, (M = .714, 95% CI [.661 – 
.767]).  Specifically, for 12 (33.3%) hospitals, PAK ranged from .809 to .978, indicating “near 
perfect” agreement; for 19 (52.8%) hospitals, PAK ranged from .612 to .794, indicating 
“substantial” agreement; for 3 (8.3%) hospitals, PAK ranged from .472 to .583, indicating 
“moderate” agreement; for 1 (2.8%) hospital, the PAK was .376, indicating “fair” agreement; 
and for 1 (2.8%) hospital, the PAK was .203, indicating “slight” agreement between expert and 
non-expert ratings on this overall prevention measure.  Percent agreement ranged from 27.9% - 
98.2%, (M = 76.2%, 95% CI [71.5% - 80.9%]) across hospitals for this measure. 
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Question 3.  What is the average of the within hospital agreements between expert 
participant ratings and non-expert participant ratings for each of the 11 NDNQI pressure 
ulcer risk and prevention measures across hospitals?  The average Cohen’s kappa value, the 
average PAK value, and the average percent agreement across hospitals for each of the risk and 
prevention measures are presented in Table 27.  The average Cohen’s kappa value ranged from 
.216 for Routine Repositioning as Prescribed within the Last 24 hours, indicating “fair” 
agreement, to .819 for Risk Status, indicating “near perfect” agreement.  For 10 of the 11 
measures, however, Cohen’s kappa values indicate only “fair”, n = 7 (63.6%), or “moderate”, n = 
3 (27.3%) agreement. 
The average PAK value ranged from .500 for Nutritional Support within the Last 24 
hours, indicating “moderate” agreement, to .997 for Risk Assessment Scale Used, indicating 
“near perfect” agreement.  Specifically, for 7 (63.6%) of the NDNQI PrU risk and prevention 
measures, PAK values ranged from .839 to .997, indicating “near perfect” agreement; for 1 
(9.1%) measure, the PAK value was .790, indicating “substantial” agreement; and for 3 
(27.3%%) measures, PAK values ranged from .500 to .577, indicating “moderate” agreement 
between expert and non-expert ratings on each of these risk and prevention measure.  The mean 
percent agreement for each measure across hospitals ranged from 57.6% to 99.8%. 
Question 4.  What is the intraclass correlation coefficient (agreement) between 
expert participant ratings and non-expert participant ratings for each of the 11 NDNQI 
PrU risk and prevention measures across hospitals?  The ICCs for Cohen’s kappa values 
across hospitals, and the ICCs for PAK values across hospitals, are presented in Table 28.  For 
this study, ICC = the variability of kappa values between hospitals, divided by the sum of the 
variability of kappa values between hospitals and the variability of kappa values within hospitals. 
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Table 28. 
Aim 1 Question 4: Intraclass Correlation Coefficients for Cohen’s Kappa and Prevalence-
Adjusted Kappa Values across Hospitals for Pressure Ulcer Risk and Prevention Measures (N 
= 72 Cohen’s Kappa Values; N = 72 PAK Values) 
 
       ICC [95% CI]          ICC [95% CI] 
            from   from 
       Cohen’s k   PAK 
 
 
Risk Measures 
Skin Assessment within 24 hours of Admission .373 [.059 – .622]       .399 [.089 – .640] 
Risk Assessment within 24 hours of Admission .573 [.309 – .756]       .295 [-.030 – .564] 
Time since Last PrU Risk Assessment  .298 [-.027 – .566]       .422 [.155 – .655] 
Risk Assessment Scale    -.513 [-.716 – -.228]       .877 [.773 – .935] 
Risk Status      .510 [.226 – .716]       .511 [.226 – .716] 
 
Prevention Measures (in Use within the Last 24 hours) 
Any Prevention     .539 [.263 – .734]       .800 [.644 – .892] 
Skin Assessment Documented   -.052 [-.368 – .276]       .718 [.516 – .845] 
Pressure-Redistribution Surface Use  .396 [.085 – .637]       .610 [.359 – .779] 
Routine Repositioning as Prescribed  .453 [.153 – .677]       .713 [.508 – .842] 
Nutritional Support    .525 [.245 – .725]       .426 [.121 – .659] 
Moisture Management    .259 [-.068 – .537]       .620 [.373 – .786] 
Note.  ICC = Intraclass correlation coefficient; k = kappa; PAK = prevalence-adjusted kappa 
165 
This formula suggests that an ICC near zero (< .22) indicates that the within-hospital variance in 
rater agreement is much greater than the between-hospital variance in rater agreement.  Support 
for this conclusion is found in Hart et al. (2006) who also defined “Near zero” as < .22. This 
aligns with the level of agreement for “poor” to “slight” (< 0 to .20) by Landis and Koch (1977).  
For this study, an ICC near zero means each hospital rated the NDNQI PrU risk and prevention 
measures with similar levels of agreement as the other hospitals rated the measures. 
Intraclass correlation coefficients (ICCs) calculated from Cohen’s kappa values ranged 
from -.513 to .573.  Only 2 of the 11 ICCs (Risk assessment scale, and Skin assessment 
documented within the last 24 hours) were near zero; i.e. < .22.  Intraclass correlation 
coefficients (ICCs) calculated from PAK values ranged from .295 to .800.  None of the 
measures’ ICCs (calculated from PAK values) are considered to be at or near zero. 
Question 5.  Where is the lack of agreement between expert and non-expert 
participant ratings on the 11 NDNQI pressure ulcer risk and prevention measures 
occurring?  Data were aggregated to present one matrix (i.e. frequency table) for each NDNQI 
PrU risk and prevention measure.  Cell counts along the diagonal indicate agreement between the 
expert and the non-expert rater, while cell counts off the diagonal represent disagreement.  To 
help identify areas of confusion, the cell(s) of disagreement with the largest counts in the table 
have been circled (Table 29). 
Some of the cells in these frequency tables are sparsely populated.  While logical because 
most patients received the intervention, this sparseness provided support for the addition of 
0.0001 to each cell count, in order to compute Cohen’s kappa and PAK values.  Five of the 11 
tables have at least 40% of their cells with a cell count of zero.  For example, the matrix for Time  
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Table 29. 
Aim 1 Question 5: Agreement Matrices—Agreement between the Expert (N = 36) and Non-
Expert (N = 84) Raters for Each of the 11 NDNQI Pressure Ulcer Risk and Prevention 
Measures 
     Risk Measures   
Skin Assessment within 24 hours of Admission 
Non-Expert 
    Yes  No        Pending 
3712 20 4 
  22 3 2 
4 0 6 
    3738  23  12 = 3773 
             
Risk Assessment within 24 hours of Admission 
Non-Expert 
    Yes  No        Pending 
3703 16 3 
15 12 4 
1 1 11 
    3719  29  18 = 3766 
             
  
Expert 
Expert 
3736 
27 
10 
3722 
31 
13 
Yes 
No 
Pending 
Yes 
No 
Pending 
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Table 29 (continued). 
Aim 1 Question 5: Agreement Matrices—Agreement between the Expert (N = 36) and Non-
Expert (N = 84) Raters for Each of the 11 NDNQI Pressure Ulcer Risk and Prevention 
Measures 
Time since Last PrU Risk Assessment 
      Non-Expert 
      >0-12      >12-24     >24-48   >48-72   >72-1wk   >1 wk    Never 
2689 290 8 0 0 0 11 
285 370 8 0 0 0 5 
11 43 29 1 0 0 0 
0 0 2 2 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
7 0 0 0 0 0 14 
       
2992 703 47 3 0 0 30 
             
Risk Assessment Scale 
      Non-Expert 
           Braden    Norton Other   Clinical Factors 
3741 0 0 0 
0 0 0 0 
0 0 0 0 
8 0 0 3 
            3749        0  0       3  = 3752 
             
  
Expert 
Expert 
2998 
668 
84 
4 
0 
0 
21 
= 3775 
3741 
0 
0 
11 
>0-12 
>12-24 
>24-48 
>48-72 
>72-1wk 
>1wk 
Never 
Braden 
Norton 
Other 
Clinical Factors 
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Table 29 (continued). 
Aim 1 Question 5: Agreement Matrices—Agreement between the Expert (N = 36) and Non-
Expert (N = 84) Raters for Each of the 11 NDNQI Pressure Ulcer Risk and Prevention 
Measures 
Risk Status 
     Non-Expert 
           YRA           YCL            No 
985 49 52 
57 73 46 
56 70 2353 
           1098          192           2451     = 3741 
             
     Prevention Measures   
Any Prevention provided within the Last 24 hours 
     Non-Expert 
            Yes  No        Pending 
1012 42 2 
69 33 5 
0 1 0 
          1081  76  7     = 1164 
             
Skin Assessment Documented within the Last 24 hours 
     Non-Expert 
            Yes  No        Contra. 
1137 12 0 
1 1 0 
7 0 0 
          1145  13  0    = 1158 
              
Note.  YRA = Yes risk assessment; YCL = Yes clinical factors; Contra. = Contraindicated 
Expert 
1086 
176 
2479 
1056 
107 
1 
1149 
2 
7 
YRA 
YCL 
No 
Expert 
Yes 
No 
Pending 
Expert 
Yes 
No 
Contra. 
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Table 29 (continued). 
Aim 1 Question 5: Agreement Matrices—Agreement between the Expert (N = 36) and Non-
Expert (N = 84) Raters for Each of the 11 NDNQI Pressure Ulcer Risk and Prevention 
Measures 
Pressure-Redistribution Surface Use within the Last 24 hours 
       Non-Expert 
           Yes No    Contra.   Unnecessary   Pt. Refused 
858 47 0 26 0 
28 75 0 41 0 
2 0 0 0 0 
7 39 0 36 0 
4 1 0 1 0 
          899 162           0 104           0        = 1165 
             
Routine Repositioning as Prescribed within the Last 24 hours 
       Non-Expert 
           Yes No    Contra.   Unnecessary   Pt. Refused 
537 80 1 65 6 
116 123 1 26 0 
7 0 0 1 1 
64 43 0 84 0 
8 1 0 0 1 
          732 247           2 176           8       = 1165 
             
Note.  Contra. = Contraindicated; Pt. = Patient; Unnecessary = Unnecessary for the patient 
Expert 
931 
144 
2 
82 
6 
Expert 
689 
266 
9 
191 
10 
Yes 
No 
Contraindicated 
Unnecessary 
Pt. Refused 
Yes 
No 
Contraindicated 
Unnecessary 
Pt. Refused 
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Table 29 (continued). 
Aim 1 Question 5: Agreement Matrices—Agreement between the Expert (N = 36) and Non-
Expert (N = 84) Raters for Each of the 11 NDNQI Pressure Ulcer Risk and Prevention 
Measures 
Nutritional Support within the Last 24 hours 
      Non-Expert 
           Yes No    Contra.   Unnecessary   Pt. Refused 
438 121 5 90 0 
55 94 8 41 0 
36 21 9 11 0 
44 65 1 121 1 
0 1 0 1 0 
      573          302      23          264        1        = 1163 
             
Moisture Management within the Last 24 hours 
      Non-Expert 
           Yes No    Contra.   Unnecessary   Pt. Refused 
588 74 0 89 0 
64 46 0 30 0 
19 1 1 4 0 
94 48 1 99 1 
0 0 0 0 0 
                  765          169        2          222        1      = 1159 
              
Note.  Contra. = Contraindicated; Pt. = Patient; Unnecessary = Unnecessary for the patient  
Expert 
654 
198 
77 
232 
2 
Expert 
751 
140 
25 
243 
0 
Yes 
No 
Contraindicated 
Unnecessary 
Pt. Refused 
Yes 
No 
Contraindicated 
Unnecessary 
Pt. Refused 
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since last PrU risk assessment reveals that while collectively rating 1,637 patients, 36 experts 
and 84 non-experts never selected the options “> 72 – 1 week”, or “> 1 week”. 
Aim 2 
Aim 2 was to examine the methods and processes used by participant raters to gather data 
on the NDNQI PrU risk and prevention measures.  Responses to the Pressure Ulcer Risk and 
Prevention Reliability Survey (n = 35 items) were used to answer this question.  Only the 120 
participant raters (n = 36 experts, and n = 84 non-experts), whose patient data were included in 
the study, had their responses to the survey included in the data analysis.  Results on the first 
three items of the survey:  job title, nursing education, and certifications are described under aim 
1 in Table 13 (p. 137).  Findings from the remaining five survey items on participant training and 
education in PrU data collection, years collecting NDNQI PrU data, other roles during PrU data 
collection, and team leader certification status are described below.  The other survey items (n = 
27) asked participant raters how they collect NDNQI PrU risk and prevention data. 
Participant Rater Characteristics (Training and education in PrU data collection, years 
collecting NDNQI PrU data, roles during PrU data collection, and skin team leader 
certification status).  The majority of experts [n = 24 (66.7%)] and non-experts [n = 60 (71.4%)] 
reported reviewing the NDNQI Guidelines for Data Collection and Submission of PrUs within 
the last 12 months (Table 30).  Twenty-six (72.2%) experts reported completing all four modules 
of the NDNQI PrU Training program within the last 12 months.  Less than half of the non-
experts [n = 40 (47.6%)] reported the same.  Surprisingly, 3 (8.3%) experts and 11 (13.1%) non-
experts reported that within the last 12 months they had not completed any of the four training 
modules, nor had they reviewed the NDNQI Guidelines for Data Collection and Submission of 
PrUs.  These three experts (and four of these 11 non-experts) also answered “No” when asked if  
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Table 30. 
Aim 2:  Participant Rater Characteristics—Training and Experience in Collecting Pressure 
Ulcer Data 
           Total 
     Expert   Non-Expert        Participant Raters 
     (n = 36)  (n = 84)  (N = 120) 
     n (%)   n (%)   n (%)   
Please select what you have completed within the last 12 months.a (Select all that apply.) 
 
 I have reviewed the NDNQI 24 (66.7)  60 (71.4)  84 (70.0) 
 Guidelines for Data 
 Collection and Submission 
 of Pressure Ulcers. 
 
 I have completed all 4  26 (72.2)  40 (47.6)  66 (55.0) 
 modules of the NDNQI 
 Pressure Ulcer Training 
 program. 
 
 I have completed only  5 (13.9)  12 (14.3)  17 (14.2) 
 some (not all) of the 4 
 NDNQI Pressure Ulcer 
 Training program modules. 
 
 None of the above.  3 (8.3)   11 (13.1)  14 (11.7) 
 
Have you received education for data collection on pressure ulcers other than reviewing the 
NDNQI Guidelines for Data Collection and Submission of Pressure Ulcers or completing 
the NDNQI Pressure Ulcer Training program?b 
 
 Yes    23 (63.9)  49 (58.3)  72 (60) 
 No    13 (36.1)  33 (39.3)  46 (38.3) 
              
a Totals do not equal the number of raters because respondents were to select “all that apply”. 
b Missing values = 2 (1.7%) 
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Table 30 (continued). 
Aim 2:  Participant Rater Characteristics—Training and Experience in Collecting Pressure 
Ulcer Data 
           Total 
     Expert   Non-Expert        Participant Raters 
     (n = 36)  (n = 84)  (N = 120) 
     n (%)   n (%)   n (%)   
How many years have you collected NDNQI pressure ulcer data?c 
 < 1 year   4 (11.1)  15 (17.9)  19 (15.8) 
 1 year    2 (5.6)   7 (8.3)   9 (7.5) 
 2 years    3 (8.3)   11 (13.1)  14 (11.7) 
 3 years    3 (8.3)   10 (11.9)  13 (10.8) 
 4 years    6 (16.7)  10 (11.9)  16 (13.3) 
 5 years    4 (11.1)  12 (14.3)  16 (13.3) 
 6 years    3 (8.3)   3 (3.6)   6 (5.0) 
 7 years    3 (8.3)   4 (4.8)   7 (5.8) 
 8 years    3 (8.3)   3 (3.6)   6 (5.0) 
 9 years         −   1 (1.2)   1 (0.8) 
 10 years   2 (5.6)   3 (3.6)   5 (4.2) 
 11 years   1 (2.8)   3 (3.6)   4 (3.3) 
 12 years        −   1 (1.2)   1 (0.8) 
 13 years        −        −        − 
 14 years   1 (2.8)        −   1 (0.8) 
 15 years        −        −        − 
 > 15 years   1 (2.8)        −   1 (0.8) 
              
c Missing values = 1 (0.8%)  
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Table 30 (continued). 
Aim 2:  Participant Rater Characteristics—Training and Experience in Collecting Pressure 
Ulcer Data 
           Total 
     Expert   Non-Expert        Participant Raters 
     (n = 36)  (n = 84)  (N = 120) 
     n (%)   n (%)   n (%)   
In addition to chart abstractor, what other role(s) in the NDNQI Pressure Ulcer Survey 
have you had?a (Select all that apply.) 
 Site Coordinator  9 (25.0)  9 (10.7)  18 (15.0) 
 Patient skin inspection— 26 (72.2)  56 (66.7)  82 (68.3) 
      Rounding on all patients 
 Patient skin inspection— 22 (61.1)  38 (45.2)  60 (50.0) 
      Rounding on selected 
      patients to confirm pressure 
      ulcer presence or stage 
 Training of pressure  25 (69.4)  28 (33.3)  53 (44.2) 
      ulcer team 
 Data entry   22 (61.1)  29 (34.5)  51 (42.5) 
 No other roles        −   8 (9.5)   8 (6.7) 
 Other (please describe) 1 (2.8)        −   1 (0.8) 
      Skin Team Leader 
  
Who usually leads your NDNQI Pressure Ulcer Survey data collection team?d 
 Someone certified in wound 27 (75.0)  65 (77.4)  92 (76.7) 
      care 
 
 Someone not certified but 5 (13.9)  12 (14.3)  17 (14.2) 
      the wound/skin care nurse 
      
 Neither of the above  2 (5.6)   4 (4.8)   6 (5.0) 
 
 I don’t know their  1 (2.8)   2 (2.4)   3 (2.5) 
      certification status 
 
              
d Missing values = 2 (1.7%)  
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they had received other education for data collection on PrUs. 
Using the value of 0.5 year for the participant raters who reported having collected 
NDNQI PrU data for < 1 year, and the value of 16 years for those who reported having collected 
NDNQI PrU data for > 15 years; the mean number of years collecting data was 5.2 (SD = 3.7) 
for the expert raters, and 3.9 (SD = 3.0) for the non-expert raters. 
All 36 experts, and most of the non-experts, n = 77 (91.7%), reported having at least one 
other role in the NDNQI PrU Survey in addition to chart abstractor.  Specifically, among the 
experts; 6 (16.7%) had one other role, 7 (19.4%) had two other roles, 11 (30.6%) had three other 
roles, 9 (25%) had four other roles, 2 (5.6%) had five other roles, and 1 (2.8%) expert rater had 
six other roles in the NDNQI PrU survey in addition to chart abstractor.  Among the non-experts; 
27 (32.1%) had one other role, 23 (27.6%) had two other roles, 21 (25%) had three, and 6 (7.1%) 
had four other roles in addition to chart abstractor.  A single participant rater (0.8%) reported 
having a role other than those listed as a response option.  This expert rater specified “Skin Team 
Leader”.  The majority of experts and non-experts reported that their NDNQI PrU Survey data 
collection team was led by “someone certified in wound care” [n = 27 (75%) experts, and n = 65 
(77.4%) non-experts]. 
Methods and processes used to collect pressure ulcer risk and prevention data.  All 36 
experts reported that they are “almost always” or “always” comfortable with their skills to 
review patient records and collect NDNQI PrU risk and prevention data (Table 31).  Seventy-
four (88.1%) non-experts reported the same.  Among all the respondents (i.e. experts and non-
experts), 75 (62.5%) reported that their hospital “almost always” or “always” provides training 
or review prior to each PrU survey.  Most respondents reported that RNs “almost always” or 
“always” collect PrU risk and prevention data, n = 111 (92.5%).  One (0.8%) rater reported that 
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b
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RNs “never” collect these data, but the three other raters at that hospital reported that RNs 
“always” do.  Participant raters among 13 (36.1%) hospitals reported that RNs are the only ones 
who collect NDNQI PrU risk and prevention data at their hospital.  Twenty-three (19.2%) raters 
among 12 (33.3%) hospitals reported that LPNs at least “sometimes” collect these data.  Twenty-
two (18.3%) raters among 15 (41.7%) hospitals reported that nurse aids at least “sometimes” 
collect these data.  Ten (8.3%) raters among 7 (19.4%) hospitals reported that physical therapists 
at least “sometimes” collect these data.  Four (3.3%) raters among 2 (5.6%) hospitals reported 
that clinical secretaries at least “sometimes” collect these data.  Finally, 1 (0.8%) rater reported 
that respiratory therapists at least “sometimes” collect these data.  Seventeen (14.2%) raters 
among 5 (13.9%) hospitals specified that others than those listed “almost always” or “always” 
collect these data.  These included dieticians (2 hospitals), nursing students (2 hospitals), 
research assistants (1 hospital), data specialists (1 hospital), diabetic educators (1 hospital), and 
the site coordinator (1 hospital). 
Forty-five (37.5%) participant raters reported that their hospital “almost always” or 
“always” evaluates the reliability of the PrU risk and prevention measures every year.  Nearly 
half “almost always” or “always”, n = 54 (45%) collect data on the floor where they usually 
work, while a third “never” do, n = 39 (32.5%).  Respondents reported that their NDNQI PrU 
risk and prevention data is “almost always” or “always” obtained from review of the electronic 
health record, n = 107 (89.2%); compared to the patient’s paper health record, n = 33 (27.5%).  
There was some confusion among participant raters with regards to whether or not persons from 
information technology retrieve any of their hospital’s PrU data in that 28 (23.3%) replied “I 
don’t know” to this survey item:  Nearly half, however, replied “never”, n = 59 (49.2%).  This 
190 
item (about information technology extracting data) had the most “I don’t know” responses than 
any other item, n = 28 (23.3%). 
Most respondents reported they “never” exclude a patient who was admitted < 24 hours 
before the skin survey, n = 79 (65.8%).  The PrU risk assessment scale score is often used to 
determine a patient’s risk status:  98 (81.7%) participant raters reported that they “almost 
always” or “always” determine risk status by risk assessment scale score.  In addition,  
88 (73.3%) raters reported that they “almost always” or “always” consider other clinical factors 
while determining risk status. 
Eighty-four (70%) participant raters reported they “almost always” or “always” rate 
Moisture Management within the Last 24 hours by direct observation.  Likewise, 24 (20%) 
reported that barrier cream at the bedside is “almost always” or “always” sufficient to rate 
Moisture Management within the Last 24 hours as “Yes”. 
Responses to the survey items on repositioning highlight disagreement in rating Routine 
repositioning as prescribed within the last 24 hours.  Thirty-two (26.7%) participant raters 
reported they “never” allow a 30-minute leeway from the time repositioning was to take place 
before rating this item as “No”, while 39 (32.5%) reported they “almost always” or “always” do.  
More than half of the respondents reported they “never” rate Routine repositioning as prescribed 
as “Patient refused” without documentation in the patient record, regardless of what the nurse 
verbally reports, n = 79 (65.8%).  At the same time, 20 (16.7%) respondents reported they 
“almost always” or “always” ask staff how to rate repositioning.  Finally, 39 (32.5%) “never” 
look in the patient record for physical therapy documentation of patient activity to rate Routine 
repositioning as prescribed, while 37 (30.8%) “almost always” or “always” do. 
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Most participant raters reported they “never” rate Nutritional support within the last 24 
hours as “Yes” for someone hospitalized for two or more days with poor intake and for whom 
the nutritional consult had not yet been completed, n = 74 (61.7%).  Finally, less than a quarter 
reported that someone “almost always” or “always” verifies their ratings if they record that a 
patient did not receive a particular PrU prevention intervention; n = 23 (19.2%). 
Chapter Summary 
Cohen’s kappa values varied widely within and across hospitals.  Because most patients 
were assessed for PrU risk, and those at risk received prevention, the prevalence of a “Yes” 
response was high; suggesting PAK may be a better estimate of inter-rater reliability than 
Cohen’s kappa.  Prevalence-adjusted kappa (PAK) values for:  (1) Skin assessment, PAK = .977, 
95% CI [.966 – .989]; (2) Risk assessment, PAK = .978, 95% CI [.964 –.993]; (3) Time since last 
risk assessment, PAK = .790, 95% CI [.729 – .852]; (4) Risk assessment scale, PAK = .997, 95% 
CI [.991 – 1.0]; (5) Risk status, PAK = .877, 95% CI [.838 – .917]; (6) Any prevention, PAK = 
.856, 95% [.769 – .943]; (7) Skin assessment documented, PAK = .956, 95% CI [.904 – 1.0]; and 
(8) Pressure-redistribution surface use, PAK = .839, 95% CI [.763 – .916] indicated substantial 
to near perfect agreement.  Prevalence-adjusted kappa values for:  (9) Routine repositioning, 
PAK = .577, 95% CI [.494 – .661]; (10) Nutritional support, PAK = .500, 95% CI [.418 – .581]; 
and (11) Moisture management, PAK = .556, 95% CI [.469 – .643] indicated moderate 
agreement.  
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CHAPTER V:  DISCUSSION, RECOMMENDATIONS, AND CONCLUSION 
 
This is the first known study to examine the reliability of the 11 NDNQI® pressure ulcer 
risk and prevention measures.  The specific aims were:  (1) Aim 1:  examine the reliability of the 
NDNQI pressure ulcer risk and prevention measures within and across NDNQI hospitals, and (2) 
Aim 2: examine the methods and processes used by participant raters to gather data on the 
NDNQI PrU risk and prevention measures. 
The Sample 
Hospital and Unit Sample 
The hospital sample size (N = 36) was comparable to previous research that examined 
the reliability of PrU identification and staging:  the study by Bergquist-Beringer et al. (2011) 
included 31 hospitals, Gajewski et al. (2007) had 20 hospitals, and 48 hospitals participated in 
the study by Hart et al. (2006).  Additional NDNQI reliability studies, not specific to PrUs, 
included slightly more hospitals in their samples than the current study, with 48 (Choi et al., 
2014) and 54 (Simon et al., 2011) hospitals respectively. 
In this study, 25% (n = 9) of participating hospitals were Magnet hospitals.  The 
percentage of hospitals participating in previous NDNQI research that were Magnet hospitals 
was 20.8% (Choi et al., 2014), 23% (Bergquist-Beringer et al., 2013), and 35% (Bergquist-
Beringer et al., 2011).  The proportion of hospitals in previous NDNQI research that were 
Teaching or Academic Medical Centers ranged from 44.5% (Bergquist-Beringer et al., 2013) to 
65% (Staggs & He, 2013), compared to 41.6% for this study.  Hospital size of < 300 staffed beds 
in previous NDNQI research was 72.1% (Choi et al., 2014) and 70.4% (Bergquist-Beringer et al., 
2013), compared to 77.8% for this study.  It is appropriate to state that the current study’s 
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hospital sample was similar to the population of NDNQI hospitals that submit PrU data because 
the study by Bergquist-Beringer and colleagues (2013) included all 1,419 hospitals that 
submitted PrU data in 2010. 
For this study, eligible unit type included adult medical-surgical, adult medical, and adult 
surgical units.  Nearly half of the NDNQI data on PrUs is submitted by these unit types.  Of the 
15,400 units that submitted PrU data for the 2nd Quarter of 2014, 7,471 (49%) units were 
classified as medical-surgical (n = 1,774), medical (n = 2,468), or surgical (n = 3,229) (NDNQI 
Statistical Analyst, personal communication, November 21, 2014). 
Participant Rater Sample 
The study’s sample of 120 participant raters (n = 36 experts, n = 84 non-experts) had 
fewer raters than the 140 raters (Gajewski et al., 2007), 162 raters (Bergquist-Beringer et al., 
2011), and 256 raters (Hart et al., 2006) in previous NDNQI reliability studies; but more than 24 
raters in the Simon et al. (2011) study.  Similar to the current study, the raters in the Bergquist-
Beringer et al. (2011) study included an “expert” at each hospital.  Previous NDNQI researchers 
reported 46.3% (Bergquist-Beringer et al., 2011) to 47% (Hart et al., 2006) of the raters were 
Staff RNs, compared to 43.3% for this study; and that 54.5% (Choi et al., 2013) to 69.7% 
(Bergquist-Beringer et al., 2011) held a Bachelor’s Degree or higher, compared to 70.8% of all 
raters (including non-nurses) for this study.  In the current study, 63.3% (n = 76) of the 
participant raters reported they were not certified in wound care, compared to 76% in previous 
NDNQI PrU reliability research (Bergquist-Beringer et al., 2011). 
Patient Sample 
Data were extracted from 1,637 patient records. All 1,637 patients were rated on the (5) 
PrU risk measures (M = 45.5 patients per hospital).  Of these patients, 553 (33.8%) were 
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considered by the expert to be “at risk” for PrU development.  However, not all non-expert raters 
agreed with the expert on risk status.  Therefore, 528 to 530 patients were also rated on the (6) 
prevention measures (M = 14.7 patients per hospital, SD = 7.0). 
Patient sample size (N = 528 to 530) was M = 14.7 patients per hospital.  In previous 
research that examined the reliability of PrU identification and staging, Bergquist-Beringer et al. 
(2011) and Hart et al. (2006) presented 25 photographs of wounds for evaluation by each rater 
(N = 25).  Bergquist-Beringer et al. (2011) also had raters round on patients, and collectively 
they staged a total of N = 591 PrUs, M = 19.1 PrUs per hospital; which is more than (but 
comparable to) the current study’s sample size.  Gajewski et al.’s (2007) sample (N = 347 PrUs) 
was smaller than the current study’s overall sample.  However, in the Gajewski et al. (2007) 
study, 6 – 108 PrUs (M = 17.4) per hospital were staged; which is more than the current study’s 
5 – 37 patients (M = 14.7) per hospital that were rated on the prevention measures.  Based on 
previous studies, the sample size for this study (of 528 to 530 patients overall, and 14.7 patients 
per hospital) was near the range of previous NDNQI studies. 
Similar to this study, previous research included slightly more female patients (52% and 
54.9%) than male patients (Bergquist-Beringer et al., 2012; Choi et al., 2013).  The percentage of 
patients found to be “at risk” for PrU development in this study (33.8%) is also comparable to 
previous research which found 37% of patients among medical-surgical, medical, and surgical 
unit types were “at risk” (S. Bergquist-Beringer, personal communication, March 11, 2014 in 
unpublished data from Bergquist-Beringer, 2011).  Finally, the average age of patients in this 
study (M = 63 years) was similar to the average age of patients in Bergquist-Beringer (2011), (M 
= 62 years). 
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Aim 1:  Calculations of Rater Agreement on the 11 NDNQI Pressure Ulcer  
Risk and Prevention Measures 
In this study, there were 2 to 4 expert/non-expert pairs at each hospital (M = 2.33), 
yielding 2 to 4 kappa values for each measure per hospital (total of 84 kappa values across 36 
hospitals).  Because most patients were rated as having received the PrU risk and prevention 
interventions, rater response was often a constant.  Consequently, SPSS and Excel would not 
compute Cohen’s kappa values.  Therefore, it was necessary to add a very small number (0.0001) 
to each cell in order for a Cohen’s kappa value to be presented.  Although this strategy has been 
suggested by others to address “constant” variables while calculating kappa (Weaver, 2007), the 
addition of 0.0001 to each cell distinguishes this study’s data analysis from other studies 
presenting kappa values.  Prevalence-adjusted kappa (PAK) values were also computed with the 
addition of 0.0001 to each cell (see Table 8, p. 120). 
Aim 1, Question 1 – Reliability of Each Measure within Hospitals 
Cohen’s kappa values provide support for the reliability of Risk status measurement 
within hospitals.  For 32 hospitals, Cohen’s kappa values for Risk status were ≥ .610 to 1.00, 
indicating “substantial” to “near perfect” agreement between the expert and non-expert raters.  
For all the other measures, the majority of Cohen’s kappa values were < .610.  In contrast, PAK 
values provide support for the reliability of all 5 risk measures within hospitals, and 3 of 6 
prevention measures within hospitals.  Specifically, the majority of hospitals had PAK values ≥ 
.610 to 1.00 indicating “substantial” to “near perfect” agreement between the expert and non-
expert raters for (1) Skin assessment within 24 hours of admission, (2) Risk assessment within 24 
hours of admission, (3) Time since last PrU risk assessment, (4) Risk assessment scale, (5) Risk 
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status, (6) Any prevention within the last 24 hours, (7) Skin assessment documented within the 
last 24 hours, and (8) Pressure-redistribution surface use within the last 24 hours. 
While considering within hospital Cohen’s kappa and PAK values, it is important to 
remember that most (69.4%) of these values were calculated from two expert/non-expert pairs, 
and some hospitals had as few as 5 to 7 patients rated on the prevention measures.  The low 
Cohen’s kappa values were likely due to the large proportion of “Yes” responses for each 
measure (Sim & Wright, 2005).  As expected, each PAK value was higher than its corresponding 
Cohen’s kappa value, highlighting the presence and effect of high prevalence of “Yes” responses 
on estimates of rater agreement.  Therefore, PAK values are likely better estimates of inter-rater 
reliability for the 11 NDNQI PrU risk and prevention measures, than Cohen’s kappa values. 
Fifteen (3.8%) Cohen’s kappa values and 1 (0.3%) PAK value, were < 0; meaning 
agreement between the expert and the non-experts was less than expected by chance alone.  A 
negative kappa value close to zero (i.e. > - .22 to < 0) is not surprising for this study’s data, and 
suggests rater agreement was no better than chance alone—the most negative Cohen’s kappa or 
PAK value was -.242.  In addition, some negative kappa values are likely by chance alone 
because of the large number Cohen’s kappa values (N = 396) and PAK values (N = 396) that 
were calculated.  These negative Cohen’s kappa and PAK values were found for 7 of the 11 
NDNQI measures, and within 12 (33.3%) hospitals.  They were present in hospitals that had both 
two and three expert/non-expert pairs. 
Aim 1, Question 2 – Overall Agreement between Expert and Non-Expert Ratings for the 
NDNQI PrU Risk Measures, and the Overall Agreement between Expert and Non-Expert 
Ratings for the NDNQI PrU Prevention Measures 
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The average Cohen’s kappa values for all 5 risk measures, and the average Cohen’s 
kappa values for all 6 prevention measures, were < .610.  Specifically, the overall Cohen’s kappa 
value for the risk measures was .498, 95% CI [.463 – .533], indicating only “moderate” 
agreement between the expert and non-expert raters.  The overall Cohen’s kappa value for the 
prevention measures was even lower at .312, 95% CI [.273 – .352], indicating “fair” agreement.  
Cohen’s kappa values leave in question the reliability of these measures overall. 
In contrast, the average PAK value for all 5 risk measures and the average PAK value for 
all 6 prevention measures, were ≥ .610, and therefore, provide support for the reliability of these 
two overall measures.  Specifically, the overall PAK value for the risk measures was .924, 95% 
CI [.910 – .939], indicating “near perfect” agreement between the expert and non-expert raters.  
The overall PAK value for the prevention measures was .714, 95% CI [.661 – .767], indicating 
“substantial” agreement.  Prevalence-adjusted kappa (PAK) values may be the better measure of 
inter-rater reliability of these measures because of the large proportion of patients who received 
the PrU risk and prevention interventions (see discussion on p. 119 – 121). 
Cohen’s kappa and PAK values for the prevention measures were uniformly lower than 
Cohen’s kappa and PAK values for the risk measures.  This may be because fewer patients were 
rated on the prevention measures.  Eight (22.2%) hospitals had as few as 5 to 7 patients who 
were rated on the prevention measures; while only 4 (11.1%) hospitals had less than 40 patients 
who were rated on the risk measures. 
Aim 1, Question 3 – Average Agreement Estimates for Each Measure across 36 Hospitals 
For each of the 11 PrU risk and prevention measures, a single Cohen’s kappa value, a 
single PAK value, and a single percent agreement was presented.  Most of these values had 
narrow 95% CIs, providing support for their accuracy. 
198 
The five NDNQI pressure ulcer risk measures. 
Cohen’s kappa.  Cohen’s kappa values provide support for the reliability of the PrU risk 
measure, Risk status.  The averaged (across hospitals) Cohen’s kappa value indicated “near 
perfect” agreement (k = .819, 95% CI [.766 – .873].  Interestingly, the prevalence of agreement 
on Risk status was more evenly distributed among the cells of agreement compared to the other 
risk measures.  This provides insight on the effect of high prevalence on Cohen’s kappa values.  
Cohen’s kappa values for the two risk measures, Risk assessment within 24 hours of admission (k 
= .472, 95% CI [.393 – .552]) and Risk assessment scale (k = .495, 95% CI [.485 – .505]), 
indicated “moderate” agreement between raters on average across hospitals.  Agreement matrices 
show that each of these measures had a very large proportion of “Yes” responses, which 
decreased Cohen’s kappa values.  Among the four response options for Risk assessment scale 
(“Braden”, “Norton”, “Other”, and “Clinical factors”); “Braden” was selected by each rater more 
than 99% of the time.  All other response options combined were selected less than 1% of the 
time.  Interestingly, the Risk assessment scale measure should be reliable because it essentially 
asks raters which risk assessment scale is used at their hospital; something one would expect all 
nurses at their hospital to know.  Also, it is well-known that the Braden Scale is the most 
commonly used PrU risk assessment scale in the U.S. (Armstrong et al., 2008).  Even so, the 
Cohen’s kappa value reflected only “moderate” agreement for this measure. 
Averaged Cohen’s kappa values for the two other risk measures, Skin assessment within 
24 hours of admission (k = .379, 95% CI [.308 – .451]), and Time since last PrU risk assessment 
(k = .324, 95% CI [.241 – .406]), indicated even lower (“fair”) agreement between raters.  
Similar to other measures, agreement matrices show each these measures had a very large 
proportion of “Yes” responses, which lowered Cohen’s kappa values.  According to the 
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agreement matrix for Skin assessment within 24 hours of admission, most of the disagreement 
among raters was between the response options of “Yes” and “No”, which is of concern, but the 
sum of the cell counts of disagreement accounted for only 1.5% of all cell counts combined.  
Time since last PrU risk assessment had the lowest average Cohen’s kappa value, and the lowest 
average PAK value, among the risk measures.  For this measure, high prevalence for the 
response “> 0 – 12” hours was apparent, but so was disagreement between this response and “> 
12 – 24” hours.  While interpreting agreement for Time since last PrU risk assessment, however, 
it is important to consider how study data were collected. 
Participant raters were instructed to consider only patient data from 7:00 a.m. the day 
before the study, to 7:00 a.m. the day of the study.  This is different than how data are collected 
for quarterly NDNQI PrU data submission:  In practice, PrU data are collected by considering 
the 24-hour period immediately prior to the time of data collection.  An example of this issue is 
as follows.  Pressure ulcer risk assessments are typically performed at the beginning of each 
shift, so it is likely that most risk assessments were performed between 7:30 a.m. and 10:00 a.m. 
on the morning that study data were collected, as well as between 7:30 p.m. and 10:00 p.m. the 
evening before study data were collected.  The participant raters, however, were not required to 
collect data within the same hour as other participant raters collected data at their hospital.  Data 
collection was to occur only within the 5-hour data collection period of 7:00 a.m. to 12:00 p.m.  
In other words, if one of the raters collected study data on a particular patient at 8:00 a.m., and 
the last risk assessment was performed at 8:00 p.m., the correct rating for Time since the last PrU 
risk assessment is > 0 – 12 hours.  However, if another rater collected study data on this same 
patient an hour later, then this rater may likely have recorded the Time since the last PrU risk 
assessment as > 12 – 24 hours.  Both raters correctly used only data within the 24-hour period of 
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7:00 a.m. to 7:00 a.m., but how they “counted back” to determine the time since the last risk 
assessment was performed, may have influenced their rating. 
Another issue with Time since last PrU risk assessment is that some participant raters 
may have incorrectly considered the risk assessment that was performed after 7:00 a.m. the day 
of the study, which is how NDNQI PrU data are collected in practice.  This would result in 
disagreement among the raters because some would select > 0 – 12 hours, while others would 
select > 12 – 24 hours.  Finally, in order to make sure participant raters were using the same time 
frame and the same risk assessment (as the other participant raters) they needed to score this 
measure as if they were collecting data at 7:00 a.m., something they were not instructed to do.  
For instance, if the last risk assessment was performed at 8:00 p.m. the evening before the day of 
the study, then unless participant raters either (a) counted back from 7:00 a.m. to arrive at > 0 – 
12 hours, or (b) collected study data on a patient at the same time that the other participant raters 
collected data on that patient; disagreement between the raters was highly likely. 
Nevertheless, the agreement matrix for Time since last PrU risk assessment (see Table 29 
in Chapter IV) clearly shows that the overwhelming majority of disagreement was between the 
two response options of “> 0 – 12 hours” and “> 12 – 24 hours”.  When data for Time since Last 
PrU Risk Assessment were collapsed by combining the response options of “> 0 – 12” hours, and 
“> 12 – 24” hours, across hospital Cohen’s kappa value increased from “fair” (.324) to 
“moderate” (.429); and the PAK value increased from “substantial” (.790) to “near perfect” 
(.899).  Although, this “new” Cohen’s kappa value was still < .610, these results suggest 
reliability would be improved by collapsing data for these two response options to “> 0 to 24” 
hours.  Collapsing these data is supported by the Institute for Healthcare Improvement (IHI, 
2015) and others (Stechmiller et al., 2008) who have established the standard of performing a 
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PrU risk assessment as every 24 hours in the acute care setting.  In addition, even a 
recommendation of performing a risk assessment “every shift” would translate to > 0 – 24 hours 
(not > 0 – 12 hours).  For example, for12-hour shifts, it is likely a risk assessment would be 
completed at 8:00 p.m. and again at 9:00 a.m. the next day, which is > 12 – 24 hours. 
Prevalence-adjusted kappa (PAK).  Prevalence-adjusted kappa (PAK) values provide 
support for the reliability of all (5) PrU risk measures.  The averaged (across hospitals) PAK 
values for four of the five risk measures (Skin assessment within 24 hours of admission, Risk 
assessment within 24 hours of admission, Risk assessment scale, and Risk status) were .877 to 
.997, indicating “near perfect” agreement between the expert and non-expert raters.  The 
averaged PAK value for the fifth risk measure, Time since last PrU risk assessment, was .790, 
95% CI [.729 – .852], indicating “substantial” agreement. 
Percent agreement.  The average (across hospital) percent agreements were large (81.2% 
to 99.8%) for the PrU risk measures.  These values were expected because of the large number of 
patients who receive the PrU risk and prevention interventions.  It is important to remember that 
percent agreement does not consider agreement by chance alone.  However, when considered 
with other agreement estimates, this commonsense statistic provides further insight.  For 
instance, Risk assessment scale had a Cohen’s kappa of .495, indicating only “moderate” 
agreement, but the raters agreed 99.8% of the time. 
The six NDNQI pressure ulcer prevention measures. 
As for NDNQI survey requirements, the PrU prevention measures in the study were rated 
only for persons who were determined to be “at risk” for PrU development.  The expert 
identified 553 patients to be at risk.  However, not all non-experts agreed with the expert on risk 
status.  Therefore, 528 to 530 patients were rated on each of the prevention measures. 
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Cohen’s kappa values.  Average (across hospitals) Cohen’s kappa values for the (6) 
prevention measures do not provide support for the reliability of these measures:  None of these 
values were ≥ .610.  The Cohen’s kappa value for Skin assessment documented within the last 24 
hours (k = .451, 95% CI [.415 – .488]), was the only average Cohen’s kappa value among the 
prevention measures that indicated at least “moderate” agreement between the expert and non-
expert raters.  Average Cohen’s kappa values for the other five prevention measures (Any PrU 
prevention within the last 24 hours, Pressure-redistribution surface use within the last 24 hours, 
Routine repositioning as prescribed within the last 24 hours, Nutritional support within the last 
24 hours, and Moisture management within the last 24 hours) indicated “fair” agreement 
between the expert and non-expert raters (k = .216 to .387).  Like the risk measures, high 
prevalence of “Yes” responses were expected and observed in the agreement matrices. 
Prevalence-adjusted kappa values.  Average (across hospitals) PAK values provide 
support for the reliability of three of the six prevention measures; (1) Any prevention within the 
last 24 hours, (2) Skin assessment documented within the last 24 hours, and (3) Pressure-
redistribution surface use within the last 24 hours.  These PAK values indicated “near perfect” 
agreement between the expert and non-expert raters (PAK = .839 – .956).  The average PAK 
values for the remaining three prevention measures (Routine repositioning as prescribed within 
the last 24 hours, Moisture management within the last 24 hours, and Nutritional support within 
the last 24 hours) indicated “moderate” agreement (PAK = .500 – .577). 
The agreement matrices show high prevalence of “Yes” responses; therefore, PAK values 
are likely better estimates of inter-rater reliability of these measures than Cohen’s kappa values.  
For the prevention interventions Routine repositioning as prescribed within the last 24 hours, 
Moisture management within the last 24 hours, and Nutritional support within the last 24 hours, 
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the agreement matrices provide insight into where the disagreement occurred (see Table 29 in 
Chapter IV).  “Unnecessary” is frequently among the cells of disagreement with the highest cell 
counts.  Notably, this disagreement pattern was present for each of the four PrU prevention 
measures that have “Unnecessary” as a response option (Pressure-redistribution surface use 
within the last 24 hours, Routine repositioning as prescribed within the last 24 hours, Nutritional 
support within the last 24 hours, and Moisture management within the last 24 hours).  There was 
similar disagreement counts between “Yes” and “Unnecessary”, and “No” and “Unnecessary”.  
This may reflect differences in hospital policy on PrU prevention, as well as individual 
differences in how raters score this item.  Maybe some data collectors are using other factors 
besides the total Braden Scale score to rate patients on the prevention measures, while others are 
not.  Perhaps some data collectors consider Braden subscale scores to rate these measures.  For 
instance, some data collectors may rate Nutritional support as “Unnecessary” if the Braden 
subscale score for nutrition is greater than 3, while others look for documentation of Nutritional 
support for all patients “at risk” (i.e. total Braden score ≤ 18) regardless of the nutrition subscale 
score.  This might also be happening with Routine repositioning as prescribed.  Some raters may 
have chosen “Unnecessary” for patients who had a combined activity-mobility Braden subscale 
score ≥ 4; while other raters looked for documentation of repositioning for all “at risk” patients.  
In other words, some participant raters seemed to have based their rating on if repositioning was 
necessary, while others looked for documentation of if it was done.  Others have reported that 
Braden subscale scores should be considered while determining the appropriate PrU prevention 
interventions (Braden, 2012).  In addition, the NPUAP/EPUAP guidelines suggest risk 
assessment subscale scores are useful in determining appropriate prevention interventions 
(NPUAP/EPUAP, 2009). 
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Percent agreement.  Average (across hospitals) percent agreement ranged from 57.6% to 
96.5% for the prevention measures.  Percent agreement was the lowest for, Nutritional support 
within the last 24 hours (57.6%, 95% CI [50.4% – 64.8%], Moisture management within the last 
24 hours (62.4%, 95% CI [54.4% - 70.3%], and Routine repositioning as prescribed within the 
last 24 hours (65.4%, 95% CI [58.2% - 72.5%]. The lowest Cohen’s kappa values and PAK 
values were also for these same measures. 
Aim 1, Question 4 – Intraclass Correlation Coefficients from Kappa Values to Examine 
Variance in Rater Agreement across Hospitals 
For this study, ICC was defined as the variance in kappa values between hospitals, 
divided by the sum of the variance in kappa values between hospitals and the variance in kappa 
values within hospitals.  Following criteria established by Hart et al. (2006), an ICC near zero 
indicates within-hospital variability in rater agreement was much greater than across-hospital 
variability in rater agreement.  This means that participant raters at a particular hospital scored 
the NDNQI PrU risk and prevention measures with similar inter-rater reliability as participant 
raters at the other hospitals that scored the measures. 
Using a level of agreement similar to Landis and Koch’s (1977) level of agreement 
categories for “poor” to “slight” agreement (i.e. < .20), Hart et al. (2006) identified that an ICC < 
.22 was considered to be “near zero”, and suggests that within-hospital variability was much 
greater than between-hospital variability (an ICC < .50 suggests within-hospital variability was 
greater than between-hospital variability).  The ICCkappa values for two measures (Risk 
Assessment Scale, and Skin Assessment Documented within the Last 24 hours) were < .22..  
However, these two ICCs were negative (ICCkappa = -.513 and -.052, respectively).  According to 
the ICC definition, (variability of kappa’s between hospitals)/(total variability of kappa’s), ICC 
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value is non-negative.  However, negative ICC values are possible due to the way of separating 
between-subject variation and within-subject variation in SPSS.  When the average covariance 
calculated from a dataset is negative, SPSS may generate negative ICC values (Nichols, 1999).  
Further examination of the Cohen’s kappa values for these two measures reveals that for almost 
all the hospitals, Cohen’s kappa values were .500 (and PAK values were 1.00).  For Risk 
assessment scale, the Cohen’s kappa value for 35 (97.2%) hospitals was .500 (see Table 17, p. 
146).  For Skin assessment documented within the last 24 hours, the Cohen’s kappa value for 29 
(80.6%) hospitals was .500 (see Table 20, p. 150).  Kappa values for the other nine measures 
were more varied across hospitals.  This was especially evident on each measure’s box-and-
whisker plot in that the two measures with negative ICCs had only a horizontal line at .500 (i.e. 
no “box” or “whiskers”). 
While the ICCs for the other nine measures were positive, they were not < .22 (ICCkappa 
ranged from .259 to .573).  In addition, in general the ICC 95% CIs were wide for all 11 
measures; also likely due to the small sample size and that ICCs were calculated from only two 
kappa values per hospital. 
When ICCs were calculated from PAK values, results revealed no measures with a 
negative ICCPAK, or an ICCPAK considered being near zero.  However, a single measure’s 95% 
CI (ICCPAK) included zero:  Risk assessment within 24 hours of admission, ICCPAK = .295, 95% 
CI [-.03 - .564].  As before, the 95% CIs were wide, perhaps because ICCs were calculated from 
only two kappa values per hospital.  Considering the above discussion, it is likely that the ICCs 
from the study (ICCkappa and ICCPAK) do not well represent the proportion of the total variability 
in kappa values that is due to between-hospital variability. 
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Differences in study results between this study and those by Hart et al. (2006) reflect 
differences in study methodology.  In the study by Hart and colleagues (2006), all raters across 
hospitals scored a common set of photographs of wounds.  In other words, the ICCs presented in 
Hart et al. (2006) estimated across-hospital inter-rater reliability.  In this study, however, 
participants rated patients only at their hospital:  ICCs in the current study do not examine 
across-hospital reliability.  These ICCs merely evaluate if the participant raters at a particular 
hospital scored the NDNQI PrU risk and prevention measures with similar inter-rater reliability, 
as participant raters scored these measures at the other hospitals.  This, and the large ICC 
confidence intervals, suggests the ICCs in the current study may not be very meaningful. 
Aim 2:  Methods and Processes Used to Collect NDNQI Pressure Ulcer  
Risk and Prevention Data 
One hundred twenty participant raters completed the Pressure Ulcer Risk and Prevention 
Reliability Survey.  Survey results suggest data collectors need training and review of the 
NDNQI Guidelines for Data Collection and Submission of Pressure Ulcers (NDNQI, 2013), 
which specify how these data should be collected. 
Participant Rater Characteristics 
Overall, participant raters were experienced in collecting NDNQI PrU data as reflected in 
the number of years they reported collecting data (M = 4.3 years), and the few raters, 8 (6.7%), 
who reported they had no other role in PrU data collection.  However, 3 (8.3%) experts and 4 
(4.8%) non-experts reported that within the last 12 months they had not reviewed or received any 
education or training for data collection on PrUs.  This is concerning because the NDNQI (2013) 
recommends data collectors receive a review in PrU data collection prior to each skin survey.  
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Nevertheless, 75 (62.5%) participant raters reported that prior to each time they collect NDNQI 
PrU data, they “almost always” or “always” receive training or review. 
Characteristics of the “expert” suggest these raters had greater expertise in wound/skin 
care and PrU data collection than the non-experts.  Compared to the non-experts, a larger 
proportion of experts:  (1) were wound/skin care nurses (47.2% to 17.9%); (2) had a Master’s 
Degree in Nursing (33.3% to 14.3%); (3) completed all four modules of the NDNQI PrU 
Training program (72.2% to 47.6%); and (4) had other roles in PrU data collection, including 
training of the PrU data collection team (69.4% to 33.3%).  In addition, 38.9% of experts 
reported having no certifications in wound care while 73.8% of non-experts reported the same. 
On the other hand, responses to some survey items suggest the experts need review of the 
NDNQI PrU data collection guidelines as much (or more than) the non-experts.  The NDNQI 
guidelines state moisture management must be documented in the patient record, but 80.6% of 
the experts “almost always” or “always” rate moisture management by direct observation, 
compared to 65.5% of the non-experts.  Furthermore, 22.2% of the experts reported barrier 
cream at the bedside is “almost always” or “always” sufficient to rate moisture management as 
“Yes”, compared to 19.0% of the non-experts.  Finally, even though they are not supposed to do 
so, 36% of the experts “almost always” or “always” collect data on the unit where they usually 
work, as do 48.8% of the non-experts. 
It is impressive that 76.7% of respondents reported that their skin survey team leader was 
certified in wound care, yet only 58.3% of the hospitals had at least 200 staffed beds.  Results 
suggest that hospitals are sufficiently concerned about PrUs that they invest in credentialing 
these individuals. 
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The Methods Used to Collect NDNQI PrU Risk and Prevention Data 
Respondents from no more than 13 (36.1%) hospitals reported that only RNs collect 
NDNQI PrU risk and prevention data.  Even though there was a large number of missing data for 
items about who else besides RNs collect these data, responses still indicate that a large 
proportion of hospitals routinely use others such as nurses aids and LPNs to collect these data.  
The NDNQI (2013) identifies who should perform skin inspections during NDNQI PrU data 
collection (LPNs/Licensed Vocational Nurses and nurse aids should not perform skin 
inspections).  However, specifications for chart reviewers—those who collect data on the PrU 
risk and prevention measures—are less specifically stated.  The guidelines state these persons 
“need skill in reading documentation in patient records” (NDNQI, 2013, p. 104), but in the 
online teaching program, it is identified that skin survey team members should be trained on PrU 
data collection guidelines, skin and risk assessment, PrU identification and staging, PrU origin, 
and data extraction from the patient record (Bergquist-Beringer & Davidson, 2014).  The 
majority of respondents (72.2%) reported completing the NDNQI PrU Training Program.  It is 
difficult, however, to compare participant rater training with raters in earlier NDNQI PrU 
reliability studies because the NDNQI PrU training program did not exist during these previous 
studies.  Chart reviewers should have received PrU team training and have demonstrated 
competence in performance of skin and risk assessments, and competence in data abstraction 
from the patient record (NDNQI, 2013).  This requirement makes it difficult for LPNs, nurse 
aids, clinical secretaries, dieticians, nursing students, research assistants, or data specialists (e.g. 
those reported in the study as persons who usually collect these data) to meet the qualification to 
review patient records.  Perhaps this affected the reliability of the study measures. 
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Only 45 (37.5%) respondents reported that their PrU data collection team “almost 
always” or “always” evaluates the reliability of this data at least once a year, as recommended by 
NDNQI.  The NDNQI also recommends that data collectors collect data on units other than 
where they usually work in order to prevent bias reporting, but almost half of the respondents (n 
= 54, 45.0%) reported that they “almost always” or “always” do collect data on the unit where 
they usually work. 
Most raters reported PrU risk and prevention data are “almost always” or “always” 
retrieved from the electronic patient record, n = 107 (89.2%).  When asked if information 
technology (IT) extracts PrU risk and prevention data, 28 (23.3%) reported “I don’t know”.  This 
item had the largest number of “I don’t know” responses of all the items (with the second highest 
number being n = 16 (13.3%) for item #23 about allowing a 30-minute leeway for repositioning).  
There is no information as to the number of hospitals whose IT departments extract PrU risk and 
prevention data (S. Bergquist-Beringer, personal communication, February 9, 2015).  
Nevertheless, the location of data on PrU risk and prevention within the electronic patient record 
may have varied by unit and could have influenced study results. 
Responses within survey items varied, highlighting patient scenarios where disagreement 
among these raters was (and is) likely to occur while rating patients on the PrU risk and 
prevention measures.  All patients are to be included in NDNQI PrU data collection regardless of 
the time since their admission (NDNQI, 2013).  Most respondents reported they “never” exclude 
a patient admitted less than 24 hours before the survey, n = 79 (65.8%), but 17 (14.2%) reported 
they “almost always” or “always” exclude these patients.  A large majority reported they “almost 
always” or “always” determine risk status by the score obtained on the risk assessment scale, n = 
98 (81.7%); while at the same time nearly the same number reported they “almost always” or 
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“always” look for other risk factors if the risk assessment scale score does not classify the patient 
at risk, n = 88 (73.3%).  It is important that other risk factors are not overlooked because more 
than 100 factors have been associated with PrU development (Lyder & Ayello, 2008).  In 
addition, PrU risk and prevention guidelines state other risk factors should be considered when 
determining risk status (NPUAP/EPUAP/PPPIA, 2014; Ratliff et al., 2010). 
According to the NDNQI data collection guidelines (NDNQI, 2013) , only two PrU risk 
and prevention measures can be scored by direct observation of a patient in their room; Pressure-
redistribution surface use within the last 24 hours, and Nutritional support within the last 24 
hours.  However, only 13 (10.8%) participant raters reported they “never” rate Moisture 
management within the last 24 hours by direct observation, while 84 (70%) reported they 
“almost always” or “always” do.  In addition, less than half reported that barrier cream at the 
bedside is “never” sufficient to rate Moisture management within the last 24 hours as “Yes”, n = 
55 (45.8%).  Evidence of moisture management includes documentation of such interventions in 
the patient’s record.  Incontinence products or barrier creams found in the patient’s room are not 
adequate evidence of their use (NDNQI, 2013).  Documentation of the use of these products 
must be found in the patient record for evidence that the intervention was performed (Bergquist-
Beringer & Davidson, 2014). 
There were four survey items specifically asking respondents about how they rate 
Routine repositioning as prescribed within the last 24 hours.  Among all the measures, Routine 
repositioning as prescribed within the last 24 hours had the lowest across hospital Cohen’s 
kappa value of .216, 95% CI [.124 – .298], and the third lowest PAK value of .577, 95% CI [.494 
– 661].  Responses to the survey items provide insight into these values.  Patient refusal of (or 
contraindications to) repositioning must be documented in the patient record (NDNQI, 2013).  
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Most respondents reported that if the nurse tells them that a patient refused repositioning, but 
there was no documentation of this refusal, then they “never” select “Patient refused”, n = 79 
(65.8%).  Nevertheless, 9 (7.5%) respondents reported they “almost always” or “always” select 
“Patient refused” under this scenario.  When asked if they allow a 30-minute leeway from when 
repositioning was to have occurred before they rate Repositioning as prescribed as “No”, 32 
(26.7%) respondents reported they “never” allow a 30-minute leeway, while nearly the same 
number of respondents, 39 (32.5%), reported they “almost always” or “always” do.  Responses 
to this item varied within hospitals as only one hospital had participant raters who were 
unanimous in their responses to this item.  The NDNQI (2013) guidelines do not specify whether 
or not data collectors should allow a leeway.  In fact, the guidelines do not specify the time 
interval at which patients “at risk” for PrU should be repositioned other than “as prescribed” (p. 
111).  This is because many factors are to be considered while determining repositioning 
intervals (such as mattress type, patient age, and disease process).  In addition, each hospital’s 
repositioning procedure is to be followed when scoring this NDNQI measure; therefore, these 
procedures likely vary across hospitals.  Perhaps each hospital needs to make their patient 
repositioning policy and documentation of its performance more apparent. 
Responses also varied on where to look for information on repositioning.  Thirty-nine 
(32.5%) raters reported they “never” look for physical therapy documentation of patient activity 
to rate repositioning, while 37 (30.8%) reported they “almost always” or “always” do.  While the 
NDNQI PrU data collection guidelines do not specifically recommend looking for physical 
therapy documentation, responses to this survey item highlight the different methods data 
collectors use to score Routine repositioning as prescribed; methods that may affect inter-rater 
reliability.  The NDNQI may want to include patient scenarios in their guidelines and the online 
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training program to further explain how data on repositioning should be collected.  The survey 
results also suggest that inter-rater reliability may be better understood if survey data are 
examined by hospital. 
Finally, most respondents, n = 74 (61.7%), reported they “never” rate Nutritional support 
within the last 24 hours as “Yes” if a nutritional consult is ordered for a patient who has been 
hospitalized for two or more days with poor intake, but the consult has not yet been completed.  
NDNQI guidelines state “If a pressure ulcer survey is being conducted early in the patient’s 
hospital stay and a nutritional consult has been ordered, but not yet completed, this will count 
positively for nutritional support” (NDNQI, 2013, p. 103).  Although not specifically stated, 
“early in a patient’s hospital stay” is generally considered to be within the first 24 hours of 
admission. 
Lastly, the inconsistency in the number of missing data among survey items was evident.  
Specifically, six items that asked who collects NDNQI PrU risk and prevention data had missing 
data rates of 32.5% to 39.2%.  This was despite the response of “I don’t know” being an option.  
In contrast, the rate of missing data for all the other survey items ranged from 0.8% to 3.3%. 
Implications for the Conceptual Framework 
Donabedian’s model establishes the relationships between structures, processes, and 
outcomes.  An assumption of the model is that the reliability of the NDNQI PrU process 
measures has been established (Donabedian, 2005).  This study provides evidence to support the 
inter-rater reliability of eight NDNQI PrU risk and prevention process measures.  They are (1) 
Skin assessment within 24 hours of admission, (2) Risk assessment within 24 hours of admission, 
(3) Time since last PrU risk assessment, (4) Risk assessment scale, (5) Risk status, (6) Any 
prevention in use within the last 24 hours, (7) Skin assessment documented within the last 24 
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hours, and (8) Pressure-redistribution surface use within the last 24 hours.  Specifically, 
different NDNQI data collectors evaluated the same patients and in general, came to the same (or 
similar) conclusions about the performance of these PrU risk and prevention interventions.  
However, more research is needed on the inter-rater reliability of (1) Routine repositioning as 
prescribed within the last 24 hours, (2) Nutritional support within the last 24 hours, and (3) 
Moisture management within the last 24 hours, to provide support for the equivalence of these 
process measures in Donabedian’s model. 
Implications for Practice 
Results from this study should be used to focus education efforts to clarify data collection 
procedures and improve reliability.  Specifically, education efforts should target areas of 
disagreement identified in agreement matrices and in responses to the Pressure Ulcer Risk and 
Prevention Reliability Survey.  Items from this survey, and similar items, might be integrated 
into the NDNQI PrU Training Program to clarify how PrU risk and prevention data are to be 
collected.  Often people think they understand something until they are questioned about it, such 
as was done during survey completion.  This lack of understanding was reflected in the “I don’t 
know” responses.  Clearly the results of the Pressure Ulcer Risk and Prevention Reliability 
Survey suggest confusion exists in how to rate patients within particular scenarios.  Site 
coordinators need to clearly specify how data are to be collected, especially with regard to their 
hospital’s policy on repositioning. 
Data collectors must engage in ongoing training and review of the NDNQI Guidelines for 
Data Collection and Submission.  In particular, education on when an intervention should be 
rated as “Unnecessary” (for a patient) or “No” (not received).  Raters may be unfamiliar with the 
use of Braden subscale scores to better identify appropriate PrU prevention interventions, 
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compared to use of the total Braden Scale score (Maklebust & Magnan, 2009).  Education is 
needed at the hospital level on use of Braden subscale scores to determine if an intervention is 
needed or “Unnecessary”.  On the other hand, even if a total Braden score is > 18, participant 
raters should know when to classify certain persons “at risk”, such as anyone with a history of 
PrU or someone admitted after surgery lasting 5 hours or more.  Another important consideration 
is that some hospitals may need to enhance the level of documentation in the patient health 
record to support a measure that asks if an intervention is “Unnecessary”, “Contraindicated”, or 
if the “Patient refused”. 
Even though NDNQI PrU risk and prevention data were collected on 1,637 patients by 
120 raters, many response options were never selected.  Whether or not these response options 
continue to be included in the NDNQI PrU risk and prevention measures for patients in the acute 
care setting should be considered.  Elimination of responses rarely or never selected would make 
data collection less burdensome, and may improve reliability of these measures’ data.  However, 
this must be weighed against the reason for their presence. 
Limitations 
Despite sending 750 invitations, only 63 hospitals accepted the Invitation to Participate 
(8.4% response rate).  Of these 63 hospitals; 18 withdrew, 4 never submitted data, and 5 
submitted data that were not usable.  Attrition rate was 42.9%.  Consequently, it may be difficult 
to generalize the study’s findings to other NDNQI-participating hospitals that submit PrU data.  
Moreover, the sample of hospitals, units, or participant raters may not represent the population of 
NDNQI participating hospitals, units, or data collectors that submit PrU data.  In addition, the 
number of patients at each hospital who were rated on the six prevention measures was small 
(range = 5 to 37, M =14.7), and this likely contributed to the large standard deviations observed 
215 
for some hospital’s Cohen’s kappa and PAK values.  The majority of hospitals (n = 25, 69.4%) 
had only two expert/non-expert pairs.  So agreement estimates for the majority of hospitals were 
calculated from only two kappa values.  The agreement estimates for another 10 (27.8%) 
hospitals were calculated from three kappa values, and the agreement estimates for 1 (2.8%) 
hospital was calculated from four kappa values.  On the other hand, most averaged (across 
hospital) Cohen’s kappa and PAK values (aim 1, Q3) had narrow 95% CIs, providing support for 
the accuracy of these average (across hospital) agreement estimates.  Despite the low response 
rate and high attrition rate, the sample of hospitals and participant raters is similar to samples in 
comparable NDNQI research, and reflect the population of NDNQI hospitals that submit PrU 
data.  Even so, generalizability of the survey results is limited by the > 15% of missing responses 
for the survey items on who collects quarterly NDNQI PrU risk and prevention data, suggesting 
that responses to these items may not reflect actual practice (Tabachnick & Fidell, 2007). 
Prevalence-adjusted kappa (PAK) values were presented as estimates of inter-rater 
reliability for the study measures because of the high prevalence of a single response for the risk 
and prevention measures.  However, PAK values do not convey the circumstances in which the 
initial ratings were made in that PAK values are calculated from the average cell counts of 
agreement  (Hoehler, 2000).  Nevertheless, PAK values reported, which adjusted for prevalence, 
provided insight into how prevalence affected the Cohen’s kappa values (J. Sim, personal 
communication, May 5, 2014; Sim & Wright, 2005).  The ICCs calculated in this study included 
only two kappa values per hospital (N = 72 kappa values), but average agreement estimates for 
each measure were determined from 2 to 4 kappa values per hospital (N = 84).  Therefore, the 
ICCs may not have accurately captured the ratio of the between-hospital variance in kappa 
values to the total variance in kappa values. 
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Participant raters may not have followed study protocol and inappropriately shared 
information.  Study instructions, however, stressed the importance of rating independently of 
others, and a staggered start for data collection was suggested in these instructions.  Data 
collection procedure may have adversely influenced findings for the measure, Time since last 
PrU risk assessment.  Also, the small number of “at risk” patients at some hospitals (i.e. those 
who were rated on the prevention measures), may have affected agreement estimates for this as 
well as the prevention measures. 
Participant raters may have rated patients differently than how they usually rate patients 
just because they were part of a reliability study.  The study created an artificial data collection 
situation where participants were not allowed to ask advice from other participants.  In practice, 
data collectors work in teams and PrU data collection likely involves collaboration among data 
collectors, especially if they are uncertain of how to rate a patient.  Participant raters may not 
have provided honest answers on the online survey because their responses may have revealed 
that they—or their hospital—do not follow the NDNQI data collection guidelines.  Anonymity, 
however, was assured.  Finally, intra-rater reliability is an assumption for inter-rater reliability 
testing (Gwet, 2012); but intra-rater reliability has not been established. 
Future Research 
Further research is needed to provide support for the NDNQI PrU risk and prevention 
measures.  Specifically, inter-rater reliability studies with a larger patient sample than the current 
study’s sample are needed.  Regression analysis should also be conducted on this study’s data to 
identify rater and hospital characteristics that influence reliability.  In order to improve reliability 
of the NDNQI PrU risk and prevention measures, nurse researchers should conduct additional 
research on the methods and processes used to collect these data, especially the prevention 
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measures.  In addition, intra-rater reliability must be established, as it is an assumption of inter-
rater reliability.  Responses of “sometimes”, “usually”, and “almost always” leads one to 
question intra-rater reliability.  Finally, across-hospital reliability for the 11 NDNQI PrU risk 
and prevention measures must be examined and established, especially because performance of 
PrU risk and prevention interventions is compared across hospitals.  This across-hospital inter-
rater reliability research may be an online study presenting patient scenarios to raters across 
hospitals.  For instance, actual patient scenarios could be randomly selected from existing 
electronic patient health records.  In addition, for each of these scenarios, a corresponding photo 
of the patient room could be staged—this is because some measures can be (and are) rated by 
direct observation.  These patient records and photos could then be presented to data collectors 
across the nation for them to rate each “patient” on the NDNQI PrU risk and prevention 
measures.  If future studies replicate the reliability results on the prevention intervention 
measures found in this study, their value as quality of care measures might be reconsidered. 
Conclusion 
This is the first known study to examine the reliability of the NDNQI PrU risk and 
prevention measures.  Overall findings provide support for the reliability of the five PrU risk 
measures (Skin assessment within 24 hours of admission, Risk assessment within 24 hours of 
admission, Time since last PrU risk assessment, Risk assessment scale, and Risk Status), and 
three of the six PrU prevention measures (Any prevention in use within the last 24 hours, Skin 
assessment documented within the last 24 hours, and Pressure-redistribution surface use within 
the last 24 hours).  Cohen’s kappa values were adjusted for prevalence because nearly all the 
patients received a PrU risk assessment, and most of those at risk received interventions to 
prevent them.  The overall reliability of the PrU risk measures was higher than the overall 
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reliability of the PrU prevention measures.  Education and further research are needed to 
improve the reliability of three of the six prevention measures (Routine repositioning as 
prescribed, Nutritional support, and Moisture management).  
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Appendix A 
National Quality Forum Algorithm 1: Guidance for Evaluating the Clinical Evidence 
(NQF, 2013e, p. 8) 
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Appendix A (continued) 
National Quality Forum Algorithm 1: Guidance for Evaluating the Clinical Evidence 
(NQF, 2013e, p. 9) 
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Appendix A (continued) 
National Quality Forum Algorithm 2: Guidance for Evaluating Reliability (NQF, 2013e, p. 
15) 
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Appendix A (continued) 
National Quality Forum Algorithm 3: Guidance for Evaluating Validity (NQF, 2013e, p. 
16) 
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Appendix B 
Data Collection Form 
The NDNQI® Data Collection Form© is copyrighted material, and could not be included in the 
published dissertation manuscript.  
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Appendix C 
Pressure Ulcer Risk and Prevention Reliability Survey 
 
Survey ID          (This is the 7-digit 
alphanumeric code that you have been assigned.  It is located next to your rater number on the 
print-copy of your Data Collection Form.) 
 
1.  What is your job title?  (Select one.) 
 Staff Nurse 
 Clinical Nurse Specialist 
 Advanced Practice Nurse 
 Nurse Manager 
 Nursing Administrator 
 Quality Improvement 
 Wound/Skin Care Nurse 
 NDNQI Site Coordinator 
 Other (please describe):________________________________________ 
 
2.  Registered Nurse (RN) Nursing Education?  (Select one.)  [Appropriate list will open 
following Yes/No selection.] 
 Yes (Select one)     No (Select one) 
 Associate’s Degree Nursing   High School Graduate/GED 
 Bachelor’s Degree Nursing   Associate’s Degree non-nursing 
 Master’s Degree Nursing   Bachelor’s Degree non-nursing 
 Doctorate Degree Nursing   Master’s Degree non-nursing 
       Doctorate Degree non-Nursing 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
 
3.  Please select what you have completed within the last 12 months: (Select all that apply.) 
 I have reviewed the NDNQI Guidelines for Data Collection and Submission of   
  Pressure Ulcers. 
 
 I have completed all 4 modules of the NDNQI Pressure Ulcer Training program. 
 
 I have completed only some (not all) of the 4 NDNQI Pressure Ulcer Training program 
  modules. 
 
 None of the above 
 
4.  Have you received education for data collection on pressure ulcers other than reviewing 
the NDNQI Guidelines for Data Collection and Submission of Pressure Ulcers or 
completing the NDNQI Pressure Ulcer Training program?  (Select one.) 
 Yes    No 
 
5.  How many years have you collected NDNQI pressure ulcer data?  (Select one.) 
 < 1 year  5 years   11 years 
 1 year   6 years   12 years 
 2 years   7 years   13 years 
 3 years   8 years   14 years 
 4 years   9 years   15 years 
    10 years  > 15 years 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
 
6.  In addition to chart abstractor, what other role(s) in the NDNQI Pressure Ulcer Survey 
have you had?  (Select all that apply.) 
 Site Coordinator 
 Patient skin inspection—Rounding on all patients 
 Patient skin inspection—Rounding on selected patients to confirm pressure ulcer  
 presence or stage 
 Training of pressure ulcer team 
 Data entry 
 No other roles 
 Other (please describe) ____________________________________________ 
 
7.  Who usually leads your NDNQI Pressure Ulcer Survey data collection team?  (Select 
one.) 
 Someone certified in wound care 
 Someone who is not certified in wound care but is the wound/skin care nurse 
 Neither of the above 
 I don’t know their certification status 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
 
8.  Which of the following active certifications do you hold?  (Select all that apply.) 
 CWOCN—Certified Wound, Ostomy, Continence Nurse 
 CWCN—Certified Wound Care Nurse 
 COCN—Certified Ostomy Care Nurse 
 CCCN—Certified Continence Care Nurse 
 CWON—Certified Wound Ostomy Nurse 
 CWS—Certified Wound Specialist 
 WCC—Wound Care Certified 
 No certifications in wound care 
 Other (please describe):____________________________________________________ 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
With regard to the NDNQI pressure ulcer risk and prevention measures, please rate the following 
statements: (Select one) 
 Never Sometimes Usually Almost 
Always 
Always I Don’t 
Know 
1.  I am comfortable with my skills 
to review patient records and 
collect NDNQI pressure ulcer risk 
and prevention data. 
      
2.  Prior to each time that we 
collect NDNQI pressure ulcer data, 
our hospital provides training or 
reviews. 
      
3-9.  The people at our hospital 
who review patient records to 
collect NDNQI pressure ulcer risk 
and prevention data include: 
• RNs 
      
• LPNs       
• Nurse aids       
• Physical Therapists        
• Respiratory Therapists       
• Clinical Secretaries       
• Others (please specify)       
10.  At least once a year, we 
compare pressure ulcer team 
assessments of pressure ulcer risk 
and prevention to evaluate the 
reliability of this data. 
      
11.  I collect data on the unit where 
I usually work. 
      
12.  I retrieve documentation on 
pressure ulcer risk and prevention 
from the patient’s paper health 
record. 
      
13.  I retrieve documentation on 
pressure ulcer risk and prevention 
from the patient’s electronic health 
record. 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
With regard to the NDNQI pressure ulcer risk and prevention measures, please rate the following 
statements: (Select one) 
 Never Sometimes Usually Almost 
Always 
Always I Don’t 
Know 
14.  Persons from information 
technology extract data on 
pressure ulcer risk and 
prevention from the electronic 
health record for use in the 
pressure ulcer survey. 
      
15.  If a patient was admitted to 
the hospital less than 24 hours 
before the pressure ulcer 
survey, I exclude them from the 
survey. 
      
16.  I decide if a patient is at risk 
for pressure ulcers by the score 
obtained on the risk assessment 
scale (i.e. Braden, Norton) at the 
time of the pressure ulcer 
survey. 
      
17.  If a patient’s risk 
assessment score (i.e. Braden 
or Norton Scale score) does not 
classify them as being “at risk 
for pressure ulcers”, I look for 
documentation of other factors 
indicating the patient is at 
pressure ulcer risk. 
      
18-20.  I directly observe 
patients in their rooms in order 
to rate: 
• pressure-redistribution 
surface use 
• nutritional support 
• moisture management 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
 
Questions 18-27 Apply to Patients “At Risk” for Pressure Ulcers.  With regard to the NDNQI 
pressure ulcer prevention measures, please rate the following statements: (Select one) 
 Never Sometimes Usually Almost 
Always 
Always I Don’t 
Know 
21.  If the nurse tells me a 
patient refused to be 
repositioned, but there is no 
documentation of this in the 
patient record, I select “Patient 
refused”. 
      
22.  I ask patient care staff for 
information in order to 
determine how to rate Routine 
repositioning as prescribed. 
      
23.  If repositioning is 
appropriate for a patient; I 
allow a 30 minute leeway past 
the time repositioning was to 
occur before I rate Routine 
repositioning as prescribed as 
“No”. 
      
24.  To evaluate frequency of 
patient repositioning, I look in 
the patient record for physical 
therapy documentation of 
patient activity such as standing 
or ambulation. 
      
25.  If a nutritional consult is 
ordered for a patient who has 
been hospitalized for 2 or more 
days with poor intake, but the 
consult has not yet been 
completed, I rate Nutritional 
support as “Yes”. 
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Appendix C (continued) 
Pressure Ulcer Risk and Prevention Reliability Survey 
With regard to the NDNQI pressure ulcer risk and prevention measures, please rate the following 
statements: (Select one) 
 Never Sometimes Usually Almost 
Always 
Always I Don’t 
Know 
26.  Barrier skin cream at the 
bedside is sufficient for me to 
rate Moisture management as 
“Yes”. 
      
27.  If I rate that a patient did 
not receive a particular 
pressure ulcer prevention 
intervention, someone else 
reviews the patient record to 
make sure I selected the 
correct rating. 
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Appendix D 
Invitation to Participate 
Dear NDNQI Site Coordinator, 
 
We invite you to participate in the Pressure Ulcer Risk and Prevention Reliability Study.  This 
study will examine the agreement of ratings on pressure ulcer (PrU) risk and prevention 
measures between persons who collect this data for the NDNQI Pressure Ulcer Survey. 
 
No skin inspections (or data collection on pressure ulcer presence or staging) are involved.  
Study data collection is separate from and in addition to your quarterly NDNQI pressure ulcer 
data collection. 
Study Protocol: 
You will need to select 3 to 4 persons (participant raters) who usually collect data on pressure 
ulcer risk and prevention for the NDNQI Pressure Ulcer Survey.  These participant raters will 
independently review 50 patient records, and independently rate these 50 patients on the study 
measures. 
Pressure Ulcer Risk Measures                                Pressure Ulcer Prevention Measures                                                                                         
(All 50 patients)            (Those of the 50 patients who are at risk)  
1.  Skin assessment on admission.   6.  Pressure ulcer prevention. 
2.  Pressure ulcer risk assessment on admission. 7.  Skin assessment documented. 
3.  Time since last pressure ulcer risk assessment. 8.  Pressure-redistribution surface use. 
4.  Last risk assessment scale and score.  9.  Routine repositioning as prescribed. 
5.  Pressure ulcer risk status.    10.  Nutritional support. 
       11.  Moisture management. 
Participant raters will also complete an online survey about the methods they use to gather 
information on the risk and prevention measures. 
Study Dates: 
Participant raters will collect the data one morning during September 29 to October 13, 2014. 
Eligible Units: 
Only patients on adult medical-surgical, adult medical, and/or adult surgical units will be 
included in data collection. 
Please see the attachment to this email for study details and the list of units from which study 
data may be collected in your hospital. 
Please go to << INSERT REDCap URL>> to reply to this invitation.  The deadline to reply is 
August 19, 2014. 
Thank you for your consideration of participating in this study   
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Appendix D (continued) 
Invitation to Participate (Email Attachment) 
August 1, 2014 
Dear NDNQI Site Coordinator, 
 
We invite you to participate in the Pressure Ulcer Risk and Prevention Reliability Study.  This 
study will examine the agreement of ratings on the NDNQI pressure ulcer risk and prevention 
measures between persons who collect this data for the NDNQI Pressure Ulcer Survey.  The 
study is important because the data on pressure ulcer risk and prevention are used by hospitals 
for quality improvement purposes. The pressure ulcer risk and prevention study measures are: 
 
              Pressure Ulcer Risk:   Pressure Ulcer Prevention w/in the last 24 hours: 
1.  Skin assessment on admission.   6.  Pressure ulcer prevention. 
2.  Pressure ulcer risk assessment on admission. 7.  Skin assessment documented. 
3.  Time since last pressure ulcer risk assessment. 8.  Pressure-redistribution surface use. 
4.  Last risk assessment scale and score.  9.  Routine repositioning as prescribed. 
5.  Pressure ulcer risk status.    10.  Nutritional support. 
      11.  Moisture management. 
 
 No skin inspections (or data collection on pressure ulcer presence or staging) are involved. 
The study will be performed by Shirley Waugh for her PhD dissertation.  Sandra Bergquist-
Beringer, RN, PhD, CWCN, who helped develop these pressure ulcer measures, will supervise 
the study. 
If you decide to participate in this study: 
1. The site coordinator will direct the study and data collection.  Data collection must be 
completed on a morning during the study period of September 29th through October 13th. 
2. The site coordinator will identify 3 to 4 people at the hospital who usually review the 
patient record during data collection on the pressure ulcer risk and prevention measures 
for the NDNQI Pressure Ulcer Survey (participant raters). 
 a. One of these people will be the most experienced and/or skilled in patient 
  record review on your NDNQI pressure ulcer data collection team. 
 b. The others will be persons who usually review patient records   
  on pressure ulcer risk and prevention. 
 c. The site coordinator may serve as a participant rater if they usually review  
  patient records for the survey. 
3. Participant raters will independently review the records of 50 patients (total = 50 patients) 
and independently rate these patients on the NDNQI pressure ulcer risk and prevention 
measures. 
a. Only patients on medical-surgical, medical, and surgical units will be 
 included in this data collection.   
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Appendix D (continued) 
Invitation to Participate (Email Attachment) 
b. Units in your hospital from which study data may be collected are listed on 
the Unit List, which is attached as a separate document.  These units are 
identified by name with corresponding unit ID and unit type. 
c. Data collection for this study is separate from and in addition to your   
 quarterly NDNQI pressure ulcer data collection. 
d. Each participant rater will enter their data into an Excel file that will be sent to 
 you.  The Excel file is named the Data Collection Form. 
e. It will take approximately 2.5 hours to collect the data. 
 
4. Participant raters will complete an online survey after data collection is completed. 
 a. This survey will take 20 – 25 minutes to complete: 
 
5. Participant raters will submit (upload) their completed Data Collection Form Excel file to 
the online survey. 
 
All information will remain confidential.  Your hospital’s identity will only be known by your 
NDNQI alphanumeric code.  Participant rater identity will remain unknown to the research team.  
Only de-identified results will be included in the final report.  Results will be reported to 
participating hospitals after the study is completed. 
Participation in the study is important to us but it is voluntary.  If you choose not to participate, 
your hospital’s membership in the NDNQI will not be affected.  You may contact Shirley Waugh 
with questions about this study at ndnqi@kumc.edu or 913-588-1691. 
This study has been reviewed and received approval from the Human Subjects Committee at the 
University of Kansas Medical Center.  If you have questions about the study, you can call 
NDNQI at 913-588-1691.  If you have any questions about your rights as a research participant, 
call 913-588-1240 or write Human Subjects Committee, University of Kansas Medical Center, 
3901 Rainbow Blvd, Mail Stop #1032, Kansas City, KS 66160-7700. 
Please go to << INSERT REDCap URL>> to reply to this invitation.  The deadline to reply is 
August 19th. 
Thank you for this consideration. 
Sincerely, 
 
Shirley Waugh, PhD Candidate Researcher 
University of Kansas, School of Nursing 
Your Unit List is attached as a separate document. 
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Appendix E 
Reply to Invitation to Participate 
Note: This was available on REDCap. 
Reply to Invitation to Participate: 
The Pressure Ulcer Risk and Prevention Reliability Study: 
 
1. NDNQI Hospital Code           
            (The alphanumeric code you use to sign-in to the NDNQI website.) 
 
2. Would you like to participate in the Pressure Ulcer Risk and Prevention Reliability Study? 
 
 Yes  No  I’m not sure, I need more information 
 
3. Site coordinator’s first and last name:        
 
4. Site coordinator’s email address:         
 
For more information, contact Shirley Waugh at 913-588-1691 or ndnqi@kumc.edu 
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Appendix F 
Overview of the Pressure Ulcer Risk and Prevention Reliability Study 
Overview of the Pressure Ulcer Risk and Prevention Reliability Study 
 
The purpose of this study was to examine the agreement of ratings on pressure ulcer risk and 
prevention measures between persons who collect this data for the NDNQI Pressure Ulcer 
Survey.  It is important that the reliability of the data on pressure ulcer risk and prevention be 
established as these data are used by hospitals for quality improvement purposes. 
 
Thank you for accepting our invitation to participate and help us in this process. 
 
The pressure ulcer risk and prevention study measures are: 
 
              Pressure Ulcer Risk:   Pressure Ulcer Prevention w/in the last 24 hours: 
1.  Skin assessment on admission.   6.  Pressure ulcer prevention. 
2.  Pressure ulcer risk assessment on admission. 7.  Skin assessment documented. 
3.  Time since last pressure ulcer risk assessment. 8.  Pressure-redistribution surface use. 
4.  Last risk assessment scale and score.  9.  Routine repositioning as prescribed. 
5.  Pressure ulcer risk status.    10.  Nutritional support. 
       11.  Moisture management.  
 
No skin inspections (or data collection on pressure ulcer presence or staging) are involved. 
The study will be conducted by Shirley Waugh for her PhD dissertation under the guidance of 
Sandra Bergquist-Beringer, RN, PhD, CWCN; who helped develop these NDNQI pressure ulcer 
measures. 
 
PRIOR TO THE STUDY: 
 
The site coordinator will direct the study and data collection at your hospital. 
 
The site coordinator will identify 3 to 4 people at the hospital to participate in the study 
(participant raters).  These people must be among those who usually review patient records 
during data collection on the pressure ulcer risk and prevention measures for the NDNQI 
Pressure Ulcer Survey 
• One of these people will be the most experienced and/or skilled in patient record  
 review on your NDNQI pressure ulcer data collection team. 
• The others will be persons who usually review patient records     
 during pressure ulcer data collection. 
• The site coordinator may serve as a participant rater if they usually review patient records 
for NDNQI Pressure Ulcer Survey. 
 
DATA COLLECTION: 
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The NDNQI Pressure Ulcer Risk and Prevention Measures: 
 
Participant raters will independently review the records of 50 patients, and independently rate 
these patients on the NDNQI pressure ulcer risk and prevention measures.  This will be like what 
they do for the NDNQI pressure ulcer survey except that this study will be separate from and in 
addition to your usual pressure ulcer survey.  It is important that participant raters collect the data 
in their usual manner. 
 
Data collection (for this study) is to begin on medical-surgical, then medical, and lastly surgical 
units until data have been collected on 50 patients.  The goal is for participant raters to collect 
data on the same 50 patients.  Therefore, the units in your hospital from where data can be 
collected, and the order that the participant raters will proceed through these units, have been 
provided to you in a separate document, the Unit List. 
 
Participant raters will collect patient data on pressure ulcer risk and prevention using the Data 
Collection Form provided.   
• This data collection form was created as an Excel file.  
• Participant rater numbers and corresponding Survey ID are located on the form. The site 
coordinator will assign each participant rater a number (with corresponding Survey ID) 
following procedures identified in the Site Coordinator Instructions. 
 
Participant raters will collect study data without discussing or sharing the information with the 
other participant raters.   
 
Patients will be identified by room/bed number, but no link between patients and their room/bed 
number will be maintained.  The identity of the participant raters and patients will be unknown to 
the research team. 
 
The Methods Used to Collect NDNQI Pressure Ulcer Data: 
 
After data collection is completed, participant raters will complete an online survey (on 
REDCap).  The purpose of the online survey is to gather select information about the participant 
raters, and examine the methods and processes used to collect data on the NDNQI pressure ulcer 
risk and prevention measures.  Also, each participant rater will upload their completed Data 
Collection Form Excel file onto the online survey site. 
 
 
ADDITIONAL INFORMATION: 
 
A teleconference for the site coordinators and participant raters has been scheduled for 
September 9th at 10:00AM (Central Daylight Time).  Teleconference details are included in the  
Teleconference Instructions.  The purpose of this teleconference is to explain the study and data 
collection procedures, review study materials, and answer any questions the site coordinator 
might have. 
Thank you for taking the time to participate in the  
Pressure Ulcer Risk and Prevention Reliability Study!  
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Appendix G 
Site Coordinator Instructions 
 
Site Coordinator Instructions 
 
PRIOR TO THE STUDY: 
 
1. Recruit 3 to 4 people at the hospital to participate in the study (participant raters).  Recruit 
these people from those who usually review patient records during data collection on the 
pressure ulcer risk and prevention measures for the NDNQI Pressure Ulcer Survey. 
a. Recruit the person most experienced and/or skilled in reviewing patient records. 
 
b. Recruit 2 to 3 other team members. 
 
c. You may serve as a participant rater if you usually review patient records for the 
NDNQI Pressure Ulcer Survey. 
 
2. Assign each participant rater a rater number. 
a. Assign the person most experienced and/or skilled in reviewing patient records to 
be “Rater 1”. 
 
b. Assign each of the other participant raters to be “Rater 2” or “Rater 3” if you have 2 
other participant raters, and “Rater 4” if you have 3 other participant raters. 
 
3. Establish the date and time of the study. 
a. Talk to the participant raters to coordinate the study date and time. 
 
b. The data collection period is September 29nd to October 13th. 
 
c. Select a single day during September 29th to October 13th to perform the study. 
 
d. The study will be performed between 0700 and 1200 the day of the study. 
 
e. Data collection (for this study) is separate from your quarterly NDNQI pressure ulcer 
data collection. 
 
4. Note the units on which the data will be collected.  Only adult medical-surgical, adult 
medical, and adult surgical units are eligible.  
a. The names of eligible units in your hospital and their NDNQI unit ID, and NDNQI 
unit type are listed here in your Unit List, which is attached as a separate document. 
 
5. Distribute the Overview of the Pressure Ulcer Risk and Prevention Reliability Study  and 
Participant Rater Instructions to each participant rater. 
 
269 
6. Distribute the Data Collection Form to Participant Raters.  
a. Print a Data Collection Form for each participant rater. 
 
b. On this form, mark the rater number that has been assigned to each participant rater. 
• The participant’s corresponding Survey ID is located next to the rater number. 
 
• The Survey ID is the hospital alphanumeric code you use to sign-in to the 
NDNQI, followed by the number “1” if the rater is the most experienced 
and/or skilled in chart review; or “2”, “3”, or “4”. 
 
c. The Data Collection Form will be used by participant raters to collect the data. 
 
d. Distribute the appropriate print form and electronic form to each participant rater.  Be 
sure the most experienced/skilled chart reviewer is assigned to be Rater 1. 
 
e. You and the participant raters may choose to record data as it is collected (a) onto the 
print-copy of the Data Collection Form, or (b) directly into their electronic Data 
Collection Form. 
• If a print-copy is used for data collection, then participant raters will need to 
enter the data into their electronic Data Collection Form file after data 
collection has been completed. 
 
• Participant raters MUST ENTER THEIR OWN DATA into the e-file. 
 
DATA COLLECTION – THE DAY OF THE STUDY: 
 
7. Generate a list of patients (patient name and room/bed #) who are on each eligible unit at 
0700.  This list will be called the Patient List. 
a. Patients on these Patient Lists should be ordered by room/bed # (NOT alphabetically 
by patient name). 
 
b. ONLY PATIENTS ON THE PATIENT LISTS WILL BE INCLUDED in the study. 
 
8. Review study procedures with the participant raters just before data collection is to begin. 
a. Verify with each participant rater that they have the correct rater number and 
corresponding Survey ID – the most experienced and/or skilled in patient record 
review must be “Rater 1” with the Survey ID ending in “1”. 
 
b. Instruct participant raters to retain their print-copy of the Data Collection Form with 
their Survey ID. 
 
c. Instruct participant raters they will use their Survey ID later to login to the survey site 
to upload their completed Data Collection Form and complete an online survey. 
 
d. Organize data collection so that participant raters collect data INDEPENDENTLY of 
each other. 
270 
• While participant raters are to collect data on the same morning, they 
SHOULD NOT collect data together! 
 
• Consider staggering data collection start time by 15 to 30 minutes to prevent 
collaboration among participant raters. 
 
9. Instruct participant raters to INDEPENDENTLY REVIEW 50 patient records, and 
INDPENDENTLY RATE these patients on the NDNQI pressure ulcer risk and prevention 
measures. 
a. Begin with 3 documents; the Unit List, the Patient Lists, and the Data Collection 
Form. 
 
b. Start with the first unit on the Unit List.  On this unit, begin with the lowest room bed 
#.  Is there a patient in this room/bed #? 
  
      No - move to the next bed.  (If the room has 2 beds, this would be Bed 2.  If the  
               room has one bed you would move to the next highest room #.) 
 Yes - Is THIS patient on the Patient List? 
  No - move to the next bed. (If the room has 2 beds, this would be Bed 2.   
   If the room has one bed you would move to the next room.)  
  Yes - review this patient’s record and enter the findings on the   
   first line of the Data Collection Form (“Pt. 1”).  Move to the next  
   room/bed # where there is a patient. 
 
• Continue data collection until data collection is completed on this unit.  
    
• Be sure to identify patients by their room/bed # on the Data Collection Form. 
 
• If the patient in the room/bed # is different than the patient on the Patient List, 
DO NOT COLLECT DATA ON THAT PATIENT.  Participant raters should 
NOT SEEK TO FIND patients who are no longer in their room. 
 
• It is important participant raters collect data in their usual manner. 
 
c. When data collection on this unit is completed, data collection should proceed to the 
next unit on the Unit List. 
 
d. Collect data on each unit in the order that the units are listed on the Unit List.  Always 
start with the lowest room/bed # within that unit, and continue in order to the highest 
room/bed # on that unit—until 50 patients have been rated. 
• Collecting data starting with the 1st unit on the Unit List and continuing by 
unit in the order the units are listed on the Unit List is ESSENTIAL so that 
participant raters rate the same 50 patients!! 
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e. During data collection, CONSIDER ONLY PATIENT CARE PROVIDED THE 24-
HOUR PERIOD BEGINNING 0700 THE DAY BEFORE DATA COLLECTION 
TO 0700 THE DAY OF DATA COLLECTION!! 
• Using only this 24-hour period is necessary to ensure that each participant 
rater is considering the same patient data as the other participant raters. 
 
f. It will take approximately 2.5 to 3 hours to collect data.  However, data collection 
may take a little longer than expected if data collectors are unfamiliar with the study’s 
Data Collection Form (30 – 45 minutes) may also be needed. 
 
10. Remind participant raters: 
a. Do not discuss their choices with others. 
 
b. Do not make any changes to their data. 
 
c. We will not know who they are. 
 
d. We expect variation between participant raters’ ratings. 
 
e. This variation does not reflect negatively on the participant rater or their institution. 
 
AFTER DATA COLLECTION IS COMPLETED: 
 
11. Refer participant raters to their Participant Instructions for information regarding the online 
survey. 
a. Remind participant raters that they have until OCTOBER 27th to login to REDCap to: 
• Upload their completed Data Collection Form Excel file. 
 
• Complete the online survey. 
  
b. The REDCap survey is available at http://redcap.kumc.edu/surveys/?s=VFuoTGEmIZ  
 
c. Once participant raters access the online survey, they must enter their Survey ID 
located on their print-copy of the Data Collection Form.  
 
THANK YOU for participating in the study!! 
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Appendix H 
Participant Rater Instructions 
 
Participant Rater Instructions 
 
This study requires you (“participant rater”) to independently review 50 patient records and rate 
these 50 patients on the NDNQI pressure ulcer risk and prevention measures.  You will then 
access an online site to submit your data and complete a survey. 
 
PRIOR TO DATA COLLECTION: 
 
1. Establish the date and time of the study in conjunction with the site coordinator and other 
participant raters. 
a. The data collection period is September 29th to October 13th. 
 
b. Select a single day during September 29th to October 13th to perform the study. 
 
c. The study will be performed between 0700 and 1200 on the day of the study. 
 
d. Data collection (for this study) is separate from your quarterly NDNQI pressure 
ulcer data collection. 
 
2. Receive a print-copy and an electronic copy of the Data Collection Form from the site 
coordinator – you will use this form to collect data. 
a. On this form, your site coordinator has identified your rater number and 
corresponding Survey ID.  You will use this unique and anonymous Survey ID 
later when you access the online survey. 
 
b. The Survey ID does not contain information that would make it possible to 
identify you. 
 
c. You and the site coordinator may choose to record the data as it is collected (a) 
onto the print-copy of the Data Collection Form, or (b) directly into an electronic 
Data Collection Form file. 
 
d. If the print-copy is used for data collection, then YOU will need to enter your data 
into your own electronic Data Collection Form file after data collection has been 
completed. 
 
e. BE SURE TO DOUBLE CHECK YOUR DATA ENTRY—YOU MUST BE 
CAREFUL TO ENTER THE DATA WITHOUT ERROR!! 
 
f. No other person should enter the data you collected into your electronic file for 
you. 
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DATA COLLECTION: 
 
3. Only adult medical-surgical, adult medical, and adult surgical units are eligible for 
inclusion in the study.  Eligible units in your hospital and the unit order from which data 
are to be collected are listed in your Unit List, which is a separate document.  This Unit 
List includes unit name, NDNQI unit ID, and NDNQI unit type. 
 
4. On the morning of data collection, the site coordinator will generate a list of patients 
(patient name and room/bed #) who are on each eligible unit at 0700.  ONLY PATIENTS 
ON THESE PATIENT LISTS WILL BE INCLUDED IN THE STUDY. 
 
5. Prepare to collect data INDEPENDENTLY of the other participant raters.   
a. Please do NOT COLLECT data alongside other raters. Consider staggering data 
collection start time by 15 to 30 minutes to prevent collaboration among 
participant raters. 
 
b. Please DO NOT ask others for help. 
 
6. INDEPENDENTLY REVIEW 50 patient records and INDEPENDENTLY RATE these 
patients on the NDNQI pressure ulcer risk and prevention measures on the day of the 
study between 0700 and 1200. 
a. Begin with 3 documents; the Unit List, the Patient Lists, and the Data Collection 
Form. 
 
b. Start with the first unit on the Unit List.  On this unit, begin with the lowest room 
bed #.  Is there a patient in this room/bed #? 
 
No - move to the next bed.  (If the room has 2 beds, this would be Bed 2.  If the  
  room has one bed you would move to the next highest room #.)  
 Yes - Is THIS patient on the Patient List? 
  No - move to the next bed. (If the room has 2 beds, this would be Bed 2.   
           If the room has one bed you would move to the next highest room #.) 
  Yes - review this patient’s record and enter the findings on the   
            first line of the Data Collection Form (“Pt. 1”).  Move to the next  
            highest room/bed # on this unit. 
 
• Continue data collection until data collection is completed on the first unit.  
 
• Be sure to identify patients by their room/bed # on the Data Collection Form. 
 
• If the patient in the room/bed # is different than the patient on the Patient List, 
DO NOT COLLECT DATA ON THAT PATIENT.  You should NOT SEEK 
TO FIND patients who are no longer in their room. 
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c. When data collection on this unit is completed, data collection should proceed to 
the next unit on the Unit List.  Continue collecting data according to the order 
listed on the Unit List. 
i. Collecting data starting with the 1st unit on the Unit List and continuing by 
unit in the order the units are listed on the Unit List is ESSENTIAL so that 
participant raters rate the same patients!! 
 
d. On each unit, always start collecting data from patients in the lowest room/bed # 
and continue in order by room/bed# to patients in the highest room/bed #. 
• Collecting data starting with the lowest room/bed# on the unit to the 
highest room/bed # on the unit is ESSENTIAL so that participant raters 
rate the same patients!! 
 
e. During data collection, CONSIDER ONLY PATIENT CARE PROVIDED THE 
24-HOUR PERIOD BEGINNING 0700 THE DAY BEFORE DATA 
COLLECTION TO 0700 THE DAY OF DATA COLLECTION!! 
• Using only this 24-hour period is necessary to ensure that each participant 
rater is considering the same patient data as the other participant raters. 
 
• It is not necessary for the patient to have been in that room for the entire 
24-hour period to be included in the study 
 
f. Continue collecting data until 50 patients have been rated on the pressure ulcer 
risk and prevention measures. 
 
7. RECORD your ratings on pressure ulcer risk and prevention as you collect this data on 
your Data Collection Form. 
a. Please record: 
i. Date and time you began collecting data. 
 
ii. Patient room/bed #, patient age, and patient gender. 
 
iii. NDNQI unit ID number.  [Unit name, NDNQI unit ID, and NDNQI unit 
type are included in the Unit List.] 
 
8. Do not share your ratings with others.  This is crucial to the integrity of the study!! 
 
AFTER DATA COLLECTION IS COMPLETED: 
 
9. Do not discuss your choices with others!  Do not make any changes to your data. 
a. Remember, we will not know who you are and we expect variation between 
participant raters’ ratings. 
 
b. Understand this variation does not reflect negatively on you or your institution. 
 
c. Know that individual results will not be shared or distributed. 
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10. Login to REDCap to upload your electronic Excel file containing the completed Data 
Collection Form.  This must be done on or before OCTOBER 27th. 
a. Go to https://redcap.kumc.edu/surveys/?s=VFuoTGEmIZ .  You can use any 
computer with internet access. 
 
b. Enter your Survey ID in the place requested on the online survey.  (This is a 7-
digit alphanumeric code.) 
• Your Survey ID corresponds to your rater number and has been recorded 
by the site coordinator on the top of the print-copy of your Data 
Collection Form. 
 
c. Instructions for uploading your completed Data Collection Form are on the 
survey site. 
 
11. Complete the Pressure Ulcer Risk and Prevention Reliability Survey. 
a. You will be able to access the survey only once, therefore you must complete the 
survey and file upload in one sitting. 
 
b. It will take 20 - 25 minutes to complete the survey and Data Collection Form 
Excel file upload. 
 
d. WE RECOMMEND YOU COMPLETE THE SURVEY AND ELECTRONIC 
FILE UPLOAD AS QUICKLY AS POSSIBLE AFTER COLLECTING DATA!!  
The survey, however, will be open until OCTOBER 27th. 
 
e. Complete the survey independently of others and without consulting any other 
resources. 
 
f. Answers will be stored in a separate protected database. 
 
g. Please remember your responses are anonymous. 
 
THANK YOU for your effort and time! 
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Appendix I 
Email Sent with Study Materials 
Dear Site Coordinator, 
 
Thank you for volunteering to participate in the Pressure Ulcer Risk and Prevention Reliability 
Study. Your site has been selected to participate. This email contains all necessary documents (7 
TOTAL) related to this project. 
  
A 1-hour teleconference is scheduled for Tuesday, September 9th at 11:00AM (ET), 10:00 AM 
(CT), 9:00 AM (MT) and 8:00 AM (PT). Details for the teleconference are included in the 
Teleconference Instructions, which are attached.  
 
1. Overview of the Pressure Ulcer Risk and Prevention Reliability Study Overview of the 
Pressure Ulcer Risk and Prevention Reliability Study.pdf 
 
2.  Site Coordinator Instructions 
Site Coordinator Instructions.pdf 
 
3. Participant Rater Instructions 
Participant Rater Instructions.pdf  
 
4. Data Collection Form 
Data Collection Form <<Hospital Code>>.xls  
 
5. List of Eligible Units in your hospital PrU Eligible Units <<Hospital Code>>.pdf  
 
6. Your hospital's Data Submission Link 
https://redcap.kumc.edu/surveys/?s=VFuoTGEmIZ 
Use this link and only this link to submit data for the Pressure Ulcer Risk and Prevention 
Reliability Study; you cannot submit Pressure Ulcer Risk and Prevention Reliability Study Data 
on the NDNQI website. 
 
8. Teleconference Instructions 
Teleconference Instructions.pdf  
 
Please select your participant raters by the date of the teleconference. See the Site Coordinator 
Instructions for details of how to select these individuals. We encourage you to review the study 
materials with the participant raters prior to the teleconference and ask the participant raters to 
attend.  
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Appendix I (continued) 
Email Sent with Study Materials 
Please do not hesitate to contact us with any questions or concerns. Thank you again for your 
time and effort in completing this research. 
  
 
Thank You, 
Shirley Waugh 
ndnqi@kumc.edu 
913-588-1691 
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Appendix J 
Teleconference Instructions 
PrU Risk and Prevention Reliability Study 
1-hour TELECONFERENCE Instructions 
 
Tuesday, September 9, 2014 at 
11:00 am Eastern 
10:00 am Central 
9:00 am Mountain 
8:00 am Pacific 
 
Please note:  These times reflect Daylight Savings Time.  Please adjust if your area 
does not observe Daylight Savings Time. 
 
You are receiving this email because your site has registered for the Pressure Ulcer 
Risk and Prevention Reliability Study.  Due to the volume of participants, be sure 
to dial in to the teleconference 10 minutes ahead of the scheduled time. 
 
Select your participant raters and encourage them to attend the teleconference. 
• It is imperative, however, that each site does not use more than its one allotted 
port into the conference.  Therefore, all participants at your site must call from 
the same telephone/speaker phone. 
 
To access the teleconference, please call 1-800-268-5851 10 to 30 minutes prior to 
the start time.  All calls are operator assisted.  There is NO PASSWORD for this 
conference.  You will be placed in the listen-only mode for the conference.  However, 
you will have an opportunity to ask questions.  Press ‘*1’ and the operator will 
announce you for your question of the panel. 
 
To maintain confidentiality during the question and answer, teleconference participants 
should not identify the hospital they represent.  Only first names and State should be 
used.  “Sally from Kansas,” for example. 
 
If at any point during the conference call you require operator assistance you may 
access the operator by pressing ‘*0’. 
 
If you are unable to attend, an audio-recording will be available upon request. 
 
We are looking forward to your participation. 
 
Shirley Waugh 
ndnqu@kumc.edu 
913-588-1691 
 
 
 
 
© 2014 Press Ganey Associates, Inc.  
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Appendix K 
Pilot Study Feedback and Responses 
1.  Did you understand the study based on information presented in the  
    Overview of the Pressure Ulcer Risk and Prevention Reliability Study? 
  Yes 4(100%) 
  Somewhat 
  No, not at all – please comment       
  Not applicable, I am not the site coordinator and did not read this information. 
 
 2.  Did you understand the Site Coordinator Instructions? 
  Yes 3(75%) 
  Somewhat 
  No, not at all – please comment        
  Not applicable, I am not the site coordinator and did not read the information.  
   1(25%) 
 
 3.  Did you understand the Participant Rater Instructions? 
  Yes 4(100%) 
  Somewhat 
  No, not at all – please comment       
   
 
 4.  Was the Data Collection Form readable? 
  Yes 3(75%) 
  Somewhat 1(25%) 
  No, very difficult to read – please comment      
   
5.  What form of the Data Collection Form was used to record data as it was collected? 
  Used a print-copy during data collection 4(100%) 
  Entered data directly into the electronic file as it was collected 
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Appendix K (continued) 
Pilot Study Feedback 
6.  On average, how long did it take to complete the data collection for one patient? 
  0 – 5 minutes 
 
  > 5 – 10 minutes 2(50%) 
 
  > 10 – 15 minutes 1(25%) 
 
  > 15 minutes 1(25%) 
 
 7.  How long did it take to complete the data collection for all 50 patients? 
  0 – 30 minutes 
  > 30 – 60 minutes 
  > 1 hour – 2 hours 
  > 2 hours – 3 hours 
  > 3 hours – 4 hours 1(25%) 
  > 4 hours 3(75%) 
 8.  Did you have difficulty linking to the online survey site? 
  No 3(75%) 
  Yes, but I figured it out 1(25%) 
  Yes, I had a lot of difficulty – please comment     
   
 9.  Did you have problems uploading the Data Collection Form Excel file? 
  No 2(50%) 
  Yes, but I but I figured it out 2(50%) 
  Yes, I had a lot of difficulty – please comment     
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Appendix K (continued) 
Pilot Study Feedback 
10.  Did you have any difficulty completing the online survey? 
  No 4(100%) 
  Yes, but it I figured it out 
  Yes, I had a lot of difficulty – please comment     
   
 11.  How long did it take you to complete the entire online survey, and upload your Data 
Collection Form Excel file? 
  less than or equal to 15 minutes 2(50%) 
  > 15 minutes – 30 minutes 2(50%) 
  > 30 minutes – 45 minutes 
  > 45 minutes – 1 hour 
  > 1 hour 
 12.  Could you read the questions on the online survey? 
  Yes 4(100%) 
  No, not really 
  No, very difficult to read – please comment      
    
 13.  Did you understand the questions on the online survey? 
  Yes 4(100%) 
No, not really 
  No, not at all – please comment       
   
 14.  Please describe the issues or problems in participating in this study.____3(75%)_ 
  “The electronic form had some issues with auto-fill, but was fixed.” 
  “The length of time and no access to bedside items.” 
  “There were a few bugs getting into the Excel file, but we figured it out.” 
 
Thank you for your time and valuable feedback! 
